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Abstract 
A specific challenge to the translation of cell therapies and stem-cell derived products 
is the ability to develop and manufacture such products in a cost-effective, scalable 
and robust manner. To this end, this thesis investigates the creation and application 
of a set of computational tools designed to aid bioprocess design decisions for cell 
therapy and stem-cell derived research products. 
The decision-support tools comprise advanced bioprocess economics models with 
databases tailored to cellular products. These are linked to Monte Carlo simulation 
for uncertainty analysis and techniques to identify optimal bioprocess designs that 
include brute-force search algorithms, an evolutionary algorithm, and multi-attribute 
decision making analysis. A trio of industrially-relevant case studies is presented 
within this thesis, along with an additional study included in the appendices of this 
work, in order to demonstrate the applicability of the decisional tools to bioprocess 
design for different cell therapies (allogeneic, human embryonic stem cell-derived 
retinal pigment epithelial (RPE) cells for macular degeneration, allogeneic CAR-T 
cells for oncology) and induced pluripotent stem cells (iPSCs) for drug discovery 
applications. Questions tackled included manual versus automated production, cost-
effective inflection points of planar vs microcarrier-based bioprocess strategies, and 
the identification optimal process technologies for an allogeneic CAR-T cell therapy 
based on both qualitative and quantitative attributes. The analyses highlighted key 
bioprocess economic drivers and process bottlenecks. Furthermore, the Monte Carlo 
simulation technique was used in order to capture the effects of the inherent 
uncertainty associated with cell therapy bioprocessing on manufacturing costs and 
process throughputs. Future process improvements required to create financially 
feasible bioprocesses were also identified. 
This thesis presents the application of a series of decisional tools to bioprocess 
design problems and demonstrates how they can facilitate informed decisions 
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regarding cost-effective process design in the cell therapy sector.  
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Chapter 1: Scope and Background 
1.1 Introduction 
Cell therapies have opened fresh avenues in modern medicine that have the potential 
to revolutionise healthcare; they have applications in a range of medicinal fields, 
including treatment of stroke, age-related blindness (including macular degeneration), 
and a variety of cancers. If cell therapies are to achieve their full clinical and 
commercial potential, significant challenges must be overcome with regards to 
current abilities to produce therapies of the consistent quality to support their function 
at commercially relevant scales. Reimbursement pressures have resulted in an 
increased awareness of the importance of estimating and improving manufacturing 
costs for cell therapy products. The aim of this thesis is to create and apply decisional 
tools to help identify cost-effective process designs for cell therapies and stem cell-
reived research products.  
This chapter aims to provide an introduction to cell therapies and the key topics and 
challenges surrounding their development and manufacture. Decision-support tools 
and their applications to the field of bioprocessing are also introduced. Section 1.2 
gives an overview of cell therapies, including different types of cell therapies along 
with the clinical and commercial applications of cell therapies and stem-cell derived 
products. Section 1.3 introduces product and process development in the context of 
cell therapies and gives an overview of the current risks and challenges to cell therapy 
translation and commercialisation. The concept of bioprocess economics and key 
parameters used to measure the cost of manufacturing a cell therapy and the success 
of cell therapy projects are introduced in Section 1.4. Section 1.5 outlines previous 
applications of decision-support tools to bioprocessing, and details how they are 
currently being applied within the cell therapy sector to improve bioprocess design 
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and aid effective decision-making during process development. Finally, the aims and 
organisation of this thesis is outlined in Section 1.6. 
1.2 Introduction to cell therapies 
Cell therapy is defined as the administration of live whole cells to a patient in order to 
treat a disease (American Society of Gene & Cell Therapy [no date]). Cell therapies 
can be categorised as minimally manipulated cells for homologous use (e.g. blood 
transfusions), and those which are considered as medicines by regulatory bodies, 
referred to as Advanced Therapy Medicinal Products (ATMPs) (Mount et al. 2015). 
ATMP is a broad term that encompasses gene therapy products, somatic cell therapy 
products, and tissue-engineered products. It is applied to cell therapies that utilise 
cells that have undergone substantial manipulation, or where cells are intended for 
non-homologous functions. Cell therapy products administered to human beings with 
the target of regenerating or replacing human tissue to restore normal function, or 
treating, preventing and diagnosing a disease through pharmacological, metabolic, 
or immunological mechanisms are also considered ATMPs (Mason and Dunnill 2008; 
Pla 2016). 
The prevalence of cell therapies has increased rapidly in recent years. As of 2015, 
there were 1,342 active clinical trials investigating the use of cell-based therapies, 
and 9,700 open trials (including observational and duplicate trials (Heathman et al. 
2015). This is in comparison to 1,750 open trials in 2013 (Abbasalizadeh and 
Baharvand 2013). Annual cell therapy revenues are currently in excess of US$1bn 
(Mason et al. 2012), and are forecasted to exceed US$10bn by 2021 (Bloomberg 
2012).  
Cell therapy applications are broad in range, from the treatment of stroke, to heart 
failure, age-related blindness (including macular degeneration), and a variety of 
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cancers. A summary of the target indications for which cell therapy clinical trials are 
currently being conducted is shown in Table 1.1.  
The work presented in this thesis will focus on two main classes of cell therapy and 
related products, which are outlined below along with their applications: namely, 
human pluripotent stem cell (hPSC)-derived products (Section 1.2.1) and chimeric 
antigen receptor (CAR) T-cell therapies (Section 1.2.2). However, other cell therapy 
classifications exist including adult somatic cell products, derived from cells found 
naturally in adult humans (e.g. mesenchymal stem cells (MSCs), haematopoietic 
stem cells (HSCs) and skin stem cell products such as Apligraf®), and three-
dimensional technologies for the replacement of tissues and organs (e.g. tissue 
scaffolds and structures and novel ‘organoid’ technologies).  
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Table 1.1 – Summary of indications under investigation for treatment by advanced 
cell therapies in clinical trials, and typical dose sizes required for treatment 
 Indication Dose size (nr of 
cells) 
Source/ NCT number 
hPSC-
derived 
therapies 
Macular Degeneration 5x104 – 2x105 NCT01691261, 
NCT01344993 
Spinal Cord Injuries 106  
MSC-
based 
therapies 
Ischemic stroke 106/Kg NCT01678534 
Crohn’s disease 2x106 – 8x106 per Kg NCT00294112 
Osteogenesis imperfect 106 – 5x106 per Kg NCT00186914 
(Horwitz et al. 2002) 
Myocardial Infarction 0.5x106 – 5x106 NCT00114452 
(Hare et al. 2009) 
Graft versus host disease 2x106 – 9x106 per Kg (Ringden et al. 2006; 
Prasad et al. 2011) 
Multiple sclerosis ~2x106 per Kg8 NCT00395200, 
NCT02587715 
Liver cirrhosis 106 – 3x106 per Kg NCT02705742, 
NCT02652351 
Systemic lupus 
erythematosus 
106 – 5x106 NCT02633163 
Ulcerative Colitis 3x108  - 7.5x108  
Rheumatoid arthritis 2x107 NCT02643823 
Cartilage defects 2.5x106 per cm2 NCT01626677 
Parkinson’s Disease 106 – 107 per Kg NCT02611167 
CAR-T 
cell 
therapies 
Acute lymphoblastic 
leukemia (ALL) 
1.4x106 – 1.2x107per 
Kg 
(Grupp et al. 2013) 
NCT02614066 
Chronic lymphocytic 
leukemia (CLL) 
1.5x105 per Kg (Porter et al. 2011) 
Lymphoma 2x106 – 2x107 per Kg NCT02348216, 
NCT01840566 
Glioma  NCT01454596 
Head and neck cancer 107 - 109 NCT01818323 
(van Schalkwyk, Papa, 
Jeannon, Guerrero 
Urbano, et al. 2013) 
Neuroblastoma 5x105 – 107 per Kg NCT02311621 
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107 – 2x108 NCT01822652 
Metastatic pancreatic 
cancer 
108 – 3x108 per m2 NCT01897415 
 Metastatic melanoma 109 NCT00910650 
 Prostate cancer 3x107 – 1x108 per Kg NCT01140373 
Note: “NCT” numbers (i.e. NCTxxxxxxxx) provided are the ClinicalTrials.gov registry number for a given study. 
ClinicalTrials.gov is maintained by the United States FDA and National Institute of Health (NIH) 
 
1.2.1 Human pluripotent stem cells and their clinical applications 
Pluripotent stem cells (PSCs) have the capacity to differentiate into all mature cell 
types. This makes hPSCs, which consist of human embryonic stem cells (hESCs) 
and human induced pluripotent stem cells (hiPSCs), attractive candidates for use as 
cell therapies (Takahashi et al. 2007; Robinton and Daley 2012). hESCs are derived 
and isolated from the inner cell mass of the human blastocyst. hiPSCs are derived 
from somatic cell lines (usually blood or skin cells) by a process called 
reprogramming, which involves the forced expression of one or more of the 
Yamanaka factors to drive differentiated cells to a state of pluripotency.  
hPSC-derived cell therapies currently under development consist primarily of retinal 
progenitor cells  and pancreatic β-cells derived from hESCs (Idelson et al. 2009; 
Schulz et al. 2012; Sivertsson et al. 2012). Promising results have also been observed 
for cell therapies derived from hiPSCs, such as retinal pigment epithelial (RPE) cells 
for macular degeneration (Schwartz et al. 2012; Carr et al. 2013; Nazari et al. 2015) 
(Table 1.1). hPSC-derived cardiomyocytes are also being explored for their potential 
in the treatment of heart failure, although no product has yet been entered into clinical 
trials (Zweigerdt 2007; Masuda and Shimizu 2016; Tzatzalos et al. 2016).  
1.2.2 Human pluripotent stem cell-derived products as clinical research tools 
Beyond there applications as potential cell therapies, there is a more immediate use 
of a variety of cell lineages such as neurons, cardiomyocytes, and hepatocytes 
derived from hiPSCs as research and diagnostic tools (Brock et al. 2012). hPSCs 
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offer a unique platform by which to augment, and even redefine, current drug 
discovery and drug screening programmes by the provision of a human in vitro tool 
with which to perform efficacy and toxicity screens for novel chemical entities (NCEs) 
(Ebert and Svendsen 2010; Grskovic et al. 2011).  hiPSCs in particular might provide 
a diagnostic tool capable of lowering the high late-phase failure rate of NCEs in 
clinical trials (Zeevi-Levin et al. 2012; Hochedlinger 2013). hiPSCs could also pave 
the way for personalised medicine through the medium of responder versus non-
responder “trial in a dish” models (Kiskinis and Eggan 2010). Finally, hiPSCs could 
provide a valuable tool with which to carry out mechanistic modelling of disease 
pathogenesis for poorly understood disorders such as Alzheimer’s or Parkinson’s 
disease (Soldner et al. 2009; Nguyen et al. 2016; Táncos et al. 2016). Universal 
hPSCs for use as research tools are available as commercial products, and are 
currently marketed at $2000-$3000/vial (Rajamohan et al. 2013). 
Current drug screening platforms, such as animal models, will continue to have an 
important role in the drug development pipeline. However, in some instances they 
prove to be of limited predictive value due to fundamental biochemical, physiological 
and genomic variations from humans. The cost of taking a new drug to market is 
currently estimated to be US$1.2bn - US$1.7bn (Ebert and Svendsen 2010; Kiskinis 
and Eggan 2010; Scott et al. 2013). This, when juxtaposed with an attrition rate that 
rises above 90%, has caused drug developers to display caution when committing 
candidate therapies to clinical trials (Zeevi-Levin et al. 2012; Engle and Vincent 2014; 
Hay et al. 2014).  
Patient-specific hiPSC-derived cells offer an additional branch of pre-clinical drug 
development programs in order to assess safety of NCEs, where the degree of 
efficacy of observed within a patient may depend upon a specific geno- or phenotype 
(Ko and Gelb 2014). Furthermore, the ability of patient-specific hiPSC-derived cells 
to model genetic and epigenetic variations of a broad spectrum population may also 
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augment Phase I/II clinical trials via the demonstration of a drug’s safety and efficacy 
within a target population in vitro (Engle and Vincent 2014). Thus, hiPSC-derived cells 
provide a platform upon which NCEs may be assayed for efficacy and toxicity which 
promises to be of better predictive value than current drug screening models. In this 
manner they offer a powerful medium via which the time, costs, and risks associated 
with committing a drug to clinical trials can be alleviated. 
1.2.3 Chimeric antigen receptor T-cells and their clinical applications 
CAR-T cell therapies are a form of adoptive T-cell transfer, which involves the 
isolation and infusion of T lymphocytes into a patient to treat diseases (Kalos and 
June 2013). Whilst adoptive T-cell transfer has been shown to be effective in the 
treatment of viral infections in transplant patients, CAR-T cells have emerged as a 
powerful tool in the field of oncology (Porter et al. 2011; Grupp et al. 2013). CAR-T 
cells represent the most advanced form of adoptive T-cell transfer, and are currently 
under investigation as a treatment for a range of cancers (Table 1.1). CAR-T cells are 
genetically modified in order to express recombinant antigen receptors that bind to 
tumour-specific antigens with unparalleled affinity (Levine 2015). In practice, this 
makes tumour cells ‘visible’ to a patient’s immune system (Lipowska-Bhalla et al. 
2012). Unprecedented success has been achieved in the treatment of late-stage 
cancers using CAR-T therapies, particularly leukemias, whereby complete remission 
has been observed in some patients (Brentjens et al. 2011; Kalos et al. 2011; Porter 
et al. 2011; Kochenderfer et al. 2012). 
1.3 Product development of cell therapies 
As with traditional pharmaceutical product development, the primary goal of cell 
therapy product development can be said to be to establish a bioprocess and product 
formulation to support the manufacture and delivery of a product whose critical quality 
attributes, which define its safety and efficacy, match those of the target product 
profile. In addition to this, the product must be delivered within the confines of 
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economic parameters that will determine its commercial success. Market size and 
share, reimbursement value, manufacturing costs and development costs must all be 
considered early on during product development to ensure the commercial success 
of a cell therapy.  
Despite the allocation of considerable resources and efforts by a number of different 
companies operating in the cell therapy sector, at the time of writing, few cell therapy 
products have achieved a market license in Europe and the USA (Table 1.2). This is 
a reflection of the complexity of cell therapy development and translation.  
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Table 1.2 – Cell therapies approved for marketing in Europe and the USAa 
Marketing 
area 
Product Description 
Target 
Indication 
Manufacturer 
 
USA 
Kymriah® Autologous CAR-
T cell therapy 
Acute 
lymphoblastic 
leukemia (ALL) 
Novartis 
Provenge® Autologous 
immunotherapy 
Graft versus 
host disease 
(GvHD 
Dendreon 
Corporation 
Carticel® Autologous 
cultured 
chondrocytes 
Cartilage repair Genzyme 
Gintuit® Allogeneic 
keratinocytes 
Ulcer and skin 
wound repair 
Organogenesis 
Laviv® Autologous 
fibroblasts 
Cosmetic anti- 
ageing skin 
product 
Fibrocell 
Technologies Inc. 
 
Europe 
Strimvelis® Autologous 
immunotherapy 
Severe 
combined 
immunodeficien
cy (SCID) 
GSK 
Chrondocelect® Autologous 
chondrocytes 
Cartilage repair TIGenix 
MACI® Matrix-induced 
autologous 
chondrocyte 
implantation 
Cartilage repair Genzyme 
Spherox  Autologous 
chondrocyte 
spheroids 
Cartilage repair CO.DON AG 
Holocar® Autologous limbal 
stem cells 
Corneal injury 
repair 
Chiesi 
Farmaceutici 
aMinimally manipulated products such as blood products for homologous use have been 
excluded from this list 
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1.3.1 Clinical development pathway 
The clinical development pathway of cell therapies, including clinical trials, is intended 
to provide the basis by which a cell therapy product can be proven to be consistently 
safe and efficacious across its target market.  
Table 1.3 – Overview of current phased clinical trials; patient numbers, purpose 
and length of time  
 
Trial 
Phase 
Pre-clinical I II III 
IV (Post-
market) 
Number of 
patients 
Lab & 
Animal 
testing 
10-100 100-200 1,000+ N/A 
Purpose 
Assess 
safety and 
indication of 
efficacy 
Demonstrate 
safety and 
dosage 
Evaluate 
efficacy 
Long-term 
safety and 
efficacy 
across broad 
sample 
Monitor long-
term side-
effects 
Time (nr of 
years) 
1-5 1-2 1-3 1-5 Ongoing 
 
Clinical development of new medicines, be they novel chemical entities (NCEs), or 
cell therapies is a costly and time-consuming process. The cost to develop a new 
medicine can exceed US$1bn (Kola and Landis 2004). Equally, the time to market for 
early cell therapy products ranged from 13 to 20 years (Dodson and Levine 2015). 
Indeed, the current platform consisting of phased clinical trials, outlined in Table 1.3, 
is a significant challenge to cell therapy developers, which consist predominantly of 
non-commercial entities (academia and charities) and SMEs, most of whom will lack 
the financial resources and capacity to navigate the required regulatory procedures 
(Maciulaitis et al. 2012). Lengthy post-approval testing and monitoring is also likely to 
be required for many ATMPs, particularly those involving the use of PSC-derived 
products or gene modification (Mount et al. 2015).  
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Worldwide, regulatory bodies are taking measures to curtail the time and cost 
associated with clinical development of cell therapies, particularly those which target 
severe conditions for which curative treatments are not currently available. Japan’s 
Regenerative Medicine Act (RMA) enables a rapid (2-3 years) route to market for 
ATMPs (Fujita and Kawamoto 2016) with a conditional and time limited approval. Cell 
therapy products can obtain a time-limited market approval and reimbursement based 
on the results of a small scale (Phase I/II) clinical trial to establish safety and an 
indication of efficacy. Further data on long-term safety and efficacy collected during 
the initial marketing period (up to 7 years) can then be used to support an application 
for full market approval (Fujita and Kawamoto 2016). HeartSheet (Terumo, Tokyo, 
Japan), an autologous skeletal myoblast sheet, is the first product to gain market 
authorisation through the RMA regulatory route. Key differences between the 
regulatory pathways in the RMA and the current phased trials paradigm are 
highlighted in Figure 1.1. 
The FDA’s breakthrough therapy designation is designed to expedite drug 
development for therapies which demonstrate significant improvements on existing 
medicines for serious conditions. Breakthrough designation permits an accelerated 
development path, whereby a therapy maybe entered into a pivotal (Phase II/III 
equivalent) study following a successful Phase I trial (Sherman et al. 2013). To 
alleviate the development burden for novel therapies which target an unmet clinical 
need, the European Medicines Agency (EMA) have trialled staggered market 
approval, beginning with a restricted patient population whilst the risk-benefit balance 
of a product can be established (Eichler et al. 2012). Similar to Japan’s RMA, the 
EMA adaptive pathways scheme will allow use of a therapy with restricted market 
access to supplement early-phase clinical trial development in order to pave the way 
for full market approval. 18 medicines were selected for use in an EMA pilot project 
to test the adaptive pathways scheme between 2014 and 2016  (EMA 2016). 
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Figure 1.1 The novel regulatory pathway for translation of certain regenerative 
medicine products, as outlined in Japan’s Regenerative Medicine Act (RMA). Figure 
adapted from Fujita and Kawamoto (Fujita and Kawamoto 2016). 
All of the novel regulatory pathways above acknowledge a key caveat to drug (or in 
this instance, cell therapy) development; namely, that not all products granted these 
expedited market pathways will in fact fulfil the potential suggested by their pre-clinical 
and early clinical data. Therefore, updated approval pathways do not grant long-term, 
unrestricted market authorisation for ATMPs. Rather, they offer the opportunity to 
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monitor the safety and efficacy of ATMPs during a limited period of conditional 
approval, before a product may be submitted for full marketing authorisation.  
A clearer route to market is beginning to emerge for ATMPs. This is a reflection of the 
acknowledgement of regulatory bodies that current, binary, regulatory pathways are 
unlikely to prove appropriate for novel therapies under development. Whilst this may 
be the case, it is still vital that developers of ATMP products identify critical quality 
attributes, and appropriate assays by which these can be measured, as early as 
possible following conception of a product. This will ensure that product quality can 
be assured prior to first-in-man trials, and lay the foundations for clinical translation.   
1.3.2 Process development and manufacturing of cell therapies 
Cell therapies are highly complex products. Thus, it is important to develop a robust 
manufacturing process that is conducive to the production of a safe and efficacious 
therapy. When examining process options for cell therapy manufacture, it is important 
to consider not only the operational performance but also the consequences on the 
economics, quality, regulatory compliance, safety, and flexibility. These key 
considerations are summarised in Table 1.4.  
Guidelines and regulations concerning the production of cell therapies are known as 
current Good Manufacturing Practice (cGMP), and all aspects of a manufacturing 
process must be compliant with this set of regulations. Equally important to cell 
therapy production are current Good Tissue Practice (cGTP) guidelines, which 
govern the handling of tissue acquisition which acts as the starting material for cell 
therapy bioprocesses (Palau and Van Deusen 2016). The underlying concept of 
cGMP and cGTP regulation is to ensure reproducibility of product quality as a result 
of a comprehensively designed and robust bioprocess and tissue acquisition protocol 
(Römhild 2016). 
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In early phase clinical trials, risk of failure is high and developers of ATMPs have 
understandably strived to keep development costs low at this point of the translation 
cycle. It has been acknowledged that there has been a lack of investment with regards 
to developing a scalable and cost-effective manufacturing strategy, characterised by 
the ‘fail quickly, fail cheaply’ business model employed by many in the industry (Shaw 
et al. 2014; Mount et al. 2015). A key challenge in the development of ATMPs, and 
even in more established sectors such as antibody-based therapies, is the fact that 
product quality (including safety and efficacy) must be established by the end of 
Phase I trials. However, efforts to realise a scalable cost-effective process which can 
offer business sustainability, often occur far later than this (Farid et al. 2000; Shaw et 
al. 2014) 
In the cell therapy industry, where there is significant heterogeneity in process design, 
even for products of the same nature, translation of these bench-top processes to 
standardised commercial manufacturing strategies has proven a significant 
challenge. One contributing factor to this is that, unlike traditional pharmaceutical 
products, it is challenging to characterise and prove the therapeutic equivalence of a 
population of cells (Caplan et al. 2016). 
Delaying investment in process development may therefore cause substantial 
comparability-related risks for a product in the latter stages of the clinical translation 
cycle. Scale-up and adaptation of an early process design to one that will satisfy the 
demands of late-phase trials and commercial manufacturing may necessitate time-
consuming and costly bridging studies before clinical development of a product can 
continue. Not only does this require significant financial resources, but it can add 
significantly to the time-to-market of a cell therapy product. This could be particularly 
damaging to the sustainability of both an ATMP as a commercial product, and to the 
organisation developing such a product. 
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Table 1.4 – Bioprocess development considerations for cell therapy products 
 
Criteria Example 
Operational Performance 
Expansion yields (harvest densities) 
Expansion folds  
Differentiation efficiencies 
Downstream process (DSP) yields 
Purity 
Resource utilization 
Scalability 
Lot processing time 
Economic 
Capital investment 
Cost of goods (materials, labour, quality 
control, indirect) 
Economies of scale - scale-up versus scale-out 
Fresh versus frozen product transportation and 
storage 
Process development costs 
Supply chain replenishment 
Product shelf-life 
Reimbursement value 
Quality Control & Regulatory 
Compliance 
cGMP and cGTP standards 
Process robustness and reproducibility 
Process validation, acceptable ranges of 
operation 
Product characterisation 
Quality, consistency and source of raw 
materials 
Automated versus manual processing 
Safety 
Contamination and containment 
Live human tissue handling  
Patient safety - side-effects, risk of tumour 
formation 
Flexibility 
Process changes 
Manufacturing demand changes 
Process bottlenecks 
Process scalability 
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The development of a scalable, robust, and cost-effective manufacturing process is 
a vital part of the development of a cell therapy, and should be considered as early 
as possible. Whilst the costs of cell therapy manufacture (and the price to the end 
user) are likely to remain high due to their complexity, market competition may 
eventually force reductions in selling prices (Caplan et al. 2016). The development of 
cost-effective manufacturing processes is therefore likely to be an important factor in 
determining a cell therapy’s commercial success in such an environment. 
Optimisation of the manufacturing process, alongside consideration of manufacturing 
costs, early on during product development may help to reduce the time and cost 
associated with product development in the long-term, as well as increasing the 
likelihood of achieving a robust, scalable and cost-effective cell therapy bioprocess 
design (Shaw et al. 2014; Dodson and Levine 2015; Mount et al. 2015; Hassan et al. 
2016).  
1.3.3 Challenges constraining cell therapy commercialisation 
Safety concerns  
There are a variety of safety concerns associated with cell therapies. This is not to 
say that factors affecting the safety of cell therapies cannot be controlled and the risk 
to patients cannot be reduced to similar levels associated with biopharmaceutical 
products. However, risks are inevitable when the complexity of cell therapy products 
is fully considered. Unlike pharmaceutical drugs, which are naturally metabolised by 
the body, populations of therapeutic cells are likely to be incorporated into living tissue 
and survive in the body for an extended period of time (Caplan et al. 2016). Caution 
is required from a regulatory perspective in order to fully understand what effects cell 
therapies cause within the body, and the mechanisms by which these occur. Mount 
et al. (2015), define the three main safety concerns associated with cell therapies as 
tumorigenicity, immunogenicity and complications arising from the method of 
implantation of cells.  
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The risk of tumorigenecity in hPSC-derived therapies is high. This owes itself to the 
potential for teratoma formation as a result of the presence of undifferentiated cells 
(Brederlau et al. 2006). It is important that undifferentiated PSCs are removed from 
the process stream in order to mitigate such risks. Extensive assays have been 
developed in order to screen for the risk of tumorigenicity in PSC-derived products, 
which must be carefully monitored throughout the clinical development process 
(Kawamata et al. 2015) 
Genetically engineered cell therapies, including CAR-T cells and iPSC-derived 
therapies, are also at risk of tumorigenicity (Herberts et al. 2011). However, 
improvements in viral vectors and scientific understanding related to genetic 
modifications of human cells have alleviated concerns related to insertional 
mutagenesis though the activation and suppression of genes (Mount et al. 2015) 
Immunogenic responses are a risk in many allogeneic, or universal, cell therapies, 
where conditions such as graft versus host disease (GvHD) can result from cell 
therapy transplantation (Yang et al. 2015). Furthermore, CAR-T cell therapies, which 
harness the immune response to treat target indications, have been shown to cause 
immunogenic reactions within the body. Silencing of genes that induce the expression 
of T-cell receptors (TCRs) can prevent alloreactivity of transplants that is associated 
with the use of allogeneic CAR-T cell therapies (Valton et al. 2015).  
Generally, PSC-derived and many MSC-based therapies are not thought to be at 
great risk of immunogenicity, although this is likely to depend on dose size, repetition 
of doses and site of administration (Li et al. 2004; Drukker et al. 2006; Nasef et al. 
2008; Mount et al. 2015). Immunogenicity may not be a risk to patients if cells are 
administered to an immune-privileged site. This is thought to be the case with 
therapies which target age-related macular degeneration (AMD) and retinal pigment 
cell (RPC)-related disorders (Carr et al. 2013; Nazari et al. 2015). However, ocular 
immune privilege is not absolute, and its mechanims are not fully understood (Zhou 
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and Caspi 2010 – article 1); researchers should be therefore be cautious in assuming 
ocular immune privlege when considered human trials for cell therapies. 
Tissue-engineered products, consisting of complex three dimensional structures, will 
likely require complex surgical procedures in order to implant a therapy into patients 
(Fabre et al. 2016; Feric and Radisic 2016). As with all surgical procedures, the risk-
to-benefit ratio in this instance must be carefully weighed up by the medical 
practitioner responsible for a patient. 
Reimbursement 
Cell therapies are expensive to manufacture (Simaria et al. 2014; Hassan et al. 2015; 
Weil et al. 2017), and expensive to develop (Want et al. 2012; Mount et al. 2015; 
Caplan et al. 2016; Hassan et al. 2016). Whilst factors such as market competition, 
increased potency, and economies of scale associated with commercial manufacture 
of cell therapies will affect the cost of manufacturing, cell therapies are likely to 
command a high price tag in order to generate profits for their companies (Caplan et 
al. 2016). A balance between what manufacturers consider a fair price, and what 
healthcare providers are willing to, or can afford to, pay for ATMPs must be reached 
in order for successful cell therapy commercialisation. 
There are a variety of factors that affect the reimbursement value of a cell therapy. 
Health Technology Assessments (HTAs) are employed to assess the cost-benefit 
ratio of new medicines. In the United Kingdom, the National Institute for Health Care 
and Excellence (NICE) has explicit cost-effectiveness controls in place that determine 
whether or not new medicines a for use by the National Health Service (NHS). NICE 
uses quality-adjusted life-years (QALYs) to assess the impacts of a treatment on the 
quality and longevity of a patient’s life (Mahalatchimy 2016). Currently a cost of 
£30,000 is set as the upper benchmark per QALY for novel treatments.  
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Most HTA bodies, particularly across Europe, use the comparative clinical efficacy of 
a novel therapy against current comparators to assess its value (Jørgensen and 
Kefalas 2015). Therefore cell therapies are most likely to achieve their target selling 
price if they target indications with unmet clinical needs (Mount et al. 2015). This could 
include conditions for which no treatment exists (e.g. dry age-related macular 
degeneration (AMD) or where palliative care is available but no curative treatment is 
currently available (e.g. certain cancers and diabetes).  
The clinical data to provide head-to-head comparisons that shape HTAs can be 
difficult to obtain for cell therapies, due to some of the clinical development challenges 
discussed in Section 1.3.1 and a shortage of access to patients. In order to combat 
uncertainty over the comparative performance of expensive ATMPs, pricing of such 
products is increasingly built on risk-sharing agreements (RSAs). RSAs allow a 
reduction in the reimbursement value received by a cell therapy manufacturer if the 
performance of a therapy does not meet expectations (Jorgenson and Kefalas 2015). 
Walker & Johnson (Walker and Johnson 2016) predict that the QALY system would 
allow a price of ~US$120,000 – US$240,000 for a CAR-T cell therapy that would 
induce long-term remission in a patient for 5-10 years. However, a recent NICE report 
judged that CAR-T medications could be worth up to US$649,000 assuming patients 
gain 10 QALYs compared to current standard of care treatments (Hettle et al. 2017). 
In Japan, both HeartSheet (Terumo), and Prochymal (JCR Pharmaceuticals Co., 
Hyogo, Japan) for the treatment of heart failure and GvHD respectively, have been 
priced between US$100,000 and US$150,000 dollars. Furthermore, Glybera, a gene 
therapy for the treatment of lipoprotein lipase deficiency was recently priced at 
US$1.4 million in Germany; the highest price medicine in existence for a rare disease 
(Yla-Herttuala 2015). Equally, Kymirah (Novartis, Switzerland) and Yescart (Gilead, 
CA, USA) have been priced at US$475,000 and US$373,000 respectively in the USA. 
These values indicate that healthcare providers and insurers are willing to pay the 
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high prices associated with cell and gene therapies providing they can offer unrivalled 
patient benefits. However, as more ATMPs that target the same indication reach the 
market, innovations that allow for either more efficient production of a therapy or 
incremental therapeutic benefits are likely to be required to drive down the cost-
benefit ratio versus comparator products, rather than the novelty of the therapy itself 
(Mount et al. 2015; Caplan et al. 2016) 
Capability and capacity for large scale production of cell therapies 
Dose sizes reported for cell therapy products currently range from 5 x 104 cells for 
indications such as macular degeneration to 109 cells for some cancers and treatment 
of conditions such as myocardial infarction and liver disease (Mason and Dunnill 
2009; van Schalkwyk, Papa, Jeannon, Urbano, et al. 2013; Simaria et al. 2014). 
Reproducible and robust cell therapy bioprocesses are required to secure a 
sustainable commercial future for cell therapies. Traditional, planar tissue-culture 
technologies such as T-flasks (both single and multi-layer) may struggle to satisfy this 
global demand for cell therapies, particularly those which require large dose sizes 
(Want et al. 2012; Simaria et al. 2014). Platforms that rely on manual operation also 
increase the risk of batch failure due to human error or a lack of reproducibility. 
Several novel platforms that offer scale-up solutions for cell therapy manufacturing 
have recently been developed. These include automated planar bioreactors for 
adherent cell culture (Collignon 2012), microcarrier-based culture of adherent cells in 
single-used bioreactors (Bardy et al. 2012), rocking motion bioreactors for single-cell 
suspension cultures (GE Healthcare [no date]), and gas permeable vessels for 
suspension culture of cells at high densities (Vera et al. 2010). 
Further to issues related to scale-up of human cell culture, there has not been a great 
deal of focus on harvest strategies following large scale culture of therapeutic cells 
(Chen et al. 2013). Translation of bench scale cell therapy culture unit operations to 
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commercial bioprocesses will be dependent on the consideration of how to detach, 
or collect cells from culture vessels and to reduce the media volume in advance of 
any DSP operations in a timely manner.  
The success of many cell therapies is also dependent on the enrichment, or 
purification of therapeutic cells at high yields, so as to reduce the burden on USP 
operations such as cell culture, or differentiation stages of the bioprocesses. The 
development of efficient, scalable and cost-effective purification processes is one the 
major challenges facing the commercialisation and licensing of many hPSC-derived 
cell therapies (Weil and Veraitch 2013). 
Any operation involving the transfer of cells from one piece of manufacturing 
equipment to another, where cells are exposed to the open environment, necessitates 
the need for expensive cleanrooms and risks contamination of process materials. 
Considerable emphasis has been placed on the need for contained processing of cell 
therapy products, which will ease the burden of cleanroom costs as well as alleviating 
the risks associated with ‘open’ manufacturing. Process platforms offering the 
potential for automated and contained bioprocessing include the CompacT SelecT 
(Sartorius Stedim, Gottingen, Germany), integrated process platforms such as the 
Prodigy (Miltenyi, Bergisch, Germany) and Cocoon (Octane, Ontario, Canada).   
Current approaches to the manufacture of cell therapies and technological 
innovations to aid cell therapy bioprocessing are reviewed in detail in Chapter 2.  
1.4 Cell Therapy Bioprocess Economics 
Owing to growing reimbursement pressures associated with novel therapies, it is 
important to not only accurately estimate manufacturing costs for stem cell and cell 
therapy products, but also identify methods by which these can be reduced. This 
section discusses factors that influence two key cost metrics; fixed capital investment 
(FCI) and cost of goods (COG).  
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1.4.1 Capital investment 
FCI represents the cost to build a manufacturing facility ready for start-up. It includes 
the cost of the building with the fixed (non-disposable) equipment, piping, 
instrumentation and utilities installed. Estimates of facility costs are often made using 
factorial estimates. These are well-established for traditional stainless steel 
biopharmaceutical facilities using the Lang Factor method (Lang 1948), which 
involves multiplying the total equipment purchase cost by the “Lang Factor”. At 
present, there are no published studies that have determined an appropriate factorial 
method for cell therapy manufacturing facilities. The Lang Factor is usually derived 
based on the analysis of costs of previous projects; as yet very few FCI benchmarks 
have been published for stem cell manufacturing facilities. Investment costs for stem 
cell facilities will also be influenced by the degree of open versus closed processing 
and the consequences on the cleanroom classification required and whether 
automated or manual process techniques are employed. Stem cell bioprocessing is 
also dependent on disposable or single-use process platforms such as T-flasks, 
CellStacks and single-use bioreactors (SUBs). To this end, a Lang Factor method 
adapted for disposable-based biopharmaceutical facilities has previously been used 
to approximate the FCI associated with stem cell manufacturing (Pollock et al. 2013). 
Ongoing work at University College London is focused on developing a Lang Factor-
style method which more accurately describes the FCI required for a cell therapy 
manufacturing facility. 
1.4.2 Cost of goods 
COG represents the cost to manufacture a cell therapy product and comprises direct 
(e.g. materials) and indirect (e.g. maintenance) costs. Direct costs are a function of 
utilisation and vary according to the scale and demand of a given bioprocess. Indirect 
costs include costs that are independent of resource utilisation and include 
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expenditures such as facility overheads and depreciation that are often estimated in 
proportion to the FCI.  
Economies of scale are a relevant factor affecting COG for all bioprocesses, including 
those designed for the manufacture of cell therapy products, as demand and lot size 
are varied as well as dose for cell therapies and required cell population sizes for cells 
as drug screening tools. Outputs of COG calculations are usually expressed as COG 
per cell population for screening tools or COG per dose for therapeutic applications. 
1.4.3 Process economic drivers 
In order to achieve cost-effective bioprocesses for the manufacture of cell therapies, 
efforts need to focus on increasing the overall productivity and/or decreasing the 
overall production costs. Hence, critical process economic drivers for cell therapy 
processes can include an array of different parameters such as expansion and 
differentiation yields, target cell recovery during purification, and the cost of resources 
such as media and labour. Chapter 2 seeks to give an overview of advances made 
with regards to the performance of key unit operations in cell therapy bioprocesses, 
and the platforms that might support commercial-scale production of cell therapy 
products. 
1.4.4 Project valuation 
Decisions pertaining to bioprocess design will inevitably impact upon bioprocess 
economic metrics such as COG and FCI. These metrics can be used to feed into 
project valuation models in order to compare different projects proposed to solve a 
similar problem. One measure of the value of a project is the discounted cash flow, 
which is used to calculate a project’s net present value (NPV) (Novais et al. 2001). 
Whilst many factors contribute to decisions regarding the feasibility and potential 
value of a project, those with a greater NPV are generally seen as a favourable 
proposition.  
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1.5 Decision-support tools and bioprocess modelling 
In any bioprocess, it is important to determine a cost-effective, robust manufacturing 
process early on during product development. Changes to a manufacturing process 
once a product has entered clinical trials can result in the need for bridging studies, 
affecting both the monetary cost of product development and the time taken to get a 
product to market (Farid et al. 2000).  
Decision-support software capable of the evaluation of different bioprocess strategies 
and designs can greatly improve the design of cost-effective, robust bioprocesses. 
Furthermore, in silico assessments of the operational and economic feasibility of 
bioprocess designs allow effective decisions to be made with regards to bioprocess 
design prior to committing a product to clinical trials. This can save cell therapy 
manufacturers both time and money during product development. 
1.5.1 Applications of decisional tools 
To date, much of the research into process simulation models and decisional tools in 
the biotechnology arena has been associated with the biopharmaceutical protein 
sector. Process simulation can be applied to a variety of bioprocessing scenarios. 
Thus far, applications have varied from equipment selection for a manufacturing 
process designed to produce material for clinical trials (Suzanne S. Farid et al. 2005), 
to evaluation of full-scale manufacturing flowsheets (Lim et al. 2006), and the 
appraisal of potential post-validation changes to bioprocesses (Chhatre et al. 2007). 
The identification of key process economic drivers associated with different 
bioprocesses may also highlight areas where process optimisation efforts should be 
focused for maximum effect (Farid 2009). 
Decisional tools investigating process feasibility are able to select optimal processes 
based not only on throughput but also based on multiple criteria (including operational 
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and environmental process attributes) (Suzanne S. Farid et al. 2005; Pollock et al. 
2013). 
Uncertainty is inherent within the field of bioprocessing. Contamination risks, 
variability in process yields and equipment failure can all impact on manufacturing 
costs associated with a cell therapy. Stochastic modelling, such as Monte Carlo 
simulations, of bioprocesses has allowed evaluation of biopharmaceutical production 
processes under manufacturing uncertainty (Suzanne S. Farid et al. 2005; Lim et al. 
2006; Stonier et al. 2012; Pollock et al. 2013). Stochastic modelling produces a 
significantly larger amount of data than deterministic modelling as thousands of 
simulations must be evaluated in order to gauge the risks associated with a given 
solution to a bioprocess design problem (Stonier 2013).  
Decisional tools have been shown to be of great value in the biopharmaceutical 
industry; aside from the more general applications mentioned above, exploration of 
topical process design scenarios via individual case studies have highlighted how 
they can be used to contibute to the the bioprocess industry.  
Decisional tools have been used to illustrate bioprocesses can be designed to cope 
with ongoing technological advances (in both processing equipment and in molecular 
biotechnology resulting in increased target product titers) (Farid 2001; Novais et al. 
2001; Stonier et al. 2012; Pollock et al. 2013). Decisional tools provided detailed COG 
analyses where potentially hidden costs of ancillary tasks (e.g. buffer and media 
preparation and storage) and their impact on overall manufacturing costs were 
considered for the first time (Farid 2009). The importance of this was demonstrated 
by Sinclair and Monge (2002) who provided a detailed study of the effect of the use 
of disposable technologies for buffer preparation and storage on overall COG. 
Early examples of decisional tools within the bioprocessing sector focused on how 
the use of disposable processing equipment might impact upon manufacturing COG 
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and FCI (Farid et al. 2000; Novais et al. 2001; Sinclair and Monge 2002). In the case 
of Farid (2000) and Novais et al. (2001), NPV calculations were provided in order to 
demonstrate the feasibilty of disposable based bioprocesses within the 
biopharmaceutical sector.  
Further applications of decisional tools have seeen them applied to DSP or 
purificaiton design problems as a result of advances in biotechnology associated with 
mAb expression systems, which saw achievable cell culture titers for therapeutic 
antibodies increase drastically (Stoner et al. 2012). The identification of DSP 
production bottlenecks that would liklely result from increased cell culture yields was 
one area where decisional tools were able to demonstrate their applicability to 
industrial process design problems. Furthermore, decisional tools have been shown 
to be adept platofrms for the exploration of purification strategies and column sizing 
that could help alleviate such issues whilst taking into account the impact of such 
strategies on manufacturing COG (Stonier et al. 2012; Allmendinger et al. 2016). The 
Stonier et al. (2012) study also highlighted the manner in which decisional tools could 
be used to highlight issues and solutions that go beyond those which may perhaps 
be considered intuitive to bioprocess experts; buffer storage limitations were shown 
to be a limiting factor in the potentially capacity of legacy bioprocess facilities. Stonier 
et al. (2012) demonstrated that the development of purificaiton platforms resulting in 
a reduction of buffer consumption may be a potential solution to this problem.  
Pollock et al. (2013) demonstrate the value of decisional tools in assessing the 
economic viability of novel technologies. Traditional fed-batch cell culture strategies 
were compared to first-generation and emermging pefusion culture platofrms; next 
generation perfusion cell culture platofrms were shown to be singificantly more cost-
effective than fed-batch methods. This case study shows how decisional tools can be 
used to explore the use of new technologies and their effect on manufacturing COG 
in silico in order to demonstrate their feasilibility.  
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Taking the examples above, it is evident that decisional tools have a place in aiding 
cost-effective bioprocess design, but can also be used to explore future proofing 
strategeis of legacy facilities by exploring the use of novel manufacturing strategies 
and technologies in silico in order to evaluate their impact on facility design, 
manufacturing cost of goods and a variety of resource requirements (Farid et al 2000; 
Stonier et al. 2012). 
1.5.2 Decision-support tools and their applications in the cell therapy sector 
As a relatively nascent field, the cell therapy sector is challenged by a lack of 
consensus as to the optimal bioprocess strategy and design for many products. Cell 
therapy products are likely to experience manufacturing cost of goods that are larger 
than those associated with conventional pharma products (Prescott 2011). As such, 
prudent and swift bioprocess design is required in this sector. As has been shown by 
their application to bioprocessing of biopharmaceutical products, decisional tools can 
help promote effective decision-making with regards to cell therapy bioprocessing. 
At the time of writing, a small, but growing collection of studies investigating the 
applicability of decision-support tools to cell therapy bioprocessing is in existence. 
Commercially available flowsheeting software packages have been employed to cost 
stem cell process designs at fixed scales (Darkins and Mandenius 2013). Simaria et 
al. (2014) and Hassan et al. (2015) present the development and application of 
decisional tools that integrate models for mass balancing, equipment sizing, and 
bioprocess economics with optimization algorithms for allogeneic MSC production. 
The tools were used to predict the most cost-effective upstream and downstream 
technologies for commercial MSC manufacture across a range of different scales and 
doses. The analyses presented in these works illustrate how such tools can be used 
to determine the scale at which planar technologies cease to be cost-effective in 
contrast to microcarrier-based SUBs, when downstream processing bottlenecks 
occur, as well as future required performance capabilities of promising technologies 
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to close existing technology gaps and meet COG targets. Project valuation tools have 
been developed to assess the impact of process changes throughout the clinical 
development pathway of an allogeneic hMSC therapy (Hassan et al. 2016). 
Furthermore, the studies above summarise the key factors that influence COG values 
for stem cell products; these include process efficiencies, technology choices and the 
resources required and unit costs based upon these choices (Simaria et al. 2014; 
Hassan et al. 2015; Hassan et al. 2016). It can therefore be said that the application 
of decisional tools in the cell therapy sector thus far has been not only to demonstrate 
the optimal process technology choices from a cost-perspective in a given scenario; 
but also to demonstrate limitations in existing technologies for cell and gene therapy 
bioprocesses in order to highlight the need for scalable, cost-effective technologies 
(Simaria et al. 2014; Hassan et al. 2015; Hassan et al. 2016; Weil et al. 2017). Use 
of decisional tools for such scenario analyses and gap analyses may eventually help 
shape TPPs for future process platforms in order that they allow manufactruing within 
a target COG threshold.  
1.5.3 Limitation and Decisional Tools 
The evidence and research reviewed up to this point in this section demonstrates the 
value of decisional tools; indeed this thesis aims to further demonstrate the 
applicabiltiy of such tools to the cell therapy sector (this is expanded in Section 1.6).  
Whilst there is a strong case to be made for the use of decisional tools within the 
biorpcoess industry, there are certain challenges and limitations to their use. One 
such limitation is the fact that decisional tools require a great deal of time and effort 
to produce, which may discourage their use in indutrial settings. General purpose 
software, which can be used for many different types of process are challegning to 
develop may help with this. A commercially available software, BioSolve (BioPharm 
Services, Buckinghamshire, UK) is available for bopharmaceutical process design, 
and can be tailored to individual processes to a certain extent. However many 
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bioprocesses particiularly those for cell and gene therapy prodcuts require specific 
processes that general use software may struggle to capture in a necessary amount 
of detail. The devleopment of decisional tools therefore requires considerable time 
and effort in order that an appropriate level of proess specific detail be captured. This 
is evident in case studies of decisional tools published for cell and gene therapies to 
date, whereby process designs for MSCs have been explored (Simaria et al. 2014; 
Hassan et al. 2015; Hassan et al 2016). General purpose tools, may fail to accurately 
capture all resources required as part of a bioprocess, thus limiting the value of the 
tool itself. 
A further limitation of decisional tools in the bioprocess sector is the fact that, whilst 
uncertainty can be accounted for using methods such as the Monte Carlo simulaiton 
method, they do rely on in silico  analysis; translation of the findings of a tool into 
practice is not always a trivial act. For example, bioprocess design choices have 
sometimes been based upon company know-how and experience in th mAb sector 
(Pollock et al. 2013). The qualitative aspects of receptiveness to, and effort required 
to make, process design changes that a decisonal tool may suggest are cost-effective 
are somewhat harder to accurately quantify using decisional tools.  
Finally, whilst rigour has undoubtedly been at the heart of research into decisional 
tools to date, it is impossible to be 100% accurate in the estimation of resource 
requirements. Generally a 10% margin of error is taken as read when analysing the 
results of decisional tools, which can sometimes make it difficut to distinguish 
between closely matched solutions to process design problems (Farid 2002).  
Despite their limitations, decisional tools have played a prominent and positive role in 
helping to shape bioprocess design considerations in the biophmarmaceuitacal 
sector to date. Furthermore, they are beginning to emerge asa powerful platform upon 
which to analyse and evaluate cell and gene therapy manufactruing strategeis and 
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process design. As outlined in Section 1.6, this thesis aims to further explore their 
applicability in this sector. 
1.6 Thesis aims and objectives 
This chapter has sought to provide an overview of cell therapies and highlight key 
issues related to their development and manufacturing. Furthermore, the applications 
of process simulation and decisional tools to the field of cell therapy and the broader 
bioprocess sector have been detailed.  
A literature review has revealed that at present there are few existing studies, or tools, 
which allow the evaluation of bioprocess designs and manufacturing strategies for 
cell therapies. Those that do exist focus on adult cell types, such as MSCs (Simaria 
et al. 2014; Hassan et al. 2015; Hassan et al. 2016). No such studies were found to 
exist for hPSC-derived cell therapies, or those which involve ex vivo genetic 
modification, such as CAR-T cell therapies.  
The aim of this thesis was to investigate the applicability of decisional tools, which 
capture both technical and business perspectives of cell therapy manufacturing, to 
advanced cell therapy bioprocess design. It is hypothesised that this approach is likely 
to facilitate informed decision-making with regards to bioprocess design during the 
early phases of product development. To this end, a series of case studies was 
carried out, whereby decisional tools developed as part of this thesis were used to 
analyse bioprocess design for three independent cell therapy or stem-cell derived 
products. The remainder of this thesis is therefore formed of chapters which seek to 
investigate the applicability of decisional tools to the cell therapy industry.  
Chapter 2 examines current and future trends in cell therapy bioprocesses, and their 
applicability to large-scale commercial cell therapy production. An overview of cell 
therapy bioprocesses, and the unit operations contained therein, is provided. Analysis 
and appraisal of currently available bioprocess platforms is carried out, and this was 
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used as a basis to determine selection of technologies to be included in the decisional 
tools described in subsequent chapters. 
In Chapter 3, the materials and methods by which the work in this thesis was carried 
out are detailed. The core framework, or architecture, of the decisional tools 
developed is presented. Following this, the process models developed to capture 
different unit operations and bioprocess economic attributes of a given bioprocess 
are described. Finally, the computational methods by which optimal bioprocess 
designs and manufacturing strategies were identified are outlined, along with 
computational techniques used to deal with uncertainty in bioprocessing.  
In Chapter 4, a case study is presented whereby a decisional tool is applied to the 
production of patient-specific induced pluripotent stem cells, to provide a platform for 
drug screens probing the potential for stratified pain medication. A brute-force search 
algorithm was applied in order to provide a bioprocess economic comparison of 
automated vs. manual bioprocess platforms. The Monte Carlo simulation technique 
was applied in order to provide evaluation of bioprocess techniques under 
uncertainty. The processing of patient-specific hiPSC-derived cell lines for drug 
screening purposes (Chapter 4) was investigated because, at the time the work was 
carried out, this was perceived as a more immediate, tangible application of hiPSCs 
than cell therapies.  
Analysis of an hPSC-derived cell therapy bioprocess is provided in a case study 
detailed in Chapter 5. Different bioprocess strategies, including directed vs. 
spontaneous differentiation and microcarrier-based vs. planar-based cell culture, are 
evaluated for the production of a hESC-derived cell therapy. The evolutionary 
algorithm developed in order to identify the most cost-effective process flowsheet for 
each manufacturing strategy is the first of its kind to be applied to cell therapy process 
design. Stochastic modelling techniques were used to incorporate manufacturing 
uncertainties into the analysis. Finally, different business models with regards to the 
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production and distribution of a cell therapy product are explored from a quantitative 
and qualitative viewpoint. A decisional tool to evaluate different bioproess strategies 
for hESC-derived cell therapies was developed in order to build upon the work 
dscribed in Chapter 4, so as to demontrate the applicability of the approaches detailed 
in this thesis to allogeneic hPSC cell therapies. The type of cell therapy used to 
explore this approach, a patch of hESC-derived RPE cells for the treatment of age-
related macular degeneration, was an approach that had resulted in early success in 
first-in-man trials. This was therefore selected as the focus of the work in Chapter 5. 
Chapter 6 describes the application of a decisional tool to bioprocess design for an 
allogeneic CAR-T cell therapy. Different process flowsheets were evaluated from a 
bioprocess economic perspective. Sensitivity analyses were used to highlight key 
process economic drivers, and scenario analyses were used to highlight how future 
process improvements might impact upon COG as a percentage of target selling 
price. Multi-attribute decision making (MADM) analysis is used in order to highlight 
the benefits of accounting for operational, as well as financial, attributes in the 
evaluation of different bioprocess designs. In Chapter 6, the development and 
application of a decisional tool to investigate bioprocess economics associated with 
allogeneic CAR T-cell production was conducted in order to prove the applicability of 
such methods to the wider cell and gene thearpy industry. Whereas previous sections 
(Chapters 4 & 5) focus on hPSC-derived cells for a variety of applications, Chapter 6 
focuses on a gene therapy approach in order to demonstrate the versatility of 
decisional tools in the cell and gene therapy space. 
Chapter 7 provides a summary of the contributions of this work to the field and details 
proposals for future work. Appendix A presents a manuscript that describes an 
integrated experimental and economic approach to bioprocess design. This 
manuscript was co-authored with colleagues in the Department of Biochemical 
Engineering and has been submitted for publication in a peer-reviewed journal. 
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Academic papers published by the author through the course of this work are 
attached in Appendix B. Finally, Appendix C is used to highlight the importance of 
process validation, and how this might be achieved for a cell therapy bioprocess.  
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Chapter 2: Cell therapy bioprocessing 
Cell therapy bioprocesses are complex procedures. They often involve multiple unit 
operations and significant variations can be observed between the bioprocesses used 
to produce different types of cell therapies (e.g. allogeneic vs autologous and somatic 
cell types vs hPSCs).  
This chapter provides an overview of cell therapy bioprocesses, and the technologies 
that are used to support them. Section 2.1 outlines the typical differences in the 
manufacture of different types of cell therapies; autologous and allogeneic cell 
therapy production is discussed, as is the production of somatic cell and pluripotent 
stem cell therapies. Sections 2.2 through 2.5 discuss key unit operations associated 
with cell therapy production including cell culture (Section 2.2), differentiation (Section 
2.3), genetic modification (Section 2.4), and downstream processing operations 
(Section 2.5). In these sections current techniques and technologies are introduced 
and evaluated based on currently available literature. Novel techniques and future 
trends are also introduced. Section 2.6 outlines current efforts aimed at the creation 
of contained bioprocess platforms. Finally, manufacturing and distribution strategies 
are discussed in Section 2.7.  
2.1 Bioprocess flowsheet variations for different types of cell 
therapies 
Significant differences occur between commercial production techniques for different 
classifications of cell therapies. This section aims to introduce the strategies used to 
scale production for commercial purposes for both autologous and allogeneic cell 
therapies. Additionally, typical process flowsheets and the unit operations contained 
therein are introduced for both adult cell therapies (MSCs and CAR-T cell therapies) 
and hPSC-derived therapies. Key differences in the processes used to produce the 
above therapies are also detailed. 
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2.1.1. Autologous vs. allogeneic cell therapy bioprocess flowsheets 
Autologous cell therapies 
Autologous, or patient-specific, cell therapies are derived from a patient’s own biopsy. 
Cells are then processed according to the specific demands of the therapy, and 
returned to the patient, either surgically, or via an infusion. Autologous cell therapies 
can negate the risk of immunological responses as the therapeutic material is derived 
from the patient. However, there have been instances of immune responses to CAR-
T cell therapies where a patient’s cells have undergone significant modification as 
part of the production process (Tey 2014). Due to the fact that the patient’s own cells 
must be processed, autologous cell therapies are unsuitable for use as ‘off-the-shelf’, 
emergency products.  
Allogeneic cell therapies 
Allogeneic, or universal, cell therapies rely on a single source of cells to treat many 
patients. Cells are collected from a donor sample to create a master cell bank (MCB). 
The MCB is then used as the source to create cell populations that are processed 
according to the demands of the specific therapy. The final cell populations are then 
used to treat multiple patients. Allogeneic therapies are more adept at satisfying ‘off-
the-shelf’ supply models, where emergency treatment might be required. Allogeneic 
therapies increase the risk of eliciting an immune response within a patient, and 
immunosuppressive therapies are sometimes administered in combination with 
allogeneic products.  
Scale-up vs scale-out approaches 
Allogeneic bioprocess design can be approached using a scale-up methodology. This 
is a manufacturing approach analogous to that of the pharmaceutical industry, 
whereby many doses are produced per manufacturing lot. This approach allows 
economies of scale to be achieved that are beyond those of the scale-out approach 
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required of autologous cell therapy manufacture (Mason and Dunnill 2009). Due to 
the fact that many doses can be produced within the same manufacturing lot, 
allogeneic processes are not limited in the same capacity that autologous processes 
are; they are generally less labour-intensive and result in reduced capital investment 
per dose than autologous therapies. However, this is also dependent on the choice 
of technology and bioprocess strategy (see Sections 2.2 – 2.7).  
Some therapies, such as allogeneic CAR-T cell therapies may require a hybrid 
approach, whereby a bioprocess may be scaled-up to a certain point, before it is 
scaled out. This is due to limitations on the number of doses that can be produced 
from each donor sample. Allogeneic therapies benefit from having a fixed process 
schedule; there is a guaranteed supply of raw material for the production process 
coming from a working cell bank. This is in contrast to autologous cell therapies, for 
which process scheduling can be complex in instances where production can only 
begin once a patient’s material is received at a manufacturing facility. Furthermore, 
donor-to-donor variability adds an additional layer of complexity to autologous 
process design and scheduling – although occasionally, pre-screening of a patient’s 
cells can help to predict their performance within a bioprocess.  
Patient samples must be strictly segregated for autologous therapies to avoid cross-
contamination. Therefore, autologous cell therapies necessitate that a scale-out, 
rather than a scale-up approach to bioprocess design be adopted, whereby the 
manufacturing scale, or lot size, is kept constant and replicated for each patient 
(Figure 2.1). From a manufacturing perspective, autologous treatment results in a one 
lot = one patient treatment. Autologous cell therapy bioprocesses are more labour-
intensive compared to allogeneic manufacturing strategies; they require the same 
process to be carried out multiple times at a relatively small scale. Furthermore, this 
can increase the capital investment required, particularly in instances where complex, 
automated platforms are used within a bioprocess. Unless a piece of machinery is 
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designed to handle multiple patient samples in a segregated manner, each patient 
sample being processed at any given time requires a separate piece of equipment. 
The need for multiple pieces of fixed equipment can be alleviated somewhat by 
scheduling a bioprocess to maximise equipment utilisation. There are now a number 
of specialist pieces of equipment that aim to provide an automated, contained 
platform for autologous cell therapies; these are discussed in Section 2.6.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 (adapted from Brandenberger et al. (2011)) A comparison of the scaling 
strategies used for a) an allogeneic cell therapy bioprocess, which is scaled using a 
‘scale-up’ approach so that one lot can produce doses for multiple patients, and b) an 
autologous cell therapy bioprocess, which is scaled using a ‘scale-out’ approach, 
whereby the bioprocess is replicated for each patient equating to a one lot = one dose 
manufacturing paradigm 
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2.1.2 Adult cell therapy bioprocesses vs pluripotent stem cell-derived 
bioprocesses 
Typical bioprocess flowsheets for MSC-based cell therapies (adult stem cell), CAR-T 
cell therapies (adult cell) and pluripotent stem cell-derived therapies are shown in 
Figure 2.2. Whilst all cell therapy bioprocesses share common unit operations, such 
as expansion (or cell culture), different types of cell therapies demand that specific 
unit operations and manipulations be included in a bioprocess.  
Unit operations common to all cell therapy bioprocesses 
All cell therapy bioprocesses require certain unit operations that are common to every 
type of cell therapy (see Figure 2.2). These include tissue acquisition, cell culture, 
harvest, and formulation stages. Tissue acquisition involves the collection of a biopsy 
from a donor or patient in order to provide the starting material for a bioprocess. Cell 
culture is the expansion of a cell population to a clinically relevant size. Harvest 
strategies involve separation of cells from cell anchorage materials and media used 
in culture-based unit operations. Formulation stages involve the manipulation of a cell 
therapy product into its final form, suitable for administration to patients.  
Unlike PSC-derived, or CAR-T cell therapy manufacturing, bioprocesses by which 
MSC-based therapies are produced do not contain any unit operations that are 
specific to the type of cell therapy being produced. However, tissue acquisition for cell 
line creation is seen as a key phase in MSC bioprocesses as it presents a potential 
source of process variation. This is particularly true for autologous therapy processes, 
where different MSC lines often display variable expansion capabilities, in terms of 
both achievable lot sizes and growth kinetics (Lo Surdo and Bauer 2012).  
Additionally, MSCs are cultured at relatively low densities compared to hPSCs and T-
cells. Juxtaposed against lot sizes which may lie in the order of trillions of cells 
(Rowley et al. 2012), this can result in cell culture volumes comparable to those 
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observed in biopharmaceutical bioprocesses. Technologies to support the large lot 
sizes required for MSC therapies are discussed in Section 2.2. Large cell culture 
volumes place a subsequent burden on the harvest and concentration unit operations, 
which must be carried out within a short time-frame so as to maintain cell viability and 
potency (Veraitch et al. 2008). Current technologies available for harvest and 
concentration of cell populations are detailed in Section 2.5.  
CAR-T cell bioprocess-specific unit operations 
Figure 2.2b shows a typical CAR-T cell therapy bioprocess flowsheet. T-cells are 
collected by leukapheresis. This is the process by which whole blood is removed from 
a patient’s body and separated into constituent parts. The required material for a cell 
therapy is removed and the remainder is returned to the donor. Further unit operations 
must be carried out prior to T-cell culture within a CAR-T cell bioprocess. T-cells are 
activated, or stimulated in order to amplify their immune response to tumour cells. 
This is done by exposing T-cells to antigens and costimulatory molecules. In the past, 
dendritic cells and B-cells have been used for T-cell activation (Levine 2015). Either 
anti-CD3/ anti-CD28 paramagnetic beads, gels, or nanomatrix beads are most 
commonly for products currently under development. This is due to both variations in 
the activation of T-cells exposed to DCs and B-cells and the additional complexity of 
handling additional cell types within a bioprocess. Transduction, whereby 
recombinant CAR genes are delivered to the T-cells in order to be expressed, must 
also be carried out. This is the process by which a T-cell is modified to express the 
CAR protein on which its potency relies. Allogeneic CAR-T cell therapy bioprocesses 
include an additional unit operation compared to their autologous counterparts 
(Figure 2.2b). This unit operation facilitates the genetic knockout of a surface protein 
believed to cause graft versus host disease (Yang et al. 2015). There are several 
methods to achieve this, including viral transduction, electroporation and transduction 
of genes using novel mechanical membrane disruption technology (Singh et al. 2013; 
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Vannucci et al. 2013; Sharei et al. 2015). Genetic modification of cells for cell therapy 
is discussed in Section 2.4. Some allogeneic bioprocesses include a preparatory cell 
culture stage prior to gene knockout in order to boost viable T-cell numbers.  
Allogeneic CAR-T cell therapy bioprocesses include a purification step in order to 
remove cells where genetic modifications to knockout T-cell receptors that cause 
GvHD have failed. This can be performed using affinity-based cell purification 
techniques (Valton et al. 2015) which are discussed in Section 2.5.  
Pluripotent stem cell-derived therapy bioprocess-specific unit operations 
Figure 2.2c shows a typical process flowsheet for PSC-derived therapies. PSC-
derived therapy bioprocesses contain an additional, inherent degree of complexity 
compared to adult stem cell therapy bioprocesses. This is partially due to the 
differentiation unit operation that PSC-derived cell therapies necessitate. 
Differentiation is a culture-based process by which pluripotent stem cells are driven 
towards a specialised progenitor lineage required for a specific cell therapy. The 
differentiation unit operation is discussed in Section 2.3. Human embryonic stem cell 
lines are derived from the inner cell mass of developing embryos. A working cell bank 
can be created directly from this source material. Induced pluripotent stem cell lines 
must be created through the process of cellular reprogramming.  
Reprogramming is the process by which an (adult) somatic cell is induced to become 
a pluripotent stem cell. iPSC lines have been via the use of a number of different 
vectors, details of which can be found in Section 2.4. Unit operations involved in the 
creation of hiPSC lines are shown in the box in Figure 2.2c marked ‘cell line creation 
for hiPSC bioprocesses’. For autologous iPSC-derived cell therapies, tissue 
acquisition and cellular reprogramming must be carried for each individual patient in 
order to create a master cell bank (this can then be used for repeat doses if 
necessary). For allogeneic iPSC-derived therapies, cellular reprogramming only 
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needs to be carried out on an individual donor’s material in order to create a universal 
iPSC line from which a master cell bank can be generated. A major advantage of 
iPSCs is that they can be used to create autologous, non-immunogenic therapies. 
However, allogeneic iPSC therapies are rare due to the cost and difficulty of cellular 
reprogramming, and concerns over their immunogenicity when used for allogeneic 
therapies are perhaps why no clinical trials currently involve allogeneic iPSC 
therapies.  
Certain DSP operations, such as cell harvesting following PSC expansion and 
purification, are not always essential to PSC therapy bioprocesses. The need for 
harvesting between culture-based operations can be negated in some integrated 
bioprocess strategies (discussed in section 2.6). Furthermore, culture conditions used 
in certain differentiation protocols promote only the proliferation and survival of target 
cell types, resulting in a very pure population of viable cells following removal of the 
culture media. This can negate the need for affinity-based purification methods such 
as MACS or FACS, which are used when hPSC therapies do require purification unit 
operations. 
Having introduced the overall bioprocess flowsheets for three key variants of cell 
therapy, the subsequent sections provide further detail on key unit operations. 
General information is given where possible. In instances where information that is 
specific to a certain type of cell therapy is discussed, this is stated clearly within the 
text.
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Figure 2.2 A comparison of typical bioprocess flowsheets for a) an MSC-based cell therapy, b) a CAR-T cell therapy and c) an hPSC-based 
therapy. Specific operations required for allogeneic CAR-T cell therapy manufacture are shown in the boxed section of panel b). Upstream unit 
operations required for hiPSC bioprocesses are shown in the boxed section at the top of panel c). Unit operations which are occasionally not 
required, depending on the bioprocess strategy employed, are depicted by shaded boxes
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2.2. Culture strategies for cell therapies 
2.2.1 Planar culture systems for therapeutic cell culture 
MSCs and hPSCs can be grown as adherent colonies, anchored to tissue culture 
plastic, feeder layers, or synthetic substrates in vessels such as T-flasks. CAR-T cells 
are cultured in suspension; traditionally this has been done in T-flasks or static cell 
culture bags. 
One concern associated with the use of traditional culture platforms, such as T-flasks 
for the growth of cells in monolayers is the lack of capabiltiy for appropriate 
environmental monitoring on control. Temperature and dissolved oxygen 
concentrations vary greatly across incubators, which are often used to house tissue-
culture plastic based vessels during cell growth. Furthermore, real-time monitoring of 
cell cultures is not feasible in such platforms and environmental homogeneity in terms 
of temperature, pH and nutrient distribution, even within the same vessel, cannot be 
ensured.  
Traditional, planar hPSC culture platforms relied heavily on the use of xenogeneic 
growth substrates and non-human feeder layers, which risk contamination of hPSC-
derived products. Furthermore, feeder layers differentially secrete signalling factors, 
resulting in poorly defined culture conditions that are unsuitable for empirical study of 
hPSC expansion (Eiselleova et al. 2008). The development of anchorage materials 
comprising of a mixture of synthetic and/or recombinant biological motifs have 
allowed hPSC culture to progress away from the use of feeder layers (Villa-Diaz et 
al. 2013).  MSCs are anchorage-dependent cells and can be characterised by their 
natural adherence to standard tissue culture plastics (Panchalingam et al. 2015). 
Conventional MSC and T-cell culture is reliant on serum-based media. Foetal bovine 
serum (FBS), is inappropriate for GMP-based manufacturing owing to the risk of both 
pathogen transmission and immune reaction in patients that is inherent in its use and 
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its lot-to-lot variability (Spees et al. 2004; Bernardo et al. 2007). The development of 
xeno-free, defined media is crucial to the robust bioprocessing of cell therapies 
(Abbasalizadeh and Baharvand 2013). Optimisation of media composition has seen 
the release of commercially available, serum-free media for the culture of both T-cells 
and MSCs  (Gottipamula et al. 2013; Smith et al. 2015). The simplicity of defined 
media may reduce costs associated with cell expansion materials by 30-60% (Wang 
et al. 2013).  
The labour-intensive nature of T-flasks limits their throughput and applicability to 
larger scale processes (Placzek et al. 2009; Want et al. 2012). This is particularly true 
of MSC-based and allogeneic CAR-T cell therapies, where lot sizes are likely to be in 
the order of billions or trillions of cells. Systems that stack multiple culture chambers 
above one another vertically have enabled greater cell yields than traditional 2-D 
culture methods at lower factory floor footprints (Rowley et al. 2012). The Cell Factory 
(ThermoFisher Scientific, Waltham, MA, USA) and CellStack/ HyperStack (Corning, 
New York, NY, USA) systems are examples of this and have been used to expand 
MSC populations to clinically relevant scales (Bartmann et al. 2007; Schallmoser et 
al. 2008). Inflated facility size requirements and subsequent capital investment costs 
associated with 2-D culture scale up are challenges facing the application of 
traditional, planar technologies at a commercial scale (Brandenberger et al. 2011; 
Rodrigues et al. 2011). 
 Automated, closed-process systems such as the CompacT SelecT (Sartorius AG, 
Gottingen, Germany), capable of handling 90 x T175 flasks simultaneously, and the 
Nunc Automatic Cell Factory Manipulator (ACFM) (ThermoFisher Scientific, 
Waltham, MA, USA), capable of manipulating 4 x 40 layer vessels, may help increase 
the throughput of 2-D cell therapy bioprocess strategies during expansion and 
differentiation (Thomas et al. 2009). Automated systems allow processing to take 
place in smaller, lower grade clean rooms compared to manual processing. The 
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closed processing offered by automation systems provides greater process control 
and reproducibility compared to manual processes (Veraitch et al. 2008). The 
Xpansion series of bioreactors (Pall Life Sciences, Port Washington, NY, USA), offers 
planar culture in a fully contained, bioreactor type environment. These vessels stack 
thin plates, which support cell growth, on top on one another, akin to the multi-layered 
vessels mentioned above. This vessel is suitable for the culture of adherent cells (e.g. 
MSCs and PSCs) (Collignon 2012). An overview of planar cell culture platforms is 
contained within Table 2.1. 
It is unlikely that planar vessels will be used in any commercial bioprocess designed 
for the manufacture of CAR-T cells. As stated above, CAR-T cells are grown in 
suspension. Restrictions in the physical depth of the media in T-flasks and stacked 
planar vessels mean that the volume of media per surface area, and thus achievable 
cell population sizes, of such vessels is limited. T-cell populations grown in T-flasks 
must therefore be passaged more frequently even that if a static culture bag was 
employed as the cell culture platform. 
The scale-up of any bioprocesses that employ manual, planar technologies is likely 
to prove challenging. However, planar processing platforms may continue to have a 
place in commercial cell therapy bioprocesses. The application of planar technologies 
in the production of autologous and low-dose allogeneic cell therapies (such as those 
targeting AMD (Table 1.1), should not be discounted. 2-D platforms are also likely to 
prove useful for the production of phenotype-specific hPSC-derived cells for 
personalised medicine drug screening that necessitate a scale-out, rather than a 
scale-up approach to bioprocess design (Rowley et al. 2012). 
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Table 2.1 (continued overleaf) Cell culture platforms for cell-based therapy production and a summary of their characteristics 
Technology Scale Advantages Disadvantages CAR-Ts MSCs PSCs 
T-flasks 25cm2 – 225cm2 Low cost per unit 
Low capital investment costs 
 
Labour intensive 
Open system 
Low process reproducibility 
Limited scalability 
Y Y Y 
Multi-layer vessels (no 
automation platform) 
500cm2 – 60,000 cm2 Low capital investment costs 
Reduced facility footprint 
 
Labour intensive 
Open system 
Difficult to achieve homogeneous 
media distribution 
Low process reproducibility 
Y Y Y 
CompacT SelecT (for T-
flask/ Cell Factory 
manipulation)  
Up to 90 x 175cm3 Closed system 
Automated  
Process reproducibility 
 
High capital investment costs 
Complex operation 
Additional media consumption  
Multiple units needed for large doses 
N Y Y 
Automated Cell Factory 
Manipulator  
Up to 4 x 60,000 cm2  Automated media exchange 
Increased reproducibility 
Reduced facility footprint 
 
High capital investment costs  
Difficult to harvest cells  
N Y Y 
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Integrity Xpansion 6,120cm2 – 122,400cm2 Closed system 
Automated 
Control of growth environment 
Low capital investment costs 
Small facility footprint 
High cost per unit 
 
N Y Y 
Static Culture Bags 1L – 50L Cheap 
Low capital investment costs 
Easy to use 
Labour intensive 
Poor control of culture environment 
Y N N 
Microcarrier culture in 
single-use bioreactors 
(SUBs) 
1L – 1000L+ Fully controlled culture environment 
Automated 
Closed system 
High process reproducibility 
High surface area: media volume 
ratio 
High capital investment costs on control 
unit 
High cost of SUB 
Few studies carried out at commercial 
scale 
 
N Y Y 
Aggregate culture in SUBs  1L – 1000L+ Fully controlled culture environment 
Automated 
Closed system 
High surface area: media volume 
ratio 
High capital expenditure on control unit 
High cost of SUB 
Few studies carried out at commercial 
scale 
Difficulties controlling aggregate size 
N 
 
N Y 
G-Rex 10cm2 – 500cm2 High cell densities achievable 
Cheap  
Efficient use of media 
Low capital investment costs 
Multiple units likely to be required 
 
Y N N 
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Rocking motion bioreactor 1L – 50L+ Fully controlled culture environment 
Automated 
Closed system 
High process reproducibility 
High surface area: media volume 
ratio 
High capital investment costs for control 
unit 
High cost of cell bag 
High media consumption 
Y N N 
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2.2.2 Three dimensional culture systems for human cell culture 
There are two main methods of 3-D human cell culture; the use of suspended 
microcarriers as adherent surfaces for anchorage-based cell growth (Oh et al. 2009; 
Chen et al. 2013) or the growth of cells in either single cell suspension cultures, or as 
aggregates (Gerecht-Nir et al. 2004; Somerville et al. 2012). Microcarrier systems are 
only appropriate for the culture of MSCs or PSCs. T-cells grow naturally in 
suspension. Many 3-D, bioreactor based cell culture systems allow online process 
monitoring, provide greater scalability potential and reduce facility size requirements 
when compared to conventional planar technologies. Advanced bioreactor systems 
also permit strict control of environmental conditions during bioprocesses (Olmer et 
al. 2012). A challenge to implementation of 3-D culture systems is exposure of cells 
to shear forces, which must be tightly controlled as they can impact upon cell viability 
and fate determination in the case of hPSCs (Chisti 2001; Leung et al. 2011). 
 A range of 3-D culture platforms exist for culture of cells for cell therapies, these are 
displayed in Table 2.1. These include static culture bags (sometimes used for 
bioprocesses involving T-cells), rocking motion, automated bioreactors such as the 
Xuri Cell Expansion System (GE Healthcare, Chicago, IL, USA), the G-Rex system, 
which is a gas permeable membrane-based culture vessel that can be vertically 
scaled (Wilson Wolf, New Brighton, MN, USA), and stirred suspension bioreactors 
that employ single use, closed bioreactors such as the CultiBag STR (Sartorius 
Stedim). The sections below are split into microcarrier-based culture systems for MSC 
and PSC culture, followed by a section on suspension-based culture of PSCs and T-
cells. The latter of the two sections has been split into two sub-sections, one on PSCs, 
and one focusing on T-cells. This is because whilst some cell culture principals remain 
the same, the variety of supporting platforms available for T-cell culture in suspension 
varies greatly from that of PSCs, which are grown as cell aggregates, rather than 
single-cell suspensions. 
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Microcarrier-based systems for therapeutic cell expansion 
Microcarriers are small beads or discs which permit propagation or directed 
differentiation of PSCs and MSCs within a 3-D bioreactor. hPSC studies investigating 
microcarriers have recently achieved expansion folds as high as 28-fold over 6 days 
(Marinho et al. 2012). MSC studies have also achieved high expansion folds, with 
values as high as 20-fold expansion per passage reported (Hewitt et al. 2011). 
Microcarrier-based expansion folds are often higher than those in 2-D expansion 
studies across similar timescales (Phillips et al. 2008; Fernandes et al. 2009; Oh et 
al. 2009; Thomas et al. 2009; Serra et al. 2010; Heathman et al. 2015). 
A critical property of microcarriers is their high surface area to volume ratio, on which 
large populations of hPSC cells may be cultured in a relatively small vessel, alleviating 
the costs associated with expensive media and supplements necessary for hPSC 
bioprocessing (Serra et al. 2010; Serra et al. 2012). Indeed, microcarriers can offer 
up to 30cm2 growth area per cm3 of media, around 10 times greater than that 
achievable on conventional T-flasks and multi-layered vessels (Panchalingam et al. 
2015).  Microcarriers are able to support expansion and long-term self-renewal of 
both hPSCs and hMSCs over multiple passages, proving the platform’s capability to 
support production of clinically relevant cell numbers (Oh et al. 2009). Microcarrier 
culture of hPSCs also results in cell colonies that generally have less than 10 layers; 
thus concentration profiles of nutrients and signalling molecules are less likely to 
occur than in aggregate-based cultures (Chen et al. 2014). This is not a concern for 
MSC culture, which grow as anchorage-dependent monolayers.  
There are a variety of commercially available microcarriers that have been 
successfully implemented for culture of both hPSCs and MSCs (Chen et al. 2013; 
Rafiq et al. 2013). Microcarriers that contain animal-derived components are 
unsuitable for use in the manufacture of cell therapies. Serum-free and feeder-free 
microcarrier platforms are available cell therapy processing, although many of these 
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utilise the microcarrier coating, Matrigel, which is derived from murine origins (Want 
et al. 2012). Recombinant human proteins can now be used as a substitute for animal-
derived microcarrier coatings in planar and 3-D microcarrier cultures (Rodin et al. 
2010; Chen et al. 2011; Rafiq et al. 2016). However, such proteins can be difficult to 
isolate, expensive to produce, and prone to lot-to-lot variation. Synthetic substrates, 
which circumvent consistency issues associated with recombinant substrates, have 
been developed in planar conditions and successfully applied to microcarrier-based 
culture of both hPSCs and hMSCs (Melkoumian et al. 2010; Villa-Diaz et al. 2010; 
Fan et al. 2013). 
Xeno-free microcarrier coatings designed to support hPSC culture utilise polymers to 
mimic Matrigel and feeder layer properties in order to encourage attachment and self-
renewal of cells. Expansion folds on xeno-free microcarriers comparable to those 
coated with Matrigel have been reported (Chen et al. 2011; Fan et al. 2013). It has 
been proposed that positively charged microcarriers can be used to successfully 
support hPSC expansion at clinically relevant scales and similar cell concentrations 
and expansion folds to coated microcarriers were achieved (Chen et al. 2014). Xeno-
free (XF) cell therapy culture methods represent a regulatory compliant approach to 
the production of hPSCs for clinical applications; they also reduce additional 
expenses incurred by the use of supplementary serums. Xeno-free and serum-free 
microcarrer cultures have also been applied to hMSC cultures. Cell concentrations of 
up to 3x105 cells per mL and 10-fold expansion have been achieved in XF conditions 
(Heathman et al. 2015). Generally xeno-free and serum-free conditions resulted in 
comparable growth kinetics and cell densities to serum-based culture (Santos et al. 
2011; Hervy et al. 2014; Heathman et al. 2015). 
Development of xeno-free microcarrier coatings is one area where a quality-by-
design (QbD) approach to product development has allowed elucidation of specific 
properties of microcarriers that affect hPSC self-renewal. Microcarrier selection 
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impacts the whole bioprocess as it can affect harvest operations as well as cell culture 
operations. Few existing studies, excluding those referred to above that aim to identify 
the effects of a specific microcarrier property on hPSC culture, specify the reasoning 
behind the choice of microcarrier used for cell culture, or indeed mention screening 
of microcarriers prior to cell culture. Rafiq et al. (2016) developed a screening 
mechanism that was shown to identify optimal microcarriers for a specific hMSC cell 
culture and harvest.  
Parallel to developing GMP-based cell culture protocols, research has focused on 
optimizing bioreactor conditions for dynamic hPSC expansion processes so as to 
increase achievable expansion folds and cell concentrations. This will help reduce 
COG associated with manufacture of cell therapies. Controlling the dissolved oxygen 
levels has been found to be critical during hPSC culture on microcarriers in SUBs; 
2.5 higher expansion folds and ~85% improvements in maximum cell concentrations 
were reported in a hypoxic environment when compared to uncontrolled conditions 
(Serra et al. 2010). Culture of MSCs in hypoxic conditions has been shown to increase 
their secretion of bioactive factors, leading to suggestions that this might improve their 
clinical efficacy (Chang et al. 2013; Binder et al. 2014).  However, the effect of hypoxic 
cell culture on MSC growth kinetics has not been studied in detail.  
The attachment of hPSCs to microcarriers as single cells can improve seeding 
efficiency from 30% to over 80% and reduce durations associated with microcarrier 
loading compared to clump seeding (Fan et al. 2013). Seeding densities have also 
been shown to have an effect on MSC culture. Lower seeding densities have been 
shown to result in increased proliferation compared to higher seeding densities 
(Fossett and Khan 2012). It has been suggested that approximately 5 cells per 
microcarrier bead may be the optimal inoculation ratio in MSC studies (Forestell et al. 
1992; Eibes et al. 2010). 
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Despite a growing bank of research examining the culture of MSCs and PSCs on 
microcarriers, very few studies have demonstrated culture of cells at clinically 
relevant, commercial scales. Rafiq et al. (2013) produced functional MSCs in a 5L 
stirred tank reactor. The maximum cell density achieved (1.7 x 105 cells per mL), was 
comparable to that achieved in a 100mL spinner flask (1.5 x 105 cells per mL).  
Aggregate Suspension Culture of hPSCs 
hPSCs can be cultured as suspended aggregates in bioreactors. When hPSCs are 
grown as aggregates the rho-associated protein kinase inhibitor (ROCKi), Y-27632, 
is used to protect single cells from dissociation-induced apoptosis(Watanabe et al. 
2007). Each cell aggregate is treated as a de facto colony. Aggregate sizes must be 
controlled in suspension bioreactors to prevent differentiation of cells in larger 
colonies (Krawetz et al. 2010; Ungrin et al. 2012; Abbasalizadeh and Baharvand 
2013). It has been reported that aggregate culture of stem cells increases the 
therapeutic potential and the differentiation efficiency of hPSCs via the sustainment 
of endogenous signalling within cell colonies  (Sart et al. 2014). Aggregate expansion 
of hPSCs also negates the need for expensive (and sometimes undefined) 
components of substrates upon which hPSCs are cultivated in adherent cultures 
(Ungrin et al. 2012). Aggregate culture of hPSCs rely more heavily on the expensive 
media supplements (such as GFs) compared to microcarrier culture (Marinho et al. 
2012).  
Several groups have proposed methods of hPSC culture through the use of cell 
aggregates with the potential to be scaled up in order to produce clinically relevant 
cell numbers (Abbasalizadeh et al. 2012; Chen et al. 2012; Ungrin et al. 2012). 25-
fold expansion has been achieved over 14 days during aggregate-based hPSC 
culture (Olmer et al. 2012) and studies into expansion of hPSCs as aggregates yield 
similar expansion-folds when compared to microcarrier systems (Olmer et al. 2010; 
Amit et al. 2011; Zweigerdt et al. 2011). Long-term maintenance of hPSCs in 
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aggregates in dynamic bioreactor conditions over several passages has also been 
proven to be feasible (Abbasalizadeh et al. 2012; Olmer et al. 2012). Aggregate-
based hPSC cultivation necessitates frequent manual interactions in order to control 
aggregate sizes which could hamper its application within the cell therapy industry 
(Singh et al. 2010; Amit et al. 2011; Serra et al. 2012). 
Agitation rates can be used to successfully modulate uniform aggregate size in order 
to improve expansion of hPSCs as aggregates and reduce cell loss due to shear 
forces (Abbasalizadeh et al. 2012; Wang et al. 2013). This is also the case with 
microcarrier cultures, where impeller speeds of between 45 and 60rpm were found to 
promote optimal cell population doubling times (Lock and Tzanakakis 2009). The 
effects of shear on hPSC self-renewal and lineage determination is an area of 
intensifying research, although currently this is a poorly understood area in terms of 
the effect of mechanical strain on hPSC fate determination (Abbasalizadeh et al. 
2012; Fridley et al. 2012).  
The importance of cell inoculation concentration has been demonstrated during 
aggregate culture of hPSCs in dynamic bioreactor conditions; seeding concentrations 
of 2-3x105 cells/mL were found to maximise viability of hPSCs (Kehoe et al. 2010; 
Abbasalizadeh et al. 2012). Single cell inoculation has also been estimated to reduce 
cell losses by up to 60% (Abbasalizadeh et al. 2012). Cell concentrations of up to 3.4 
x 106 hPSCs/mL have been achieved using dynamic, aggregate-based culture 
techniques (Kehoe et al. 2010). This represents 1.9 fold improvement over maximum 
cell concentrations achieved in planar systems, although it is significantly lower than 
the maximum cell concentrations achieved in xeno-free hPSC cultures performed in 
microcarrier-based systems (6 x 106 cells/mL) (Bardy et al. 2012).  
A few aggregate hPSC expansion processes combine xeno-free conditions with 
defined media (Amit et al. 2011; Chen et al. 2012; Wang et al. 2013). These 
investigations represent a valuable effort to remove media supplements that either 
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introduce the risk of xenogeneic material to hPSCs or expose media to lot-to-lot 
variability, although early attempts resulted in relatively modest expansion folds 
(Chen et al. 2012). 
Three-dimensional culture of T-cells for CAR-T cell therapies 
CAR-T cell therapies are a relatively new development in the field of cell therapy. 
Much of the available work on T-cell expansion has been carried out on unmodified 
cells, also intended for the use of adoptive cell therapies. However for the purposes 
of T-cell expansion, they can be considered equivalent and thus citations in this 
section may not refer directly to CAR-T bioprocesses. T-cells are grown in suspension 
as single cells. This naturally makes them more amenable to large-scale culture 
platforms than MSCs, which are anchorage-dependent, and PSCs, which must be 
grown as aggregates, or on microcarriers.  
Static culture bags have previously been used for the expansion of therapeutic T-cells 
(Sadeghi et al. 2011). However, like T-flasks, these systems are labour-intensive, can 
suffer from vessel-to-vessel variability in performance, and present an open culture 
system which will are not compatible with large-scale cGMP cell therapy manufacture.   
The G-Rex system is a static culture system in which cells grow on a gas permeable 
membrane, providing a highly oxygenated environment. This culture system allows 
removal and replenishment of media without disturbing cells within the reactor. G-Rex 
culture systems are compatible with standard tissue culture incubators, and have 
been shown to have the potential to significantly reduce the number of man hours 
associated with a T-cell culture process compared to T-flask based culture (Vera et 
al. 2010). The G-Rex 500 allows expansion of T-cell populations of up to 6x1010 in a 
single vessel (Bajgain et al. 2014), providing enough cells for autologous dose sizes. 
G-Rex devices consume less media volume than standard T-flasks and Xuri 
expansion systems. Therapeutic cells within the G-Rex have been safely 
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administered to patients (Somerville and Dudley 2012). Whilst G-Rex systems show 
comparable, sometimes even improved expansion folds relative to that of the Xuri, 
multiple vessels are likely to be required for the production of cell populations required 
for allogeneic and large dose autologous CAR-T therapies. A fully automated 
platform, capable of handling multiple G-Rex flasks in a closed environment is 
currently under development, which may alleviate concerns regarding the need for 
multiple vessels.  
Rocking motion bioreactors, such as the Xuri (previously WAVE) cell expansion 
system (GE Healthcare, Chicago, USA), provide all of the advantages of a closed-
system, fully automated bioreactor (see Table 2.1). Reliable and reproducible T-cell 
culture has been reported in rocking motion bioreactors (Hollyman et al. 2009; 
Sadeghi et al. 2011; Somerville et al. 2012; Janas et al. 2015). Rocking motion 
platforms provide agitation of the cell culture; this negates the need for impellers that 
can introduce shear stress that affects T-cell growth and expression of surface 
markers. Larger final cell population sizes and expansion folds have been reported 
using rocking motion bioreactors, as compared to static culture bags by Hollyman et 
al. (2009) and Sadeghi et al. (2011), whereas Somerville et al. (2012) reported that 
final cell population and expansion folds were equivalent to static bags. Daily media 
perfusions of between 500mL and 1000mL (in a 1L bioreactor) depending on viable 
cell concentrations were found to increase final cell counts by over 100% in 
comparison to cultures where no perfusion was performed (Janas et al. 2015). Cell 
concentrations of up to 2 x 107 cells/mL have been achieved using rocking motion 
bioreactors (GE Healthcare 2014). Culture vessels with volumes of up to 50L may be 
obtained using these systems. Like the G-Rex system, rocking motion bioreactors 
have been used to generate cells that have proven safe and efficacious when 
administered to patients (Somerville & Dudley 2012). 
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2.3. Differentiation of hPSCs   
2.3.1 Planar strategies for hPSC differentiation 
Traditional stem cell differentiation protocols were designed around bench-scale 
research paradigms and little effort was made to incorporate reproducibility and 
process robustness into these experiments (Mordwinkin et al. 2013). Directed 
differentiation strategies often involve exposing hPSCs to a cocktail of morphogens, 
at specific time-points throughout the differentiation process (Karumbayaram et al. 
2009; Zhang et al. 2009; Ghodsizadeh et al. 2010; Sullivan et al. 2010). Directed 
differentiation can reduce both the timescale and direct resource utilisation 
associated with a differentiation unit operation relative to spontaneous differentiation 
(Surmacz et al. 2012). 
Similar to hPSC expansion, early differentiation strategies relied heavily upon the use 
of xenogeneic materials (Martinez et al. 2012). Planar differentiation protocols, that 
are free of xenogeneic material, have been reported (Surmacz et al. 2012). Despite 
such progress, many differentiation protocols are inherently variable owing to the 
laboratory idiosyncrasies of individual technicians, thus reliable and robust 
differentiation processes are still in their infancy. Timescales and efficiencies also 
vary significantly between experiments even when the same cell type is targeted for 
production (Table 2.2).  
The use of small molecules within differentiation protocols has helped to improve their 
reproducibility via reduced use of recombinant growth factors (Zhu et al. 2011; Li et 
al. 2012). Several groups have created highly simplified protocols, whilst still 
improving the efficiency and processing times of 2-D differentiation processes, by 
replacing growth factors with small molecules in the preliminary stages of 
differentiation protocols (Burridge et al. 2011; Chambers et al. 2012; Surmacz et al. 
2012). A protocol with the specified aim of creating a differentiation process capable 
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of creating dopaminergic neurons for transplantation in T-flasks has been developed 
(Liu et al. 2013). This strategy enabled the production of cryopreservable 
dopaminergic neurons with a high level of efficiency, allowing better control of time 
management in within the differentiation process. This approach is well served to 
reduce bottlenecks in the downstream phases of autologous hPSC processes. 
Further advances have proven it is possible to derive progenitor cells, suitable for 
transplantation as cell therapies at high efficiencies (Diekmann et al. 2015) and in 
xeno-free and small-molecule free, defined conditions (Lippmann et al. 2014). 
Negation of the need for small molecules and growth factors also has the potential to 
drastically reduce the cost of differentiation procedures.  
  
81 
 
Table 2.2 (continued overleaf) A summary of the key performance characteristics of planar and bioreactor-based differentiation protocols 
  
Derived Cell-Type Method 
Time 
(days) 
Number of Target 
Cells per Input 
hPSC (Ratio) 
Reported 
Efficiency (%) 
Max Cell Concentration 
(Cells/mL)a 
Source 
Cardiomyocytes 2D Monolayer  9 ND 64.8±3.3 2.5 - 5 x 104 (Burridge et al. 2011) 
Cardiomyocytes 2D EB formation 60 0.81 10±2 - 22±4 ND (Zhang et al. 2009) 
Hepatocytes 2D EB formation ND ND 50±2 1-5 x 104 
(Ghodsizadeh et al. 
2010) 
Hepatocytes 2D Monolayer  14 ND 73±18 ND (Sullivan et al. 2010) 
Motor Neurons 2D Monolayer  14 ND 33.6±12 ND 
(Karumbayaram et al. 
2009) 
Neural Nociceptors 2D Monolayer 15 ND 61±2 1 x 104 
(Chambers et al. 
2012) 
Neurons 2D Monolayer ~7 ND ND 4.5 x 104 (Surmacz et al. 2012) 
Dopaminergic 
Neurons 
2D Monolayer ~28 ND 30±2 ND (Liu et al. 2013) 
Neural Progenitor 
Cells 
2D Monolayer 6 ND 90±1 5 x 104 (Lippmann et al. 2014) 
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Endoderm 
Progenitors 
2D Monolayer 4 ND 73.2±1.6 1.3 x 105 
(Diekmann et al. 
2015) 
Cardiomyocytes 2D EB formation 16-18 70 87±3.4 4.5 -6 x104 (Weng et al. 2014) 
Cardiomyocytes 
SUB 
Microcarriers 
16 0.33 15.7±3.3 1.36 x 106 (Lecina et al. 2010) 
Haematopoietic Cells 
SUB 
Microcarriers 
7 4.41 ND ND (Lu et al. 2013) 
Cardiomyocytes  
SUB Cell 
Aggregates 
18 23 
100 % Beating 
Aggregates  
4.3 x 105 – 5.2 x 105 
(Niebruegge et al. 
2008) 
Hepatocyte-like cells 
(HLCs) 
SUB Cell 
Aggregates 
21 ND 18±7 3-5 x 105 (Vosough et al. 2013) 
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2.3.2 Bioreactor-based systems for hPSC differentiation 
Concentrated research into bioreactor-based differentiation strategies has stemmed 
from the need to translate differentiation from a lab-scale area of research into 
processes capable of producing industrially relevant cell numbers in a reproducible 
manner. A number of studies in which hPSCs have been successfully differentiated 
in bioreactor conditions have been carried out, either attached to microcarriers (Lu et 
al. 2013) or in the form of cell aggregates (Lecina et al. 2010; Vosough et al. 2013). 
Differentiation strategies developed in 3-D bioreactors, particularly stirred-tank 
vessels, lend themselves to large-scale processes far better than their planar 
counterparts as labour-intensive tasks, such as media exchanges, can be fully 
automated in such vessels, which also offer processing advantages such as online 
environmental monitoring and control. Research carried out on SUB-based 
differentiation of mPSCs suggests that the use of spinner flasks resulted in a 12-fold 
reduction of the man hours spent in the laboratory when compared to planar 
techniques (Zwi-Dantsis et al. 2011).   
hPSCs can be differentiated towards a number of clinically relevant lineages in SUBs 
including cardiac (Niebruegge et al. 2008), haematopoietic (Lu et al. 2013), neuronal 
(Bardy et al. 2012) and hepatocyte-like (Vosough et al. 2013) (summarised in Table 
2.2). Bioreactor-based differentiation will be necessary in order to produce certain 
hPSC-derived cell products at commercially relevant scales, however it must be 
considered that such processes will only be made more cost-effective by making 
concurrent improvements in differentiation efficiencies and through the reduction of 
expensive media supplements in such protocols. Bioreactor-based differentiation 
would benefit from the translation of highly efficient protocols demonstrated in planar 
systems (Chambers et al. 2012; Surmacz et al. 2012; Weng et al. 2014) to SUB 
systems. Such protocols have the potential to result in differentiation efficiencies that 
are higher than those achieved with SUB-based bioreactors alone. A novel, 
84 
 
microparticle-based approach to morphogen delivery to PSC aggregates was 
reported as a method to achieve up to a 12-fold reduction in morphogen use during 
bioreactor-based differentiation protocols (Bratt-Leal et al. 2013). Such systems 
provide a valuable method by which to reduce material costs associated with SUB-
based hPSC culture.  
One question arising from the birth of SUB-based hPSC differentiation is how a 
dynamic, controlled environment might be harnessed to augment processing 
strategies in this area (Leung et al. 2011). One of the reasons for the lack of 
characterisation with regards to the effects of shear on hPSCs, is that different 
dynamic culture systems result in different shear profiles. Thus, drawing comparisons 
across separate studies is difficult (Fridley et al. 2012). However, scale-down studies 
suggest that shear stress during early hPSC differentiation promotes mesodermal, 
endothelial and haematopoietic phenotypes even when the presence of morphogens 
promoting these lineages were absent (Ahsan and Nerem 2010; Wolfe et al. 2012; 
Wolfe and Ahsan 2013). Interestingly, in early stages of differentiation, hPSCs lineage 
determination seems to be insensitive to the magnitude of shear stress; however in 
later stages, progenitor cell activity appears to be more magnitude-sensitive (Adamo 
et al. 2009; Wolfe and Ahsan 2013). Shear forces have been shown to partially negate 
the need for costly media supplements in published studies (Wolfe et al. 2012; Wolfe 
& Ahsan 2013); broadening our knowledge of the way that shear stress impacts upon 
hPSC culture must be seen as an important factor in bioprocess optimization. Hypoxic 
environments, which can be tightly controlled within SUBs, have also been shown to 
enhance differentiation of hPSCs towards both ectoderm and mesoderm cell lineages 
(Niebruegge et al. 2008; Bae et al. 2012).  
Novel, microfluidic systems could be a key tool in elucidating the effects of specific 
environmental parameters on hPSC propagation and differentiation. Microfluidic 
bioreactors provide an ultra-scale down, high throughput platform by which to study 
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single cells or colonies in strictly defined conditions (Cimetta et al. 2009; Wang and 
Bodovitz 2010; Prabhakarpandian et al. 2011; Reichen et al. 2012). The cellular 
processes governing hPSC fate are complex and cannot be attributed to a single 
given parameter. Microfluidic devices are well placed, as a low cost development 
platform, to enhance our understanding of how defined microenvironmental 
conditions can affect hPSC activity (Macown et al. 2014). 
The effect of the biochemical properties of microcarriers on hPSC fate determination 
is poorly understood. It has also been suggested that the mechanical properties of 
microcarriers, such as their stiffness and size can also be investigated and optimised 
for specific purposes (Sart et al. 2013).  Rational design of microcarriers could provide 
an optimized bioprocess platform with which to manufacture specific hPSC-derived 
cell lineages. This would enable better control of cells’ microenvironment and thus 
allow more efficient differentiation processes that do not rely as heavily on expensive 
media supplements as current platforms do. 
2.4 Genetic engineering of cells for cell therapies 
Genetic engineering and phenotype modification techniques have a significant role to 
play in the production of efficacious cell therapies. Human induced pluripotent stem 
cells (hiPSCs) can be derived from adult stem cells by forced expression of defined 
transcription factors (Takahashi et al. 2007). This has led to the possibility of 
autologous hiPSC-derived therapies (Kimbrel and Lanza 2015). Cellular 
reprogramming of hiPSCs is a labour intensive, lengthy process. Efficiencies, or the 
percentage of somatic cells successfully reprogrammed to pluripotency, are generally 
in the region of 0.1-1%, with some notable exceptions (see Table 2.3). CAR-T cells 
are also produced through genetic modifications that cause the expression of the 
CAR on the surface of the T-cell protein (Gross et al. 1989). Furthermore, allogeneic 
CAR-T cell therapies depend on genetic engineering techniques to ensure the 
knockout of TCRs that are known to cause graft versus host disease. CAR-T cells 
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can be further modified to prevent the expression of surface proteins known to interact 
with combination drugs that are sometimes administered alongside cell therapies in 
cancer patients (Valton et al. 2015). Expression rates of CARs in genetically modified 
T-cells are far higher than iPSC reprogramming efficiencies; expression rates can 
vary from 20%-80% depending on the delivery system used (Table 2.3).  
The majority of approaches to genetically modify T-cells and to derive hiPSCs have 
relied upon transgene expression via viral transduction (Rao and Malik 2012; Kalos 
and June 2013). Gammaretroviruses have been used extensively for the delivery of 
transgenes to both T-cells and somatic cells for hiPSC derivation (Takahashi et al. 
2007). In immunotherapy, gammaretroviruses have been well-established as safe 
and efficacious in clinical settings (Rosenberg et al. 1990). Gammaretroviruses are 
belived to be less prone to silencing in hESCs and somatic cell lines; they are also 
believed to minimize the risk of producing immunogenic peptides, which may make 
them more suitable for therapuetic applications than other retroviral systems (Maetzig 
et al. 2011).  
Gammaretroviral and lentiviral vectors are examples of integrating viruses. In hiPSC 
production, integrating viral vectors are seen as a disadvantage due to the integration 
of exogenous sequences into the host genome. Integrating vectors drive long-term 
expression of transgenes, which is a safety concern for cell therapies (Rao & Malik 
2012). However, such characteristics can be harnessed in CAR-T cell therapy 
production as it can boost long-term expression of CARs following viral transduction. 
Integrating vectors have been shown to be safe in long-term adoptive cell transfer 
studies (Scholler et al. 2012). Lentiviral vectors, another example of an integrating 
viral vector, have also been explored for use in CAR-T cell therapy production. Both 
gammaretroviral and lentiviral vectors are characterised by their high transduction 
rates. However, whereas retroviruses only transduce replicating cells, lentiviruses 
can also transduce quiescent cells and thus result in a higher percentage of CAR-
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bearing T-cells (Sandrin et al. 2002; June et al. 2009; Vannucci et al. 2013). Indeed 
60-80% of a cell population expressing a CAR has been reported using lentiviral 
vectors (Cribbs et al. 2013; Cellectis 2014) (Table 2.3).  
The focus of derivation of hiPSCs using viral vectors has moved towards non-
integrating viral vectors such as adenoviruses and the Sendai Virus. Adenoviral 
vectors only allow expression of the transcription factors required to drive cells 
towards pluripotency for a short period of time; this results in reprogramming 
efficiencies that are several magnitudes lower than that of other vectors (Table 2.3) 
(Stadtfeld et al. 2008; Zhou and Freed 2009). Adenoviral vectors have been applied 
to T-cells for CAR expression with only limited success (June et al. 2009). Sendai 
vectors are able to derive hiPSCs at efficiencies comparable to that of lenti- and 
retroviral vectors (Fusaki et al. 2009; Ban et al. 2011), and are readily available as 
off-the-shelf cGMP grade reprogramming kits. Viral vectors are hampered by high 
costs and their complex production process, which represents a field within the 
bioprocess industry in its own right. T-cells that bear a specific type of CAR require 
the creation of a bespoke viral vector in order to deliver transgenes to the cell. The 
design of these vectors is not trivial, and requires highly skilled personnel. 
Non-viral vectors benefit from lower manufacturing costs and are theoretically safer 
because no viral elements are introduced to the host cell’s DNA (Kalos and June 
2013). Non-viral methods of transgene expression include episomal vectors, 
microplasmid DNA, and transposon technology (Rao and Malik 2012; Singh et al. 
2013). Electroporation and mechanical membrane disruption techniques have been 
used to deliver non-viral vectors to cells (Manuri et al. 2009; Sharei et al. 2015). 
Electroporation is a conventional method to introduce transposons, such as the 
piggyBac and Sleeping Beauty, to T-cells. Delivery of transposons to T-cells via 
electroporation results in CAR expression levels similar to those observed when 
transgene delivery is carried out using retroviral vectors (Nakazawa et al. 2011; Singh 
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et al. 2013). A novel approach to cytosolic delivery of cargo to T-cells involves passing 
cells through microfluidic channels to cause temporary membrane disruption. 
Molecules can then pass through the disrupted membrane into the cytoplasm of the 
cell (Marx 2016). The CellSqueeze platform (SQZBiotech, Boston, MA, USA) has 
been used to deliver functional macromolecules to T-cells, resulting in higher 
expression rates compared to electroporation (Sharei et al. 2015). In the field of 
hiPSC derivation, mRNA and miRNA molecules have been used for highly efficient 
reprogramming of somatic cells (Table 2.3) (Anokye-Danso et al. 2011). The 
simplicity of such systems makes them attractive candidates for derivation of iPSCs.  
Vessels that are impermeable to gas, such as disposable bioreactors that are 
designed to fit rocking motion bioreactors, are not ideal for transduction of cells via 
viral vectors. Therefore, transduction is currently carried out in static cell culture bags, 
or static planar vessels.  Retronectin-coated culture vessels are used during 
transduction of T-cells. This promotes co-localisation of virus’ and T-cells, which 
enhances the levels of CAR expressing T-cells (Hanenberg et al. 1996; Dodo et al. 
2014). Transduction can be carried out within the CliniMACS Prodigy (Miltenyi Biotec) 
as part of a fully integrated bioprocess (see Section 8 for details). Microfluidic 
membrane disruption technologies, such as CellSqueeze (SQZBiotech) may also 
allow transduction to be carried out as part of an integrated bioprocess. However, the 
microfluidic nature of such devices might limit their throughput and their subsequent 
applicability to large-scale bioprocesses. Higher expression rates of transgenes 
delivered to T-cells will result in the production of higher numbers of functional CAR-
T cells in a  given culture vessel, leading to more efficient manufacturing processes.  
Derivation of hiPSCs is hampered by low reprogramming efficiencies and it technical 
difficulty (Rao & Malik 2012). It is a lengthy, labour intensive process that can take 
many weeks. As such many reprogramming protocols depend on the use of well-
plates, rather than bioreactors. hiPSC lines are often generated from single colonies 
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following reprogramming in order to create homogeneous cell banks, therefore only 
a small number of hiPSCs are required. For allogeneic hiPSC cell therapies, viewing 
hiPSC-derivation as a precursor to the bioprocess may be adequate; once a cell line 
is created, a working cell bank can be maintained to satisfy demands of a bioprocess. 
However, for autologous cell therapies, reprogramming must be carried out for every 
patient, it is therefore important to consider its incorporation into an integrated 
bioprocess. Section 8 will cover the limited efforts made to integrate reprogramming 
into a full bioprocess. 
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Table 2.3 Vectors used for genetic modification of cells and their efficiencies when applied to CAR expression in T-cells and hiPSC 
reprogramming 
Vector Type Genome Integrating Transgene 
expression rates in T-
cells (%) 
Reference hiPSC 
reprogramming 
efficiency (%) 
Reference 
Retrovirus Yes 23-51 
(Quintás-Cardama et al. 2007; Pule et al. 
2008) 
0.02-0.08 
(Takahashi et al. 2007; Park et al. 
2008) 
Lentivirus Yes 38-80 
(Zhou et al. 2003; Tumaini et al. 2013; 
Cellectis 2014) 
0.02 (Yu et al. 2009) 
Adenovirus No   0.0002 (Zhou and Freed 2009) 
Sendai Virus No ND N/A 0.1-1 (Fusaki et al. 2009; Seki et al. 2010) 
Transposon 
(Electroporated) 
No 20-50 (Manuri et al. 2009; Singh et al. 2013) 0.02 (Kaji et al. 2009) 
siRNA (CellSqueeze)a No 50-70 (Sharei et al. 2015) ND N/A 
mRNA/ miRNA 
Dependent on delivery 
mechanism 
ND  1.4-10 
(Warren et al. 2010; Anokye-Danso 
et al. 2011) 
a) CellSqueeze technology has not yet been shown to facilitate the expression of CARs on CAR-T cells in published studies, results here indicate gene knockout of surface proteins, which 
have application in the production of allogeneic CAR-T therapies. 
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2.5 Downstream processing of cell therapies 
2.5.1 Cell harvesting, washing and concentration 
The harvest of cells take place following cell culture based unit operations such as 
expansion or differentiation and is usually carried out in two stages. For MSCs and 
PSCs the first harvest step is detachment, or dissociation of cells from the cell culture 
anchorage material (for example tissue culture plastic or microcarriers). If aggregate 
culture is used, then aggregate dissociation must first take place in order to create a 
suspension of single cells. Secondly, ‘separation’ takes place, separation is generally 
not necessary for aggregate-based culture. This stage involves removing any 
microcarriers from the cell culture broth so as to produce a cell-only suspension. CAR-
T cell expansion employs single-cell suspension culture and therefore does not 
require a detachment or dissociation step.  
Detachment of cells from microcarriers is usually carried out using proteolytic 
enzymatic separation. In PSC-based cultures, this has been done using a 
recombinant trypsin enzyme (TrypLE Express) (Oh et al. 2009; Santos et al. 2011), 
or collagenase (Lock and Tzanakakis 2009). MSCs have been dissociated from 
microcarriers via the use of trypsin, accutase, trypsin-accutase mixtures, and 
collagenase (Weber et al. 2007; Goh et al. 2013). Thermo-sensitive polymers have 
also been used to negate the use of dissociation enzymes, which have been shown 
to affect cell viability and hPSC differentiation if cells are exposed to them for too long 
(Yang et al. 2010; Tamura et al. 2012). The culture broth is reduced to below 32oC to 
allow cell detachment in this instance (Tamura et al. 2012). Yang et al. (2010) 
reported harvest yields of 82.5% (92% viability) for MSCs grown on thermo-sensitive 
microcarriers. Thermo-sensitive polymers may affect the growth characteristics and 
fate determination of MSCs and PSCs. Furthermore, it may be difficult to achieve 
homogenous polymer coatings of commercially available microcarriers.  
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Different enzymes have been shown to perform with varying degrees of success 
depending on the type of microcarrier being used during harvest protocols (Rafiq et 
al. 2016). However, there has been little focus in published studies on scalable 
harvest strategies and protocols for cell therapy manufacture (Chen et al. 2013). 
Many of the studies referred to above relied on the use of sieves to separate cells 
from microcarriers; this approach is not one which can be translated to GMP cell 
therapy manufacturing. Nienow et al. (2014) and Heathman et al. (2015b) presented 
a scalable protocol for the harvest of MSCs from microcarriers. Detachment was 
carried out using trypsin-EDTA (Nienow et al. 2014) or TrypLE (Heathman et al. 
2015b) accompanied by agitation in a SUB. Harvest efficiencies of greater than 95% 
were reported in these studies (>99% viability). Separation of microcarriers to form a 
cell-only suspension can be carried out using volume reduction techniques, such as 
tangential flow filtration (TFF). TFF offers a scalable platform for cell harvesting that 
result in high cell viability rates, even when scaled and adapted for cGMP conditions 
(Brandenberger et al. 2011). Cunha et al. (2015) explored the use of different filtration 
devices and found that polypropylene filters with pore sizes of greater than 75μm 
resulted in the removal of microcarriers and recovery of over 80% viable cells. The 
concentration of cells in the retentate was 10-fold that of the feed stream. 
Other volume reduction techniqes, such as centrifugation can also be used for the 
separation of cells. The kSep system (Sartorius Stedim) is a fluidised bed 
centrifugation (FBC) machine, which operates in a similar manner to small-scale, 
conventional cell separation systems used for blood-product processing such as the 
COBE 2991, or Elutra Cell separation system (these systems are small scale and 
inappropriate for allogeneic cell therapy bioprocesses). The kSep system can handle 
volumes of up to 1,000L in a single run (Brandenberger et al. 2011). Few studies have 
investigated the separation stage in detail. Nienow et al. (2014) reported that filtration 
resulted in the build-up of microcarriers on the filter, acting as a de facto ‘filter-cake’ 
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which resulted in reduced harvest yield due to the entrapment of cells. One solution 
to this issue is to provide a larger surface area for the filtration; this would reduce the 
depth of the microcarrier build up. Hassan et al. (2015) considered the use of 
tangential flow filtration (TFF) and fluidised bed centrifugation in the form of the kSep 
system for downstream processing of allogeneic MSC therapies in a bioprocess 
economic appraisal. It was observed that TFF is generally considered more 
appropriate for smaller lot sizes, whilst FBC proved economically viable for large lot 
size (>~1011 cells per lot).  
In the manufacture of CAR-T cell therapies, the detachment (or dissociation step) is 
unnecessary as cells are grown in single-cell suspension. However, beads, matrices, 
or gels used for activation of T-cells must be removed from the culture broth. This can 
be done by a washing, or separation stage in a manner similar to microcarrier 
separation in MSC and PSC therapy bioprocesses. Indeed, there are many cell 
processors that have been applied to blood product processing for many years that 
can be used in CAR-T cell therapies. Autologous CAR-T cell therapy products are 
only likely to result in media volumes of 5-10L, therefore small scale systems such as 
the Haemonetics CellSaver, COBE system from Terumo, and LOVO (Fresnius Kabi, 
Germany) can be integrated into a closed and sterile bioprocess for washing and 
concentration stages (Kaiser et al. 2015; Levine 2015). For large-scale production of 
allogeneic cell therapies, it is likely that scalable system such as the kSep will need 
to be employed to handle the media volume associated with this form of manufacture. 
Similar to the fields of MSC and PSC bioprocessing, there are few available examples 
of studies that focus on the washing and concentration of therapeutic T-cells following 
cell culture. 
It is important to consider the timescale available for washing and concentration of 
cells. It has been observed that holding times of greater than six hours can adversely 
affect the viability of both MSC and PSC populations (Pal et al. 2008; Veraitch et al. 
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2008). A maximum of four hours can therefore be permitted for dissociation and 
separation (or volume reduction) of cells followed by holding in ambient culture 
medium (Veraitch et al. 2008; Hassan et al. 2015; Heathman et al. 2015b).  
2.5.2 Purification of cells for cell therapies 
The purification of therapeutic cell populations is essential to most cell therapy 
bioprocesses. Obtaining a pure population of the therapeutic cell type helps to ensure 
the safety and efficacy of cell therapy products. Mesenchymal stem cell therapies can 
be manufactured without the need for purification; a single, homogenous population 
of cells is the start point of MSC-based bioprocesses, and these same cells are the 
final therapeutic entity. In the case of allogeneic CAR-T cell therapies and many PSC-
derived therapies purification is an essential step.  
There are a range of techniques for separation of specific human cells from a general 
population. These include physical separation (using density gradients or exploiting 
physical variations in the size of cell populations), immuno-separation techniques and 
novel approaches such as microfluidic platforms (Table 2.4) (Diogo et al. 2012; 
González-González et al. 2012; Weil and Veraitch 2013). 
Physical separation techniques include some of those described in Section 2.5.1. 
Examples of these include centrifugation using the COBE 2991 Cell Processor 
(Terumo BCT), counter flow elutriation using the Elutra Cell Separation System 
(Terumo BCT) (Powell et al. 2009) and density gradient separations using the Sepax 
(GE Healthcare). Such systems are low resolution and are generally only used as 
preparative isolation steps in USP operations, such as the isolation of lymphocytes 
following apheresis. Apheresis technology is well established, and has evolved to 
become relatively cheap, closed off, high throughput processes (Levine 2015). 
Centrifugation techniques can also be used for removal of materials used for T-cell 
activation. Aqueous two phase systems can also be used for cell separations; ATPS 
is a highly scalable platform and is used in many other chemical and biological 
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processes. However, it is hampered by low specificity which limits its use in DSP 
operations (Weil & Veraitch 2013).  
Immuno-separation techniques rely on the use of antibodies specific to target cell 
surface proteins. Magnetic activated cell sorting (MACS) and fluorescent activated 
cell sorting (FACS) are two widely used immuno-affinity platforms. Immuno-
separation techniques (particularly those which are affinity-based) result in higher 
selectivity than physical purification strategies and are therefore appropriate for DSP 
unit operations which demand a homogeneous cell population.  
FACS is achieved by first tagging target cells with an antibody linked to a fluorescent 
marker. Cell samples are then passed through a laser; this causes excitation of the 
fluorescent marker and results in light emission. Phenotype-specific cells are then 
separated by the application of either a positive or negative charge to cells tagged 
with light emitting fluorophores. FACS is a binary sorting system that processes single 
cells in sequence. FACS results in the highest target cell purities of any available 
purification technology; typical purities are in the region of 98% (McIntyre et al. 2010). 
However, its throughput is limited to cell numbers in the magnitude of 107 per hour 
(Weil and Veraitch 2013). This makes it unsuitable as a purification option for all but 
low-dose autologous cell therapies due to the process times associated with the 
technology. Additionally, fluorescent markers must be removed from cells following a 
FACS operation. The cost of cGMP-grade antibodies and the capital costs associated 
with FACS equipment are a challenge to its applications beyond analytical purposes. 
Furthermore, FACS has proven a more complex platform to use than technologies 
such as MACS. It therefore requires the use of highly trained staff, and necessitates 
a significant time period for set-up before each run.  
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Table 2.4 Summary table of cell separation and purification techniques and their advantages and limitations 
Category  
Platform Separation 
criteria 
Advantages  Limitations 
Physical-based 
separation 
techniques 
Density-gradient 
centrifugation 
Size and density 
- Label free 
- High throughput 
- High cell concentrations achievable 
- Low selectivity 
Aqueous two-
phase systems 
Hydrophobicity, 
size, net charge 
- Label free 
- Scalable 
- High cell viability 
- Low selectivity 
- Requires repeated extraction steps 
- Difficulties recovering separated cells 
Immuno-separation 
techniques 
Magnet-activated 
cell sorting (MACS) 
Expression of 
surface proteins  
- High selectivity  
- High throughput 
- Closed system & automated platforms 
- Commercially available 
- May require multiple steps 
- Magnetic bead removal  
- High antibody costs 
Fluorescent-
activated cell 
sorting (FACS) 
Expression of 
surface proteins 
- High selectivity 
- Capacity for multiparameter sorting 
- Automated 
- Low throughput 
- Flurouphore removal from cells 
- Skilled technicians required 
- High capital expenditure 
- High antibody costs 
Novel platforms Microfluidic devices 
Cell size, 
expression of 
surface proteins 
- Cheap fabrication - Can be automated 
- Efficient use of antibodies 
- Can create lab-on-a-chip systems for 
analytical & scale-down purposes 
Low capacity, difficult to scale 
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Cells are prepared for MACS by incubation with paramagnetic beads that are coated 
in antibodies specific to a surface protein on the target cell type. This creates labelled 
target cells that are held by a magnetic field. Unlabelled cells then pass through the 
device and are disposed of. Other than resultant cell populations that are of a high 
purity, advantages of MACS include its ease of use and high throughput; 2 x 1010 
cells can be processed within 30 minutes (Grützkau and Radbruch 2010). The latter 
two characteristics of MACS listed above place it at the forefront of existing platforms 
for the purification of cells for cell therapy; particularly where large lot sizes are 
required. The CliniMACS platform (Miltenyi Biotec, Germany) is the most commonly 
used MACS technology. Typical purities and viable cell yields achieved using 
CliniMACS range from 70-99% and 93%-99% respectively, although these values do 
depend on the cell type targeted for isolation (Lang et al. 2004; Chou et al. 2005; 
Schriebl et al. 2010; Weil and Veraitch 2013).  
Whilst MACS has been shown to be capable of separating cardiomyocytes and 
undifferentiated hPSCs following differentiation (Uosaki et al. 2011), Schriebl et al. 
(2010) predict that it would still require 31 stages to eradicate every non-target cell 
from a differentiated PSC therapy. This would prove impractical due to the cell losses 
encountered in each stage. A combination of positive and negative selection 
techniques during MACS-based separation could be used to boost the purity of target 
cell populations (Weil & Veraitch 2013). 
Novel purification systems are predominated by the use of microfluidic devices, which 
offer a ‘lab on a chip’ platform for cell processing. Microfludic devices are low-cost 
due to the ease of their fabrication. They can also harness existing immuno-
separation techniques such as FACS and MACS (Didar and Tabrizian 2010). 
Microfluidic devices may offer reduced antibody costs compared to the systems 
described above. Owing to the limited loading volume that can be handled by a single 
unit, microfluidic devices may be limited to analytical purposes, unless run in parallel 
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(González-González et al. 2012). In order to run in parallel, more must be done to 
ensure the robustness and reproducibility of purifications carried out on microfluidic 
devices. 
Production of allogeneic CAR-T cells involves the knockout of genes that prevent the 
expression of T-cell receptors (TCRs) that cause GvHD in patients. The gene 
knockout process is not 100% efficient. Specific T-cells, namely those that still 
express unwanted TCRs, must be separated from the final cell population before the 
therapy is administered to a patient (Yang et al. 2015). Separation of TCR- cells from 
the cell population cannot be carried out using apheresis methods employed in 
autologous CAR-T cell therapy production; they will therefore depend on high 
resolution, immuno-separation techniques (Valton et al. 2015). Similarly, the 
production of PSC-derived therapies requires the isolation of target cells that are 
specialist, progenitor cells. Depending on the performance of the differentiation unit 
operation, these cells may not be the majority cell type within a given population. 
Where passive separation techniques are not appropriate, PSC-derived therapies will 
depend on high-resolution purification platforms to provide a homogeneous 
population that are free of undifferentiated, or partially differentiated PSCs (which 
have the potential to form teratomas in vivo (Brederlau et al. 2006).  
Occasionally, PSC-derived therapies can be purified through the use of culture, or 
formulation-based techniques. For example, in the production of retinal-pigment 
epithelial cell therapies for AMD, cells are sometimes transplanted as patches, 
whereby differentiated retinal pigment epithelium (RPE) cells are cultured as a 
monolayer in order to allow cell-cell interactions to form. These culture conditions do 
not support the viability of cells other than the patchwork RPE cells, and thus can 
usually be transplanted as a single cell type without the need for cell sorting.  
Purification of cells at high resolution is among the most challenging areas within cell 
therapy bioprocessing. On the one hand, cells must be recovered at very high purities; 
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higher even than those currently being achieved using MACS systems (Schriebl et 
al. 2010). One the other hand, the time available for purification is limited. High 
throughput, high capacity solutions are required in order to not exceed the maximum 
holding time whereby cell viability and function is affected. The development of large-
scale cell culture technologies discussed in Section 4 will only further this 
requirement. Leading academics in the cell therapy field have acknowledged that at 
present there is no gold standard cell purification system for achieving a 
homogeneous cell population (Schriebl et al. 2010; Diogo et al. 2012; González-
González et al. 2012; Weil & Veraitch 2014). Future improvements in this field will be 
required for the translation of cell therapies to the clinic. 
2.6 Integrated and continuous bioprocess strategies for cell 
therapies 
Integrated bioprocesses, whereby multiple unit operations are carried out in a self-
contained piece of equipment, are being explored as an alternative to segregated 
bioprocess strategies. Integrated bioprocesses negate the need for labour-intensive 
processes that usually take place following cell culture operations, such as hold steps 
and transfer of cellular material. Processing cell therapies in this manner can help to 
reduce bottlenecks and increase the throughput associated with cell therapy 
bioprocesses. Additionally, integrated bioprocess protocols offer greater containment 
capabilities, reducing the potential for contamination within the bioprocess. 
To date, work in the cell therapy field has focused predominantly on integration of 
culture-based unit operations, such as expansion and differentiation of hPSCs. 
Several studies have reported integrated expansion and differentiation operations 
where continuous culture strategies have been employed (Lock and Tzanakakis 
2009; Bardy et al. 2012; Ungrin et al. 2012; Fonoudi et al. 2015). Figure 2.3 illustrates 
how these strategies differ from segregated culture and differentiation of hPSCs. Only 
a handful of investigations into this relatively new area of hPSC bioprocess research 
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have been published and these are summarised in Table 2.5. Early investigations 
incorporating expansion and differentiation focused on overcoming the technical 
hurdles of carrying out two different operations in one integrated process step; as 
such only modest yields of target cells were achieved (Lock & Tzanakakis 2009). 
Recent studies have sought to optimize integrated iPSC bioprocesses via strategies 
such as the determination of optimal aggregate size during hPSC culture and 
differentiation (Ungrin et al. 2012). Switching feeding regimes from once to twice per 
day was found to double the achievable cell density during the expansion phase of 
an integrated bioprocess, although process economic analysis comparing the two 
approaches was not offered (Bardy et al. 2012). The reported expansion folds and 
differentiation efficiencies for integrated bioprocesses compare well with separated 
systems of a similar nature.  
One of the challenges facing fully integrated cell therapy bioprocessing is a lack of 
technologies and bioprocess designs that support end-to-end bioprocessing in a fully 
contained manner. To date, no studies have produced an integrated process for 
hPSCs from derivation all the way through to differentiation. This has been achieved 
with mouse iPSCs (miPSCs) in a SUB (Fluri et al. 2012). Few studies exhibiting 
“suspension culture reprogrammed iPSCs” exist, all of which are carried out with 
miPSCs (Fluri et al. 2012; Baptista et al. 2013). Translation of integrated miPSC 
production techniques described by Baptista et al. (2013) to hiPSC processing may 
be particularly useful, as continuous derivation of large numbers hiPSCs would help 
reduce the bottlenecks bought about by cellular reprogramming. Moreover, it may 
provide a “black box” platform to derive, expand and differentiate a patient’s cells in 
a single, contained unit that could be installed at point-of-care centres for relevant 
disease types.  
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Figure 2.3 Continued overleaf
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Figure 2.3 Cell therapy bioprocess strategies and their characteristics. a) Segregrated bioprocess strategies for CAR-T cell therapies (left upper 
panel) and hPSC-derived therapies (right upper panel) and typical technologies that are used in these processes. b) Integrated bioprocess 
strategies, which allow unit operations to be carried out as a single process in a self-contained system, for CAR-T cell therapies (left lower panel) 
and hPSC-derived therapies (right lower panel). Unit operations which are segregated in each bioprocess strategy (i.e. those that require transfer 
of cellular material between pieces of equipment) are separated by horizontal lines. 
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The potential for perfusion based culture has been described for MSC therapies (dos 
Santos et al. 2014). Perfusion culture supports continuous, integrated bioprocess 
systems for MSCs, whereby up-stream and downstream processing operation can be 
run in a fully contained manner at large scale. (Cunha et al. 2015), describe perfusion 
MSC culture followed by continuous TFF, in order to provide higher cell 
concentrations than batch methods.  
The development of single-use bioreactors and culture-ware with ports and manifolds 
to support sterile tubing connections has allowed the conjunctive use of sterile plastic 
tubing to create bespoke closed systems for the transfer of cells between two pieces 
of equipment without exposing the cells to the open environment (Tumaini et al. 
2013). Such systems allow a reduction in the necessary grade of cleanroom (usually 
to Class C/D from Class A/B). However, tubing and seals must be set-up for each 
individual lot. For autologous processes this is likely to be a time consuming task, 
especially if a single facility handles large numbers of patient samples on a daily 
basis. When a specific type of tubing is required (i.e. for CliniMACS machinery), the 
cost of a single tubing set is greater than £1,000, and this can add significantly to the 
direct costs associated with a bioprocess. 
The CliniMACS Prodigy is a device which offers a fully integrated, contained cell 
therapy bioprocess platform (Figure 2.3). It provides a potential solution to the needs 
of CAR-T cell therapy bioprocess and has been shown to perform T-cell enrichment, 
activation, transduction, and expansion and formulation of T-cell therapies in a single-
use tubing set (Apel et al. 2013). The cell culture chamber is also capable of 
performing differentiation protocols, although the Prodigy has yet to be applied to cells 
beyond lymphocytes. Platforms such as the CliniMACS may prove invaluable to the 
cell therapy industry. The self-contained environment that the Prodigy offers allows 
multiple devices to operate within the same cleanroom area, even for autologous 
processes, resulting in a reduced facility footprint (Kaiser et al. 2015). The automated 
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nature of the Prodigy will likely reduce the labour-intensive nature of many current 
bioprocesses. At present, the approximate cost of individual CliniMACS machines is 
approximately £250,000 (US$360,000). This represents a sizeable capital investment 
on single piece of equipment, which may impair the speed of its uptake, especially 
until its effectiveness and robustness can be assured. Furthermore, the size of the 
cell culture chamber in the CliniMACS, which allows T-cell populations of up to 2x109 
cells to be produced (Apel et al. 2013), is likely to restrict its application to autologous 
cell therapy bioprocesses. Another device which targets the production of ‘device-
based’ production of autologous cell therapies is the Octane Cocoon (Octane Biotech 
Inc., Ontario, Canada). Similar to the Prodigy, the Octane seeks to allow automated, 
closed-off production of cell therapies in a single, turn-key based device. The Octane 
can be adapted for production of different types of cell therapies.  
At the time of writing, there are no solutions to the need for fully contained bioprocess 
platforms capable of handling large lot sizes. Innovations in cell culture platforms and 
integrated process protocols have allowed SUBs to be used for integrated expansion 
and differentiation processes. Furthermore, multiple unit operations can now be 
carried out in a single, contained process platform, including DSP operations such as 
volume reduction and enrichment of target cell population. However, the novel, 
contained process platforms discussed in this section face a challenge in terms of 
their scalability and applicability to allogeneic and large-dose autologous cell 
therapies. 
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Table 2.5 (continued overleaf) Summary of studies investigating the integrated expansion and differentiation of hPSCs 
Culture 
Conditions  
Cell Type 
(iPSC/ESC)  
Target Cell Type Expansion 
Max 
Cell Density 
(cells/mL) 
(Fold 
Expansion) 
Differentiation 
Max 
Cell Density 
(cells/mL) (Fold 
Expansion) 
Reported 
Differentiatio
n Efficiency 
(%) 
Process 
Time 
(Days) 
Target cells 
produced 
per input 
hPSC 
Xeno-
free 
(Y/N) 
Source 
Microcarrier 
(DE53 
Whatman) 
hiPSC 
 
Neural Progenitor 
Cells (NPCs) 
6.1 x 106 (20) 1.1 x 106 (16.6) 78±4.7 25 333 N 
(Bardy et 
al. 2012) 
Microcarrier 
(DE53 
Whatman) 
hESC NPCs 
4.3 x 106 
(21.3) 
1 x 106 (17.7) 83±8.5 23 371 N 
(Bardy et 
al. 2012) 
Aggregate 
Culture  
hESC 
Definitive 
Endoderm 
Progenitors 
(DEPs) 
ND (5000)a) ND (23.5) >80% 22 65,000a) N 
(Ungrin et 
al. 2012) 
Microcarrier 
(Collagen 
coated 
Hyclone)  
hESC DEPs 1 x 106 (34-45) 4 x 105 (ND) 84.2±2.3% 12 4 N 
(Lock and 
Tzanakaki
s 2009) 
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Aggregate 
Culture 
hESC Cardiomyocytes 
8-9 x 105 (4-
4.5) 
ND 85-95% 12-35 ND Y 
(Fonoudi 
et al. 
2015) 
Parameters given for both expansion and differentiation. ND = No data given 
a) hESC cells underwent four round of expansion during this study, followed by differentiation as oppose to one round of expansion that took place in the other 
studies shown in the table. This may explain the disparity in performance parameters when compared to other studies in the table. 
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2.7 Manufacturing and distribution models for cell therapies 
Specific challenges arise from the fact that cell therapies must be delivered to the 
patient as viable populations of living cells. Traditional manufacturing and distribution 
models may not be appropriate for some cell therapies due to this unique 
characteristic. This section will briefly cover the different options available to CBT 
manufacturers; namely centralised, and decentralised manufacturing.  
Centralised manufacturing (Figure 2.4) involves the use of one large facility to cater 
for a large area of the global market (e.g. one facility in Europe, and a further facility 
in the USA to cater for North America, and so on). This is a traditional model that is 
often employed by the pharmaceutical industry. The advantages of centralisation 
include spreading indirect costs over large production volumes and minimising 
interactions with suppliers and customers (Medcalf 2016). Furthermore, centralised 
manufacturing could represent less of a regulatory burden in that a product is 
manufactured at one facility and quality control and assurance mechanisms need only 
demonstrate consistency across manufacturing lots, rather than consistency across 
multiple facilities A carefully designed manufacturing process operated at a single site 
is the easiest to implement. Conversely, this approach might also represent a greater 
risk; in the rare instance of a facility shutdown the production process is halted entirely 
at a high cost. Decentralised manufacturing models would de-risk the process from 
this perspective (Trainor et al. 2014).  
Decentralised manufacturing models utilise multiple manufacturing facilities, these 
are generally positioned close to point-of-care centres and clinics licensed to 
administer the cell therapy in question. Decentralised facilities offer several potential 
benefits compared to centralisation. Foremost, decentralised facilities may offer 
greater market access for cell therapies by delivery of a product to a greater number 
of clinics (and therefore patients) than centralised models. Decentralised facilities 
also offer a reduction in delivery distances and times from a manufacturing facility to 
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a patient. This can be particularly useful for both ‘made to order’ therapies, for which 
the short supply chain will enhance the responsiveness of the manufacturing process, 
and fresh products (Medcalf 2016). Fresh products have a limited viable lifespan, 
usually in the order of hours rather than days or weeks associated with cryopreserved 
therapies; short supply chains associated with decentralised models allow these 
products to be delivered to a wider market than would be feasible using a centralised 
model. Even for cryopreserved products, centralised facilities can result in the need 
for long distance supply chains that are reliant on cold chain storage which can be 
difficult to validate and maintain. Furthermore, not all clinics have the capability to 
handle incoming cryopreserved materials (Medcalf 2016). 
Trainor et al. argue that true decentralisation would be represented by a 
manufacturing model that allows autologous cell therapies to be manufactured within 
the same clinic from which patient biopsies are sourced (Figure 9.3). This would 
require the use of bench-top culture units that would be fully contained and at least 
partially automated. The arguments for such manufacturing models include their 
ability to reduce logistics and shipping costs associated with transportation of 
autologous cell therapies and patient materials, additionally they avoid the risk of 
cross-patient contamination. Realisation of manufacturing models such as this may 
come in the form of the ‘autonomous microfactory’, such as the Octane Cocoon 
(Octane Biotech Inc.), which could be utilised in a franchise-based model to produce 
cell based therapies (Trainor et al. 2014; Medcalf 2016). Whilst this model may prove 
to be an attractive prospect for low demand, autologous therapies due to a highly 
responsive manufacturing process set-up, it is currently unclear as to how this sort of 
business model and manufacturing facility would be regulated. It may therefore prove 
infeasible as a manufacturing option in the near-term. As technical advances in cell 
therapy manufacturing progress, it may be possible to realise the conceptual ‘GMP-
in-a-box’ manufacturing model. In this case, autologous cell therapies can be 
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produced on a bench-top module outside of a cleanroom. This would involve a tissue 
acquisition being loaded into a fully automated module that could then carry out all 
the necessary steps to produce a cell therapy. Whilst not currently available, the 
GMP-in-a-box manufacturing model would prove advantageous as it would negate 
labour and transportation costs associated with autologous cell therapies. However, 
it is as yet unclear how such a model could be achieved from a regulatory perspective. 
It is also unclear how the business model for such a system would work as this might 
create a scenario where clinics act as de facto franchises for cell therapy 
manufacturers.  
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Figure 2.4 Cell-based therapy manufacturing and distribution strategies and the 
advantages, disadvantages and additional considerations associated with these. a) 
Centralised manufacturing: one facility is used to cater for a single market area and 
the therapy is then distributed to multiple clinics. b) Decentralised manufacturing (off-
site): multiple facilities are used to cater for a single market area; one facility may 
cater directly for an individual clinic, or a small number of clinics within a specific 
location. c) Decentralised manufacturing (on-site): a manufacturing facility, most likely 
using ‘GMP in a box’ piece of equipment, is based at a clinic and the production 
process is carried out on site.   
a) 
b) 
c) 
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2.8 Conclusion 
In this chapter, the basic properties of cell therapy bioprocesses have been outlined, 
including their structure, key unit operations, and key similarities and differences 
between bioprocesses for cell therapies of different types. Furthermore, the 
techniques and technologies currently available for use within each stage of a cell 
therapy bioprocess have been summarised. 
Traditionally, low throughput, manual technologies such as T-flasks were used for cell 
culture-based unit operations (such as expansion and differentiation). However, the 
recent emergence of contained, automated bioreactors that negate the need for 
manual interventions coupled with the development of xeno-free, defined culture 
conditions have made robust, cGMP processes easier to attain for cellular products.  
The downstream unit operations contained within a bioprocess are dependent upon 
the type of cell therapy that is to be manufactured. MSCs are anchorage-dependent 
cells; enzymatic removal of cells from growth surfaces is the preferred method of 
achieving dissociation within a bioprocess. Optimised protocols are being developed 
in this area. Further to this, high-throughput volume reduction equipment is now 
available for bioprocesses involving all types of cell therapy. Fluidised bed 
centrifugation (FBC), spinning membrane filtration (SMF), and tangential flow filtration 
(TFF) are three popular, scalable methods by which to achieve concentration of 
therapeutic cells.  
Options for high-resolution enrichment, or purification, of target cell sub-populations 
from a varied input population are currently limited. Whilst MACS technologies offer 
the current gold standard in the industry in the form of a robust and relatively high 
throughput process platform, further improvements must be made to accommodate 
process options for the enrichment of rare cell types within a population.  
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Integrated contained process platforms, such as the Cocoon (Octane) and the 
Prodigy (Miltenyi), now offer automated, closed processing options for autologous cell 
therapies, particularly in the CAR-T cell space. Platforms such as these may afford 
the opportunity to de-risk cell therapy bioprocesses by reducing human error and 
contamination associated with transfer of process materials between separate pieces 
of equipment.  
Finally, the nuances of cell therapy bioprocessing are forcing manufacturers to rethink 
traditional manufacturing and distribution models. Whereby traditional pharmaceutical 
and biopharmaceutical products have often been produced at a large, centralised 
facility, the time-sensitive nature of fresh cell therapy products may necessitate a 
different approach. Decentralised, satellite facilities have been proposed as an option 
for the production of autologous therapies and fresh, allogeneic therapies that have 
a limited lifespan following formulation. 
This chapter has highlighted that while there has been progress in improving 
bioprocesses for cellular products, challenges exist still to achieving cost-effective 
manufacture. Current and future cell therapy bioprocess practices, as summarised in 
this chapter, were used as the problem domains for the decisional tools developed 
within this thesis. The generic processes outlined in this chapter were used as the 
basic inputs for the unit operations to be included in the tools, as Chapter 3 describes, 
with adjustments made to capture the specifics of different bioprocesses considered 
within this work. 
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Chapter 3: Materials and Methods 
3.1 Introduction  
The field of human cell bioprocessing is a relatively nascent, emerging field. 
Pressures to deliver both cell therapies and human stem cell-derived cells for use as 
research tools at affordable prices have, and will continue to, drive efficient 
manufacturing strategies and bioprocess platforms.  
In Chapter 1, the importance of making effective decisions with regards to 
manufacturing strategies and process designs early on in product development was 
highlighted. Such decisions must be made with due consideration given to both 
technical and financial aspects of bioprocess design. Process simulation tools are a 
valuable asset to companies seeking to identify cost-effective manufacturing 
strategies and process designs in the early stages of product development. 
This chapter introduces the tools that have been developed for the research 
presented in this thesis. Section 3.2 outlines the architecture of the models 
developed. This is followed by a description of the models used to compute mass 
balances and process costs within the decisional tools in Section 3.3 & 3.4. Section 
3.5 details the different approaches to the identification of optimal process designs 
that have been employed. Stochastic modelling approaches that were used to deal 
with process uncertainty are outlined in Section 3.6. Finally, the data collection 
methods used throughout this research are highlighted in Section 3.7. 
3.2 Model Architecture   
A series of decisional tools have been developed to allow the identification of cost-
effective process designs within the cell therapy sector. The tools developed all follow 
a similar architecture and (unless stated otherwise) consist of a deterministic 
bioprocess economics model and linked database, an algorithm used to identify 
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optimal manufacturing strategies and/or bioprocess designs, and a stochastic 
analysis algorithm (Figure 3.1).  
The information database houses not only key input information associated with the 
specific bioprocess that is being evaluated by the decisional tool, but also technical 
and cost data pertaining to technologies, materials and media to be tested by the 
case studies reported in Chapters 3, 4 & 5.  
The bioprocess economics model is used to compute mass balances and process 
costs for a given manufacturing strategy or bioprocess design. An overview of the 
bioprocess economics model developed is given in Section 3.3. 
Specific bioprocess designs or manufacturing strategies can be encoded manually 
into the bioprocess economics model, however the algorithms that were developed 
were designed to generate possible process configurations (within set constraints), 
from the database of specified technologies and bioprocess designs. Key output 
parameters for each process configuration generated by the algorithm were then 
evaluated using the bioprocess economics model. Cost-effective process designs 
and manufacturing strategies were identified in this manner; the outputs of the 
bioprocess economic model were used to evaluate and assess each bioprocess 
configuration from a financial perspective. 
The stochastic analysis algorithm was also linked to the bioprocess economics model 
in order to capture variations in key outputs of the bioprocess economics model under 
manufacturing uncertainty. 
Figure 3.1 shows an how the components described above work together to provide 
meaningful outputs associated with a bioprocess such as process costs, resource 
utilisation, cost-effective process designs and information on process robustness 
under uncertainty. 
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Figure 3.1 Schematic of the model architecture employed for the computational tools. 
An optimisation algorithm is linked to a detailed process economics model. The 
process economics model performs mass balancing and equipment sizing 
calculations, and computes key performance metrics. The optimisation algorithm 
identifies the best sequence of process technologies to use within a given 
manufacturing strategy. The stochastic analysis algorithm is also linked to the process 
economics model. Random values are assigned to variable inputs according to the 
probability distributions assigned in the stochastic analysis algorithm. The outputs of 
each individual simulation from the stochastic modelling process are used to draw 
conclusions about the robustness of a bioprocess under manufacturing uncertainty. 
3.3 Process Models 
Previously published process models have focused on a mass balance of materials 
across specific unit operations within a bioprocess. However stem cell and cell 
therapy bioprocesses present a unique scenario in that the final population of living 
cells is the product. Therefore, the focus of the process models developed in this 
thesis is on the flow of viable target cells through the process. Consequently a set of 
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equations has been constructed to model this parameter for each specific unit 
operation; i.e. in this case a ‘mass balance’ of cells has been developed. 
The process models described in this chapter were used to calculate the composition 
and size of cell populations within each stage of the bioprocess. The process models 
described in this section allowed target product yield to be determined rapidly under 
different scenarios. This information fed directly into the number of manufacturing lots 
required to meet product demands and in turn the cost-effectiveness of a bioprocess. 
Furthermore, the process models detailed in this section provided an insight into 
resource utilisation and the impact that different process designs have upon this. The 
identification of the impacts of different process designs upon the utilisation of key 
resources allowed a deeper analysis of how and why certain process designs proved 
more cost-effective than others.  
The process models outlined in this section reflect those that were used in a variety 
of decisional tools created as part of this work. For the most part, the generic 
calculations can be applied to every case study outlined in subsequent chapters; 
however alterations in these models that are specific to an individual case study will 
be presented in the relevant chapter. Furthermore, the process models listed below 
present some unit operations that are specific only to a bioprocess utilised for a 
certain type of cell therapy (e.g. CAR-T cell, or hiPSC-derived cell); information on 
the process models applied in each case study is given in subsequent chapters where 
these case studies are presented.  
3.3.1 Cell Culture (Expansion)  
Expansion, or cell culture, operations are inherent in almost all cell therapy 
bioprocesses. It is the process by which cell populations are systematically increased 
to clinically relevant cell numbers. The achievable increase in cell population size is 
a function of the daily growth rate of a population of cells; this determines the 
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expansion fold. The expansion fold refers to the fold-increase in the number of cells 
in a population over a given time-period of cell culture.  
Passaging is a common technique in order to prevent cell concentration from 
becoming the limiting factor on the expansion fold that is achievable within a cell 
culture unit operation. Passaging involves transferring the population of cells to fresh 
culture vessels (this could be a single, larger vessel, or multiple vessels of the same 
size) in order to disperse cells at the standard seeding density (or concentration if 
suspension culture is employed). This allows the populations to continue to expand 
without exceeding limitations in the maximum viable cell density or concentration.  
The output of a cell culture unit operation, in terms of the number of cells, nF, can 
therefore be described as: 
𝑛𝐹 =  𝑛0 ∗ (𝑓) ∗ ℎ  (3.1) 
where n0 = starting number of cells 
 f = expansion fold of the cell population 
 h = harvest yield of the unit operation (%) 
Equation 3.1 gives the output of a single stage of a cell culture unit operation. Where 
multiple passages were assumed, the total output of a cell culture operation (with all 
passages accounted for) was calculated as follows: 
𝑛𝐹 = 𝑛0 ∗ 𝑓
𝜌 ∗ ℎ𝜌  (3.2) 
where ρ =  number of passages in a cell culture unit operation 
The application of Eq. 3.1 and 3.2 to each individual passage within a cell culture unit 
operation (where applicable) allows computation of the resource utilisation associated 
with each individual passage, and allows cost-effective technologies to be selected 
for each phase of the cell culture operation.  
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3.3.2 Viral Transduction 
Genetic engineering of cells is used to alter cell phenotype for a variety of purposes. 
A detailed overview of the techniques used to achieve this, and the reasons behind 
their applications can be found in Chapter 1. Viral transduction is a genetic 
engineering technique that has applications in the production of hiPSCs from a 
population of somatic cells and also in the generation of CAR-T cells.  
The efficiency of a viral transduction process can be defined as the percentage of 
cells in a starting population (N0) that are converted to the desired phenotype. Viral 
transduction does not result in 100% conversion of a starting cell population to the 
target cell phenotype. Therefore a process model has been developed to capture both 
the number of target cells produced by this process, but also the number of non-target 
(or contaminating cells) remaining in the cell population.  
The final number of target cells, nF target, from a viral transduction, or electroporation 
unit operation was calculated as follows: 
𝑛𝐹 𝑡𝑎𝑟𝑔𝑒𝑡 =  𝑒𝑉𝑇 ∗  𝑒F 0 < 𝑒𝑉𝑇 ≤ 1 (3.3) 
where eVT = efficiency of the transduction process  
The number of non-target cells produced within a viral transduction unit operation can 
therefore be described thus: 
𝑁𝐹 𝑛𝑜𝑛−𝑡𝑎𝑟𝑔𝑒𝑡 = (1 − 𝑒𝑉𝑇) ∗  𝑛F 0 < 𝑒𝑉𝑇 ≤ 1 (3.4) 
The composition of the cell populations computed using this method could be used 
to estimate the yield of target cells within a bioprocess and the level of whole cell 
impurities present in a bioprocess stream.  
3.3.3 Electroporation 
Electroporation, in addition to viral transduction, is a technique by which genetic 
modifications can be made to cells in order to alter their phenotype. Electroporation 
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can be used to deliver non-viral vectors to cells. Typical non-viral vectors include 
transposons, which are used to deliver mRNA encoding transgenes into cells. Similar 
to transduction, the efficiency of an electroporation process is represented by the 
percentage of a population of cells that successfully exhibit a target phenotype 
following the unit operation. In order to capture the composition of the cell population 
following electroporation, the following equations were applied: 
𝑛𝐹 𝑡𝑎𝑟𝑔𝑒𝑡 =  𝑒𝐸𝑃 ∗  𝑛F 0 < 𝑒𝐸𝑃 ≤ 1 (3.5) 
where xEP =  efficiency of the transduction process  
𝑛𝐹 𝑛𝑜𝑛−𝑡𝑎𝑟𝑔𝑒𝑡 = (1 − 𝑒𝐸𝑃) ∗  𝑛F 0 < 𝑒𝐸𝑃 ≤ 1 (3.6) 
 
3.3.4 Differentiation  
Differentiation is the process by which a target cell phenotype, for example RPE cells 
to treat macular degeneration, is derived from a population of stem cells. In the work 
presented here only hPSC differentiation towards somatic cell types is considered. 
Differentiation efficiencies vary according to both the differentiation strategy 
employed, and the phenotype of the target cell that is required (as discussed in 
Chapter 1). In this work, the differentiation efficiency is represented by the ratio of 
target cells produced to the total number of cells in the differentiation feed stream. 
Therefore the differentiation efficiency was defined as follows: 
𝑒𝑑𝑖𝑓𝑓  =  
𝑛𝐹 𝑡𝑎𝑟𝑔𝑒𝑡
𝑛𝑜
 0 < 𝑒𝑑𝑖𝑓𝑓 ≤ 1 (3.7) 
where ediff = efficiency of the differentiation process  
However, differentiation is predominantly a cell culture-based unit operation. 
Therefore, the yields, in terms of the number of target cells produced by a 
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differentiation process, NF target, and the total number of undifferentiated, or non-target 
cells (NF non-target) , was calculated as follows: 
𝑛𝐹 𝑡𝑎𝑟𝑔𝑒𝑡 =  𝑛F ∗ 𝑒𝑑𝑖𝑓𝑓 ∗ ℎ 0 < 𝑒𝑑𝑖𝑓𝑓 ≤ 1 (3.8) 
 
𝑛𝐹 𝑛𝑜𝑛−𝑡𝑎𝑟𝑔𝑒𝑡 = (𝑛F ∗ (1 − 𝑒𝑑𝑖𝑓𝑓) + 𝑛0 ∗ 𝑓 ∗ ℎ 0 < 𝑒𝑑𝑖𝑓𝑓 ≤ 1 (3.9) 
where f = expansion fold of the differentiation culture as defined in equation 3.2  
The calculations above provide an estimation as to the yield of target cells that exit 
the differentiation process. Some differentiation protocols rely on the fact that non-
differentiated cells can be removed by ‘culture-based’ purification, whereby culture 
conditions mean that non-differentiated cells are unable to survive. Note, that for 
some culture-based purification protocols such as this, the expansion fold, f, is 
essentially negligible as the number of cells that die off negates any increase in the 
overall cell population, hence nF ≤ n0 in some cases. 
3.3.5 Concentration 
Concentration, sometimes referred to as washing, involves separation of media (and 
in some cases support materials such as microcarriers) from a cell population. The 
cells are concentrated in this stage as media is removed from the process stream. 
The performance of a concentration step can be quantified using a concentration 
factor (CF) and the yield of the unit operation (or percentage of target cells that are 
retained in the process stream (xconc)). The volume retained within the process stream 
can be calculated as a function of the concentration factor that can be achieved using 
a given technology: 
𝑣𝑟𝑒𝑡 =
𝑣0
𝐶𝐹
  (3.10) 
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where v0 = volume of the feed stream 
The yield of target cells present as an output of the concentration step can be defined 
as  
𝑛𝑟𝑒𝑡 𝑡𝑎𝑟𝑔𝑒𝑡 = 𝑛0 𝑡𝑎𝑟𝑔𝑒𝑡 ∗ 𝑒𝑐𝑜𝑛𝑐 0 < 𝑒𝑐𝑜𝑛𝑐 ≤ 1 (3.11) 
where econc = percentage yield of viable cells that are retained following volume 
reduction 
Devices used for volume reduction can employ either centrifugation techniques, or 
filtration in order to concentrate cell populations. Occasionally, this can result in a 
reduction in the number of non-target cells within the process stream, which may be 
separated from target cells on the basis of size or density. The number of non-target 
cells in retained in the process stream, nret non-target, was computed as follows: 
𝑛𝑟𝑒𝑡 𝑛𝑜𝑛−𝑡𝑎𝑟𝑔𝑒𝑡 =
𝑛0 𝑛𝑜𝑛−𝑡𝑎𝑟𝑔𝑒𝑡 ∗ 𝑒𝑐𝑜𝑛𝑐
𝑅𝑓
 𝑅𝑓 ≥ 1 (3.12) 
where Rf = factor by which the number of non-target cells are reduced during 
the volume reduction stage 
For volume reduction operations whereby target cells cannot be separated from non-
target cells, an Rf of 1 is assumed. An example of this is in allogeneic CAR-T cell 
manufacture where a mixed population of CAR-T cells, some of which are TCR- or 
TCR+ cells, is subject volume reduction following cell culture. In this instance the 
target TCR- cells cannot be separated from TCR+ cells during the volume reduction 
phase. 
In this instance, the composition of the feed stream, both in terms of percentage and 
number of target cells as well as the concentration of cells, is important as it may have 
an impact upon the feasibility of subsequent unit operations such as affinity 
purification and vialling of cryopreserved product (if applicable).  
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3.3.6 Purification 
Purification is an essential part of many cell therapy bioprocesses whereby a 
population of pure target cells which form the cell therapy must be extracted from a 
mixed population of cells. In this work high resolution, affinity purification techniques 
have been evaluated within case studies laid out in subsequent chapters. Affinity 
purification techniques rely on the separation of cells based on the presence (or lack 
thereof) of surface antigens.  
The performance of a purification process can be characterised using three key 
performance parameters; the total viable cell yield; zpur (%), the percentage yield of 
target cells retained in the process stream following purification; xpur, and the purity of 
the final cell population, pF (%). 
The total number of cells in the final cell population can therefore be described as: 
𝑛𝐹 = 𝑛0 ∗ 𝑧 𝑝𝑢𝑟 ∗ 𝑥𝑝𝑢𝑟 0 <  𝑥𝑝𝑢𝑟, 𝑧𝑝𝑢𝑟 ≤ 1 (3.13) 
The number of target cells collected from the purification process was therefore 
derived from the initial cell population using the equation; 
𝑛𝐹 𝑡𝑎𝑟𝑔𝑒𝑡 =  𝑛0 ∗ 𝑝𝑜 ∗ 𝑥𝑝𝑢𝑟 ∗ 𝑧𝑝𝑢𝑟 0 < 𝑝0, 𝑥𝑝𝑢𝑟, 𝑧𝑝𝑢𝑟 ≤ 1 (3.14) 
where po = the purity of the starting cell population (% of target cells) 
And the number of non-target cells, nF non-target may be described as  
𝑛𝐹 𝑛𝑜𝑛−𝑡𝑎𝑟𝑔𝑒𝑡 =  [𝑛0 ∗ (1 − 𝑝0)] ∗ 𝑧𝑝𝑢𝑟 ∗ (1
− 𝑝𝐹) 
0 < 𝑝0, 𝑝𝐹 , 𝑧𝑝𝑢𝑟 ≤ 1 
 
(3.15) 
 
3.3.7 Resource Utilisation  
It was necessary to quantify the utilisation of resources within a bioprocess; in this 
case the utilisation of media, reagents, single-use culture vessels, fixed equipment, 
123 
 
and labour were computed by the process model. The consumption and utilisation of 
such resources determines the overall cost of a bioprocess and the capacity required 
of the facility housing the bioprocess.  
In order to quantify the number of manufacturing lots per year, la, the annual demand, 
t, was divided by the output of an individual manufacturing lot, m, thus; 
𝑙𝑎 = ⌈
𝑡
𝑚
⌉  (3.16) 
The number of manufacturing lots per year, and the duration of the bioprocess has a 
significant impact upon the utilisation of both direct and indirect resources associated 
with a bioprocess; the number of manufacturing lots run in parallel, lp, was determined 
as a function of both the length of the bioprocess, bl, and the length of time that the 
bioprocess facility is in operation over the course of a year, bf ; 
𝑙𝑃 =
𝑙𝑎
⌈
𝑏𝑓
𝑏𝑙
⌉
 
 (3.17) 
A key parameter when evaluating equipment sizing strategies is the type of 
technology to be used within each unit operation and the number of units required to 
process the required number of cells in each manufacturing lot.  
For a cell population of maximum size n, the number of disposable units (ucon) 
required of a particular technology, j, for a given unit operation, i, was computed as; 
𝑢𝑐𝑜𝑛 𝑗,𝑖 = ⌈
𝑛𝑖
𝑠𝑗
⌉  (3.18) 
Where sj = the capacity of a given technology (number of cells)  
For cell culture based unit operations, whereby multiple, disposable vessels may be 
required, sj, was defined as; 
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𝑠𝑗 = 𝑑ℎ,𝑖 ∗  𝑎𝑗  (3.19) 
where dh,i = maximum cell density (for adherent culture) (cm2) or cell 
concentration (for suspension culture) (mL) allowable in a given 
technology used within a given unit operation 
 aj = surface area (for adherent culture) (cm2) or volume (for suspension 
culture) available within a given technology (mL) 
For many DSP operations it is necessary to constrain the number of process units 
required to one per manufacturing lot, particularly for back-end operations such as 
purification. This is because whilst units could be run in parallel, the pooling of 
samples together after purification was deemed an unlikely practice to be employed 
in a clinical setting owing to cGMP guidelines on product consistency.  Therefore a 
constraint was placed on process designs such that: 
𝑢𝑐𝑜𝑛 𝑖,𝑗 = 1 
𝑛𝑖
𝑠𝑗
< 1, 𝑣𝑖 ≤ 𝑣𝑗 𝑚𝑎𝑥 (3.20) 
where vi =  feed volume of a unit operation 
 vj max  = surface area (for adherent culture) or volume (for suspension 
culture) available within a given technology 
The volume of the DSP technology has been considered here because some 
technologies evaluated in the case studies presented in subsequent chapters had a 
maximum capacity given as a volume and some had a maximum capacity given as a 
total cell number.  
It is also important to note that for DSP equipment, ucon j, may refer to disposable 
tubing sets, membranes and/or cartridges rather the ‘vessels’ characteristic of cell 
culture operations. 
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Following computation of the number of disposable units required per manufacturing 
lot for each unit operation, it was possible to estimate the number of skids, or pieces 
of fixed equipment, ufixed j, required to support a given disposable technology. The 
number of skids required was calculated as function of the maximum number of 
relevant disposable vessels in use at any one time, across all unit operations. This 
was considered the best approach so that the utilisation of skids could be maximised 
by using the same skid to support the whole bioprocess, rather than a single unit 
operation, thus minimising ‘dead’ time of fixed equipment. The number of skids/ 
pieces of ancillary equipment required was therefore computed as; 
𝑢𝑓𝑖𝑥𝑒𝑑 𝑗 =  ⌈
max(𝑢𝑐𝑜𝑛 𝑖,𝑗)𝑖=1
𝑘
𝑚𝑗
⌉ ∗  𝐿𝑝  (3.21) 
where mj = capacity of ancillary equipment, in terms of the number 
of disposable vessels that one piece of equipment can 
support at a given time 
 max(𝑢𝑐𝑜𝑛 𝑖,𝑗)𝑖=1
𝑘  = maximum number of units of a given disposable 
technology, j, required at any point in the bioprocess (for 
unit operations i = 1,…,k) 
It was assumed that separate equipment would be required for parallel lots to avoid 
the risk of cross-contamination between different manufacturing lots.  
The number of operators required for a given technology was calculated as a function 
of the maximum number of units required, uj, and the number of units of a given 
technology that a team of 2 operators could handle, yj. A factor of 2 is included in 
equation 3.22 because operators were assumed to work in teams of 2, as per cGMP 
guidelines.  
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𝑊𝑗 =  ⌈
max(𝑢𝑖,𝑗)𝑖=1
𝑘
𝑦𝑗
⌉ ∗ 2  (3.22) 
where max(𝑢 𝑖,𝑗)𝑖=1
𝑛  = maximum number of units required of a specific 
technology, j, for unit operations i = 1,…,k 
The total number of operators was calculated as a function of the number of parallel 
manufacturing lots per year; it was assumed that lots in series could be handled by 
the same operators. Therefore; 
𝑤𝑎𝑛𝑛 =  [max(𝑊𝑗)𝑗=1
𝑘 ] ∗ 𝑙𝑝  (3.23) 
where max(𝑤 𝑗)𝑗=1
𝑙  =  maximum number of operators required to handle any 
technology, j = 1,…,k used in a bioprocess  
3.4 Cost Models 
The previous section focused on process models associated that were used to 
compute mass balances and calculate resource utilisation associated with a 
bioprocess. This section introduces the cost models, which utilise data generated by 
the process models described in the previous section to evaluate the financial 
performance of a bioprocess. The cost models presented in this section have been 
adapted from Farid (2002), where two key cost parameters fixed capital investment 
(FCI) and cost of goods (COG) are measured. Cost models have been adapted from 
the originals presented in (2002) in order to reflect the differences in cell therapy 
bioprocessing from biopharmaceutical protein manufacturing (as was their original 
function). 
3.4.1 Fixed Capital Investment 
Fixed capital investment costs represent the cost of any fixed equipment, along with 
the costs associated with building a facility to support a bioprocess. A Lang factor 
method was used to approximate fixed capital investment (Lang 1948). The Lang 
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factor method assigns a proportionality constant to the total equipment purchase cost 
(TEPC) in order to provide an estimate of the FCI required of a bioprocess. Therefore; 
𝐹𝐶𝐼 =  𝐹𝐿𝑎𝑛𝑔 ∗ 𝑇𝐸𝑃𝐶  (3.24) 
where FLang = Lang factor that appropriately approximates the cost of a cell 
therapy/stem cell bioprocess facility 
3.4.2 Cost of Goods 
The COG represents the cost to manufacture a cell therapy, or stem cell product. 
COG comprises direct and indirect costs. Direct costs (DC), comprise of expenditure 
on materials and labour; they are a function of utilisation. Indirect costs (IDC), are 
expenditures that are independent of resource utilisation; they consist of depreciation 
costs (or amortisation), and miscellaneous costs such as equipment maintenance, 
tax and insurance.  
Factors proposed by Farid (2002) were used to provide estimations of additional 
direct cost categories (namely, miscellaneous materials and QC/QA labour costs), 
and standard factors used in chemical engineering textbooks (e.g. Sinnott, XXXX)  
were used for indirect cost categories (namely maintenance, taxes, and insurance). 
These factors are presented in Table 3.1. 
The total COG for a bioprocess can be described as; 
𝐶𝑂𝐺 =  𝑐𝑑𝑖𝑟𝑒𝑐𝑡 + 𝑐𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡  (3.25) 
Where cdirect = direct costs 
 cindirect = indirect costs 
Direct costs are computed thus; 
𝑐𝑑𝑖𝑟𝑒𝑐𝑡 = 𝑐𝑙𝑎𝑏 +  𝑐𝑚𝑎𝑡  (3.26) 
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Where clab = labour costs 
 cmat = materials costs 
 
 
Labour costs are approximated from the value describing the number of operators 
required to run a bioprocess, wann and the annual cost of employment for one operator 
per annum, cop. The cost QC/QA, supervisory, and management staff are also 
accounted for by the factor, Flab: 
𝑐𝑙𝑎𝑏 = (𝑤𝑎𝑛𝑛 + 𝑐𝑜𝑝) ∗ 𝐹𝑙𝑎𝑏  (3.27) 
Materials costs are calculated as function of utilisation, on a unit operation basis. The 
calculation of direct costs associated with each unit operation was performed in order 
Table 3.1 Cost of goods model overview 
Cost Category Parameter Cost Factor 
Direct Supervisors 0.2 * Operating Labour 
 QC/QA 1.0 * Operating Labour 
 Management 1.0 * Operating Labour 
 Misc. materials 0.5 * Materials 
 Materials f (utilisation) 
   
Indirect Maintenance 0.1*Capital Investment 
 Local Taxes 0.02* Capital Investment 
 Insurance 0.01* Capital Investment 
 Depreciation Capital investment
Depreciation period (years)
  
129 
 
to allow in depth analysis of a bioprocess, allowing focused efforts on cost reduction 
at stage of the bioprocess where it is likely to have the most impact. Generally 
materials costs were calculated thus: 
𝑐𝑚𝑎𝑡 𝑗 =  [(∑ 𝑣𝑚 𝑘 ∗ 𝑐𝑚 𝑘
𝑛1
𝑘=1
) + ∑ 𝑢𝑐𝑜𝑛 𝑖 ∗ 𝑐𝑐𝑜𝑛 𝑖
𝑛2
𝑖=1
] ∗  𝐹𝑚𝑎𝑡  (3.28) 
where cm j =  cost of a reagent, k, used within a unit operation, j 
 ccon = cost of any consumable technology, i, used within a unit operation, 
j 
 vm = volume of any reagent, k, required within a unit operation, j 
 Fmat = A factor to describe the cost of miscellaneous materials such as 
PPE 
Total material costs are then calculated by aggregating material costs from each unit 
operation; 
𝑐𝑚𝑎𝑡 =  ∑ 𝑐𝑚𝑎𝑡 𝑗
𝑛3
𝑗=1
  (3.29) 
The calculation of overall annual costs on a cost category basis is important as it 
allows the process development teams to envisage how changes in process design 
will not only affect the total COG, but also the breakdown of the COG into its 
constituent parts.  
Annual indirect costs were calculated as a function of the capital investment required 
of a facility and the depreciation period, δ, or lifespan of the facility; 
𝑐𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 =  𝐹𝐶𝐼 ∗ (
1
𝛿
+ 𝐹𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡)   (3.30) 
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where Findirect = factor which describes the cumulative cost of insurance, 
depreciation, local taxes and maintenance of a bioprocess facility 
3.4.3 Distribution and Shipping costs 
In Chapter 4, shipping costs were calculated as part of a representative case study 
seeking to compare different manufacturing strategies for an allogeneic cell therapy.  
When overland distribution was considered, shipping costs, τ, were calculated as a 
function of the number of secondary facilities, μ, and the number of hospitals, ε: 
𝜏 = 𝜇 ∗ (𝛼𝑝𝑓 ∗ 𝛽𝑝𝑓) + 𝜀 ∗ 𝜇 ∗ ( 𝛼𝑠𝑓 ∗ 𝛽𝑠𝑓)  (3.31) 
where αpf = number of deliveries made from primary to secondary 
facility 
 αsf = number of deliveries made from secondary facility to 
clinic 
 βpf = factor representing road transportation costs from 
primary to secondary facility 
 βsf = factor representing road transportation costs from 
secondary facility to the clinic 
Where overseas shipping, via air transportation, was required, shipping costs, τ, were 
calculated as follows: 
𝜏 =  𝛼𝑝𝑎 ∗ 𝛽𝑝𝑎 + 𝜇 ∗ (𝛼𝑤 ∗ 𝛽𝑤) + 𝜀 ∗  𝜇 ∗  (𝛼𝑠𝑓 ∗ 𝛽𝑠𝑓)  (3.32) 
where αpa = number of deliveries made from primary to airport 
 αw = number of air shipments 
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 βpa = factor representing road transportation costs from 
primary facility to airport 
 βw = factor representing air transportation costs inclusive of 
road transportation costs to secondary facility on arrival 
The cost factors used to represent transportation costs can be found in Chapter 4, 
where the case study that utilises the shipping cost model is described.  
3.5 Identification of optimal process designs and manufacturing 
strategies 
The work presented in this thesis focuses on the identification of cost-effective 
bioprocess designs. The bioprocess economics model described in Sections 3.3 & 
3.4 is capable of computing COG per unit for a specified process design. In order to 
ensure that the most cost-effective bioprocess design or manufacturing strategy, 
within a defined design space, was identified efficiently, algorithm-based search 
and/or optimisation tools were applied to each of the case studies presented in 
subsequent chapters. This section will focus on the algorithms and optimisation 
procedures used to carry out this process.  
The methodologies presented here involve the generation of candidate solutions for 
a given bioprocess. Within these candidate solutions, a technology, i, is assigned to 
a unit operation, j. Figure 3.2 shows a candidate solution, x, for a hypothetical 
bioprocess consisting of number of unit operations, k. The algorithms outlined below 
link with the bioprocess economics model using the closed-loop model architecture 
displayed in Figure 3.1 to generate candidate solutions and compute performance 
metrics for each solution.  
Each stage, or unit operation, within the bioprocess in the case shown above is 
subject to one discrete variable, which is the candidate technology to be used. As 
shown in Figure 3.2, the candidate technologies are encoded using an integer value 
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from a set of technologies specific to that unit operation. Therefore the design space, 
X, in terms of the number of available solutions, for the above bioprocess can be 
computed as; 
𝑋 = (∏ 𝑞𝑖
𝑘
𝑖=1
) − 𝑋𝑐𝑜𝑛  (3.33) 
where qi = number of candidate technologies available for each unit operation, 
j 
 Xcon = number of solutions that are not assessed due to constraints on 
process designs 
 
 
 
 
Figure 3.2 A candidate solution for a bioprocess containing i=k unit operations. Each 
step, i = 1,…, k is defined by a technology ji. Candidate technologies are taken from 
a set of technologies specific to each unit operation and are encoded using an integer 
value. 
3.5.1 Brute-force search algorithm 
Brute-force search algorithms are an exhaustive means of assessing all solutions 
within a given design space. All possible solutions, x1,…,xN, are evaluated 
sequentially by a brute force search algorithm such that the number of iterations 
necessary to complete the procedure is equal to X (defined in equation 3.31).  
Brute-force search algorithms hold an advantage over optimisation procedures 
outlined in subsequent sections in that they are simple to set-up in order to generate 
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results rapidly. This approach is particularly useful where a design space is relatively 
small, where approaches such as evolutionary algorithms would require a significant 
amount of effort to set-up for little gain in terms of computational effort and procedure 
run time. Brute-force search algorithms were initially used in a case study presented 
in this work (see Chapter 3). The brute-force approach was also selected in a 
subsequent case study which resulted in a small design space (i.e. few available 
solutions); this did not necessitate the use of a more advanced search and/or 
optimisation procedure (see Chapter 5). 
Figure 3.3 illustrates the framework by which a brute-force search algorithm interacts 
with the bioprocess economics model to allow the evaluation of every available 
bioprocess design, but also allows the identification of the most cost-effective process 
design within this search area.  
The bioprocess economics model described in Section 3.3 and 3.4 is able to 
calculate the COG per unit of production for a specific process design; the brute 
force search algorithm then develops every available bioprocess design (x1,…,xN) 
within a set of constraints. Key output metrics associated with each process design 
are then computed using the bioprocess economics model. The brute-force search 
algorithm then evaluates the candidate solution, x, on the basis of an objective 
function (in most cases presented here this is the COG per unit of product). Once 
the search algorithm has ensured that all bioprocess designs have been tested, the 
procedure is halted and the ‘fittest’ solution, or optimal bioprocess design, is 
identified.  
3.5.2 Evolutionary Algorithms 
An evolutionary algorithm (EA) represents a population-based optimisation 
procedure, which employ models of biological evolution. Evolutionary algorithms 
mimic biological evolution in that the ‘fittest’ (or best) members of a population are 
passed on to future generations. Variations, as in nature, occur in the form of mutation 
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and crossover. Specific nomenclature is applied to EAs that reflects their relationship 
to biological evolutionary processes. A short glossary is provided in Table 3.2.  
EAs hold significant advantages over brute-force approaches to identification of cost-
effective process designs. These advantages are most apparent when the number of 
possible solutions, X, for a given problem is large. As detailed in section 3.5.1, a brute-
force search algorithm must assess every possible solution, x, within a design space. 
In contrast, an EA will only have to compute a fraction of the possible solutions within 
this domain. This is because EAs rely on the fitness, or effectiveness, of previously 
evaluated solutions; the optimal solution can therefore be found using fewer iterations 
than brute-force approaches. The increase in efficiency achieved through the use of 
an EA as compared to a brute-force search algorithm varies depending on the values 
selected for key EA parameters outlined in Table 3.3, as these dictate the number of 
iterations required to complete the EA procedure. In this work, a specific type of EA, 
known as a genetic algorithm (GA), was developed in order to perform optimisation 
of a bioprocess based on financial performance. 
The procedure by which the GA developed is shown in the pseudo-code contained in 
Algorithm 3.1, a basic outline of the main loop of this procedure is given in Figure 3.4, 
along with visual representations of key operations within the GA. In the algorithm, N 
denotes the size of the current solution P, also referred to as the parent population in 
Figure 3.5. The GA begins by initialising a population, Pop, of fixed size, ψ, with 
randomly generated solutions (or chromosomes) which satisfy bioprocess sequence 
constraints (introduced in Chapter 4). A solution, x, is evaluated via the method 
evaluate(x, H); this serves as the interface between the bioprocess economics model 
and the optimisation procedure. The method evaluate(x, H), allows a candidate 
solution, x, to be encoded in to the bioprocess economics model so that the fitness 
of x can be evaluated using the objective function.  
135 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Schematic displaying the interaction between the brute-force search algorithm and a bioprocess economics model. Each 
solution, x, is encoded into the bioprocess economics model and key outputs are computed. The solutions are then evaluated on the 
basis of an objective function, f(x), and the optimal bioprocess design is identified. The algorithm continues until all feasible solutions, 
x1,…, xN have been evaluated.  
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. 
Following this, in the main loop (Figure 3.4), binary tournament selection is used to 
select parents from the randomly generated population, Pop. This gives rise to the 
population, PopTournament, of size ψ. A visual representation of binary tournament 
selection is given in Figure 3.5a. Genetic operators are then used to create an 
Table 3.2 Glossary of terms associated with evolutionary computing 
Term Definition 
Population A set of solutions 
Fitness The quality of a solution 
Objective function Function used to quantify the fitness of a solution 
Chromosome An encoded solution; usually represented as a string of 
values 
Gene/ locus An individual piece of information that makes up a 
chromosome 
Crossover Process by which two solutions exchange sections of their 
genetic information in order to introduce variation into a 
population 
Crossover rate The probability of crossover occurring between two parent 
solutions 
Mutation Process by which the individual gene’s within a solution are 
subjected to random change 
Mutation rate The probability of mutation occurring at each locus within a 
solution 
Parent Solution used to generate new solutions 
Offspring Solution resultant of a crossover operation 
Generation One iteration of the evolutionary procedure (involving 
selection, crossover & mutation) 
Environmental 
selection 
Process by which solutions are selected to either form a 
parental population, or process by which solutions are 
selected  to form the population of a successive generation 
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offspring population, OffPop, of size N. Crossover is used, whereby two parents are 
subjected to single-point crossover (Figure 3.5b) in order to generate two offspring 
solutions. Following this, variation is introduced into OffPop by subjecting 
chromosomes to random bit mutation (Figure 3.5c).  
Table 3.3 Key parameters associated with a GA and their assigned values 
Parameter Value Assigned 
Population size (ψ) 30 
Number of generations (G) 30 
Mutation rate (rm) 0.1 
Crossover rate (rc) 0.7 
Algorithm runs (R)   10 
Mutation is applied at random according to a fixed probability, rm, (Table 3.3) to any 
stage of the bioprocess (j = 1,…,k), within a solution, x. The parent and offspring 
populations are combined and then subjected to elitist sorting, whereby the fittest 
solutions are carried over to form 90% of ψ for the next generation. Elitist sorting 
ensures that any offspring that only the fittest members of the combined parent and 
offspring populations are passed on to the successive generation. The remaining 10% 
of the population in the subsequent generation are randomly generated immigrant 
solutions. Immigrant solutions are usually reserved for dynamic optimisation 
problems, where the objective function may change during optimisation; they were 
included in this study as localised convergence was observed when random 
immigrants were omitted from the algorithm. The introduction of immigrant 
chromosomes into a population represents an instance of GA fine tuning. Tuning of 
evolutionary approaches to optimisation is a common practice used to maximise the 
efficiency and effectiveness of a procedure (2012). The procedure described in the 
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text above and the pseudo-code presented in Algorithm 3.1 represents a single GA 
‘run’. In order to ensure that the optimal solution was indeed identified, multiple runs 
for each scenario tested by the GA were carried out, so that the convergence of the 
optimal solutions could be tested. The values assigned to rm and rc in Table 3.3 were 
decided upon as a result of the use of standard values for basic GAs. The number of 
generations, runs and population size were derived as a result of tuning of the GA in 
order to ensure that an optimal solution could be reached using the minimal number 
of iterations. 
Whilst EAs often prove significantly more efficient to run (in terms of the time take to 
complete a procedure) than brute-force algorithms, they are considerably more 
complex to set-up and often require fine tuning to ensure that they do in fact find the 
optimal, or ‘fittest’ solution within a given design space (Allmendinger 2012). For 
smaller design spaces, the increased effort associated with compiling an EA 
sometimes means that brute-force approaches can be more appropriate in order to 
generate rapid results. An EA was applied in the case study presented in Chapter 4 
because the size of the design space meant that the computing time required to carry 
out a brute-force procedure proved infeasible. 
Measuring the accuracy and reliability of the evolutionary algorithm 
In order to ensure that the evolutionary algorithms used in this work did capture the 
optimal solutions in an accurate and reliable manner, measures of convergence were 
used during EA fine-tuning. Metrics such as the average fitness for each generation 
across all runs and the standard error associated with these values were measured. 
The convergence across all runs was also measured for each generation in order to 
ensure that the optimal solution could be found within an acceptable number of 
generations.  
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Finally, different scenarios evaluated by the EA were selected to be tested via brute-
force analysis. This was done to ensure that the optimal solution identified by the EA 
could be reproduced via brute-force analysis; this would ensure its accuracy. Only 
selected scenarios were tested in this way, as running all scenarios tested by the EA 
using a brute-force search procedure would consume too much time for the purposes 
of this study. 
In order to measure the savings in processing time that were achieved through the 
use of an EA, compared to brute-force procedures, a timer function was encoded into 
the algorithms used to run both the EA and brute-force analysis. This was used to 
extrapolate total savings in processing time across all the scenarios tested using the 
EA.  
The results of the analysis of the accuracy and reliability of the EA are presented in 
Chapter 4, along with the results of the case study to which the EA was applied. 
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Figure 3.4 Visual representation of the path taken by the main loop EA procedure. 
Pop in each generation is subject to tournament selection to produce 
PopTournament, a parental population. PopTournament is subject to single-point 
crossover and mutation, which gives rise to OffPop. OffPop is then combined with 
Pop and elitist sorting is conducted in order to preserve the fittest solutions from each 
generation. Immigration allows new, randomly generated solutions to form part of Pop 
for the successive generation.  
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Figure 3.5 Visual representations of a) binary tournament selection, b) single point 
crossover and c) random bit mutation. In a) binary tournament selection, two solutions 
are selected randomly from Pop  and the fittest of the two solutions is entered into the 
parental population, PopTournament. In b) single-point crossover, two hypothetical 
parent solutions are shown. A crossover point is assigned at random (e.g. 2 in this 
instance) and all genes beyond this point are swapped between the two parents to 
create two offspring solutions. Crossover occurs according to the probability rc. In c) 
random bit mutation causes alleles associated with randomly selected genes in a 
chromosome to change value according to some probability, rm. 
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Algorithm 3.1 The GA procedure and its interaction with the bioprocess economics model 
Required: Objective function; f, population size; ψ, maximum number of generations; G, 
historical solutions; H, number of available technologies, T. 
1: g= 0 (generation counter), Pop = Ø, OffPop = Ø, PopTournament = Ø 
 // initialise population: 
2: while [Pop] < ψ do 
3: Randomly generate x // ensure x satisfies sizing constraints 
4: x = evaluate (x,H); Pop = Pop ∪ {x} 
5: end while 
6: g = g +1 
 //Main loop 
 While g <G do 
7: PopTournament = Ø 
OffPop = Ø 
8: repeat 
9: Choose two parent solutions xp from Pop and select solution which best satisfies 
the objective function; PopTournament = PopTournament ∪ {xp} 
10: until [PopTournament] = ψ 
11: repeat 
12: Generate two offspring x[1] and x[2] by selecting two parents from PopTournament, 
and then recombine and mutate the offspring with one another // ensure offspring 
satisfies Eq. X 
13:  evaluate(x[1], H ); evaluate (x[2],H); OffPop = OffPop ∪ {x[1]} ∪ {x[2]}  
14:  until [OffPop] = ψ 
15: Merge = Pop ∪ OffPop; Pop = Ø 
16: Applying elitist sorting to Merge according to f1 
17: Re-generate Pop by selecting the best 0.9*ψ solutions from Merge  
18: while   0.9*ψ < [Pop] < ψ do 
19: Randomly generate x // ensure x satisfies sizing constraints 
 end while 
20: g = g+1 
 end while 
 //interface with BEM: 
21: evaluate (x, H) 
22: embed x into bioprocess shown in Fig.1 
23: run BEM and check if x satisfies utilisation constraints 
24: Compute f1  for x 
25: Update H  by returning x and f1 
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3.5.3 Constraint handling strategies 
Virtually all bioprocesses are subject to constraints in one form or another. In order 
that the solutions to the bioprocess design evaluated by the bioprocess economics 
model be feasible, constraint handling strategies were built into the optimisation 
procedures described above. Two types of constraints were applied to bioprocess 
designs in this study; sizing (or sequential) constraints and utilisation constraints.  
Sizing constraints refer to constraints placed on the size of a technology used for a 
unit operation, or set of unit operations. It was determined that for expansion unit 
operations that involve multiple stages (or passages), technologies in the process 
train must follow an ascending order in terms of their available growth area, or volume 
such that; 
𝑎𝑗 ≥ 
𝑖=𝑛+1 𝑎𝑗 
𝑖=𝑛   (3.34) 
Utilisation constraints refer to constraints placed on the minimum, and or maximum 
feasible utilisation of the available capacity within a piece of equipment. Furthermore, 
many large-scale SUBs, particularly those used for microcarrier-based and 
suspension bioreactors have a minimum utilisation threshold, below which their use 
is deemed infeasible (Sartorius Stedim 2012; GE Healthcare [no date]). It was 
therefore necessary to apply a utilisation constraint on the use of a technology such 
that; 
𝜔𝑗 𝑚𝑖𝑛 ≤ 𝜔𝑗 ≤ 𝜔𝑗 𝑚𝑎𝑥 
0 < 𝜔𝑗
< 1 
(3.35) 
Where ωj min = maximum utilisation for a given technology, j 
 ωj max = minimum utilisation for a given technology, j 
When dealing with brute-force search algorithms, it is relatively easy to deal with 
constraints; any solution, x, which does not comply with the sizing constraints can be 
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skipped so that it is not even considered in the optimisation procedure. For the 
utilisation constraint, a penalty function was put in place such that any solution, x, 
which does not comply with the utilisation constraint above, then f1(x) ∞. This 
resulted in any solutions that did not comply with the above constraints being 
assigned a poor objective function value relative to others that were tested; this 
ensured that infeasible solutions were not put forward as the optimal process design 
when brute-force procedures were employed. 
The GA procedure generated random solutions, all of which were required to form 
part of a population in order for the GA to progress. To ensure that the technologies 
selected for expansion followed the ascending order described in Eq 3.32, a sorting 
algorithm was used to arrange the random technologies selected for the expansion 
stages into ascending order of size  (as determined by available growth area and/or 
volume for cells). This is a strategy known as forcing in common evolutionary 
computation parlance. Whilst it is useful as it eliminates the possibility of non-feasible 
solutions being evaluated, its drawbacks include the fact that it may destroy and 
rearrange a piece of solution that would have resulted in a high fitness value. This is 
likely to reduce the efficiency of the GA in terms of the computational effort required 
(Allmendinger 2012).  
Similar to the strategy outlined above for brute-force procedures, utilisation 
constraints were handled using the penalty function described above. Penalty 
functions are of particular use when elitist sorting is applied within a GA, as is the 
case in this work, because they will be eliminated from the combined parent and 
offspring population within each generation owing to their poor fitness. 
3.6 Dealing with Uncertainty 
A deterministic bioprocess economics model, such as the one described in Sections 
3.3 & 3.4 is capable of computing key output parameters (such as COG and product 
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throughput) for a given solution, x, to a bioprocess design problem. However, 
deterministic analysis alone cannot offer an evaluation of process robustness under 
manufacturing uncertainty. Process reproducibility and robustness are key 
considerations in cell therapy and stem cell bioprocess design (Veraitch et al. 2008; 
Placzek et al. 2009; Jenkins and Farid 2015). Furthermore, autologous bioprocess 
designs must take into consideration donor-to-donor variability and its effect on 
bioprocess performance. Stochastic modelling techniques provide a tool by which to 
quantify the robustness and reproducibility of bioprocess strategies by simulating 
real-life variation within key bioprocess performance parameters and measuring the 
effect on this of key output parameters.  
A basic technique for dealing with uncertainty is the use of sensitivity analyses. 
Sensitivity analyses are used to evaluate the effect of ±% changes to uncertain inputs 
in a bioprocess design problem. Sensitivity analyses are a basic tool and were 
primarily used to identify key bioprocess economic drivers (namely those that resulted 
in the largest % change in COG when varied).  
The Monte Carlo simulation method is a more complex stochastic modelling 
technique, which produces a range of possible outcomes for a bioprocess design 
problem, and allows conclusions about the likelihood these will occur to be drawn. 
Monte Carlo methods rely on repeated random sampling in order to simulate 
processes for which the value of key inputs is uncertain. The Monte Carlo method 
requires estimates of probability distributions for uncertain input parameters; these 
probability distributions are assigned to key process parameters. A sample outcome 
is randomly generated by assigning a value to each parameter tested in the simulation 
according to its specific probability distribution. This process is repeated a large 
number of times in order to generate frequency distributions of simulation outcomes. 
The output distributions of the Monte Carlo experiment can then be used to determine 
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the probabilistic properties associated with the key performance metrics of a 
bioprocess design or manufacturing strategy.  
Monte Carlo analysis was used in order to imitate the randomness and uncertainty 
inherent in cell therapy and stem cell manufacturing processes. The impact of 
uncertainty in input parameters according to the choice of manufacturing strategy was 
evaluated using Monte Carlo analysis in order to help facilitate effective decision 
making in bioprocess design.  
3.7 Multi-attribute decision making 
3.7.1 Multi-attribute decision-making models 
Previous sections have focused on selection, or identification of optimal bioprocess 
strategies from a large number of alternatives based on an objective function. 
Bioprocess design models, and business models in general often focus on 
improvements in process yields or a single financial measure, such as manufacturing 
COG or a project valuation metric (e.g. NPV) (Farid et al 2005; Simaria et al. 2014; 
Hassan et al. 2015; Hassan et al. 2016).  
It is sometimes necessary to carry out a more holistic analysis of available methods, 
so as to arrive at a preferred bioprocess design having considered multiple attributes, 
not just economic metrics. One means of achieving this is via multi-attribute decision 
making (MADM). MADM analysis provides a mechanism for qualitative, as well as 
quantitative attributes of a solution to a bioprocess design problem to be evaluated. 
MADM requires that all attributes are considered across an equivalent measurement 
scale, this is usually done by converting all attributes to dimensionless units on a finite 
rating scale. This method therefore allows preference decisions to be made on the 
basis of multiple attributes for an array of different problem solutions (Yoon and 
Hwang 1995). 
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MADM analyses have previously been applied within various decision-support tools 
in the biopharmaceutical sector in order to evaluate bioprocess designs on the basis 
of operational, environmental, and economic attributes (Farid et al. 2005a; Pollock et 
al. 2013).  
3.7.2 Additive weighting technique 
In this work, a simple additive weighting technique was applied to a multi-attribute 
bioprocess design problem where economic and operational attributes were 
considered (Chapter 6). In this method an aggregate score, W, for each alternative, 
j, can be computed by multiplying the normalised rating for each attribute included in 
the analysis by the weight (representing the importance of each attribute) assigned 
to each attribute; these products are then summed over all the attributes (Yoon & 
Hwang 1995). This can be represented mathematically as; 
𝑊𝑗 =  ∑ 𝑤𝑖𝑟𝑖𝑗
𝑛
𝑖
  (3.36) 
Where wi = The normalised weight assigned to attribute i 
 rij = The dimensionless rating of attribute i for alternative j 
The additive weighting technique relies on assigning weightings to all attributes; these 
weightings are relative to the importance of each attribute within a given field. A 
greater weighting that an attribute is given, the more important it is. Weightings are 
normalised on a 0-1 scale in order to allow an aggregate score to be computed.  
Prior to computation of the aggregate score using Eqn. 3.34, each alternative (j) had 
to be assigned a rating (x) for each attribute (i), which then had to be standardised. 
Economic attributes (e.g. manufacturing COG, FCI) were calculated using the 
bioprocess economics model described in Section 3.4. Operational attribute ratings, 
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and their relative importance, were collated from responses to a survey delivered to 
industry experts.  
Different types of attributes were assigned ratings based on a number of different 
dimensions and measurement units. All attribute ratings were therefore standardised 
by converting them to a dimensionless, 0-100, scale. Standardisation was achieved 
by giving each attribute a rating that was a fraction of a feasible range of the best and 
worst attainable value for any given attribute. The dimensionless rating for each 
attribute, rij, was therefore calculated thus; 
𝑟𝑖𝑗 =  |
𝑥𝑖𝑗 − 𝑥𝑖 𝑤𝑜𝑟𝑠𝑡
𝑥𝑖 𝑏𝑒𝑠𝑡 −  𝑥𝑖 𝑤𝑜𝑟𝑠𝑡 
|  (3.37) 
where xij = rating value assigned to alternative j for attribute i 
 xi best = best attainable value for attribute i 
 xi worst = worst attainable value for attribute i 
3.7.3 Weighted financial and operational scores 
The relative importance of the total weighted economic and operational scores was 
captured using combination ratios, whose sum was equal to one. Overall aggregate 
scores for each alternative solution, Wj, were therefore calculated as follows: 
𝑊𝑗 𝑜𝑣𝑒𝑟𝑎𝑙𝑙 =  (
∑ 𝑟𝑖𝑗 𝑒𝑐𝑜𝑛𝑜𝑚𝑖𝑐
𝑛
𝑖=1
𝑛
∗ 𝑅1)
+ (
∑ 𝑟𝑖𝑗 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑙
𝑛
𝑖=1
𝑛
∗ 𝑅2)  
 (3.38) 
where R1 = economic combination ratio 
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 R2 = operational combination ratio 
 R1+R2 = 1 
3.7.4 Stochastic additive weighting  
Input variables in MADM analysis include weightings assigned to each attribute and 
the ratings assigned to each attribute for each process strategy tested using the 
analysis. In order to capture uncertainty that may be associated with these input 
variables, stochastic modelling (in the form of the Monte Carlo analysis described in 
Section 3.6) was applied to the MADM analysis. This allowed probability distributions 
for the final scores of each alternative to be generated. This allowed for more informed 
decision making, and the level of confidence associated with such a decision (Farid 
2002).  
3.8 Data Collection Methods 
As highlighted in previous sections of this chapter, default input values are assigned 
to parameters within the models described. Default values have been derived from a 
thorough scoping analysis using sources such as historical literature data, vendor 
information, and personal correspondence with industry experts.  
All input values were sanity checked during interviews and meetings with experts (T. 
Allsopp, J. Bilsland, P. Whiting, J. Kirby, Yajin Ni, M. Leonard, R. Fedechko, S. Ho; 
all of Pifzer, Cambridge, England or Pfizer, St. Louis, United States at the time of 
consultation). Further to this, industry experts were called upon to consult on 
assumptions made regarding the operation of the bioprocess facilities that have been 
evaluated in case studies presented in subsequent chapters.  
Default input values defined within each case study were encoded such that 
automated alteration could be easily achieved. This was done in order to allow 
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stochastic modelling to be carried out without the need for manual intervention (aside 
from initialising the procedure). The fact that default values could easily be altered 
also made sense from a programming perspective; the model could be re-run easily 
in light of new information without the requirement for major adaptation of the tool. 
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Chapter 4 Patient-specific hiPSC bioprocessing for drug 
screening: bioprocess economics and optimisation 
4.1 Introduction 
In addition to the potential of hiPSCs to offer a raw material for the production of 
treatments for a variety of disorder with unmet clinical needs, they offer a near term 
application where drug discovery, phenotypic screen and safety testing programmes 
might be qualitatively improved (Rubin 2008; Mason and Dunnill 2009; Wu and 
Hochedlinger 2011; Robinton and Daley 2012) (See Chapter 1). Furthermore, hiPSC-
derived somatic cells offer a humanised platform to current animal models, for pre-
clinical efficacy and toxicity studies for the development of novel therapeutics (Ebert 
and Svendsen 2010). Current animal-based paradigms have proven to be of limited 
predictive value due to fundamental biochemical, physiological and genomic 
variations from humans (Pearson 2006; Kiskinis and Eggan 2010; Scott et al. 2013). 
hiPSC-derived cells also afford a predictive platform at the preclinical to clinical 
interface, pinpointing drug responders from non-responders and stratifying patients 
into treatment groups. 
This case study investigates the production of patient-specific hiPS-cell lines, namely 
a cell line which is derived from a single patient in order to capture their individual 
genotype and phenotype. Manufacture of patient-specific cell lines requires scale-out 
of the process, whereby the manufacturing scale or lot size is kept constant and 
replicated for each cell line. In contrast, manufacture of non patient-specific cell lines 
can benefit from scale-up, whereby the manufacturing scale or lot size is increased 
when larger demands of a cell line are required (see Figure 4.1a). Non patient-specific 
cell lines are more likely to be used for purposes that are independent of the specific 
genotype or phenotype of a cell.   
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Automation systems designed to accommodate planar culture vessels, such as the 
CompacT SelecT (CTS) (Sartorius, Royston, UK), have the potential to reduce the 
labour requirements, potential points of contamination, and to improve the reliability 
associated with autologous hiPSC bioprocessing (Veraitch et al. 2008; Thomas et al. 
2009; Hambor 2012) (see Chapter 2). Such systems could be implemented to help 
achieve large-scale manufacture of patient-specific stem cell products. 
An integrated decisional tool that combines both bioprocess economic modelling and 
optimisation of the manufacture of patient-specific iPSC-derived neurons for use as 
a tool in the screening of NCEs is described. The bioprocess economics model and 
integrated brute-force search algorithm are designed to identify the process design 
that minimises the COG. The use of specified automation equipment such as the CTS 
for iPSC cell bioprocessing and its impact upon the overall COG is also evaluated as 
an alternative to existing, manual bioprocessing options (Figure 4.1b). 
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Figure 4.1 Process techniques for patient-specific and non-patient-specific cell lines. a) Outline of process techniques for patient-specific 
cell lines and non-specific cell lines. The bioprocess for a single patient-specific cell line is scaled-out to achieve a higher throughput. 
Non-specific bioprocesses are scaled-up to achieve a higher throughput. b) An overview of the bioprocess strategies considered within 
this case study. Clonal processing is employed following cellular reprogramming, therefore the technology used to process each donor 
sample remains constant until this point, regardless of the scale of the bioprocess. 
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4.2 Case study set-up 
4.2.1 Tool Application 
A representative case study was developed in partnership with Pfizer’s Neuroscience 
and Pain Research Unit (Great Abington, Cambridge, UK) that focused on optimising 
the production of patient-specific iPSC-derived cells for drug screening. Specifically, 
it addressed the generation of iPSC-derived neurons to supply patient drug responder 
versus non-responder, “trial in a dish” screening platforms with which to augment 
clinical trials for NCEs. It is estimated that cell lines from 50 separate donors could be 
required to run such a screening programme. To investigate the effect of scale-out on 
the COG associated with the bioprocess, throughputs of 10, 50 & 100 cell lines per 
year were investigated by this study.  
There are a variety of analytical methods by which to carry out drug screening. 
Currently, the resting or active status of the membrane potential in functional iPSC-
derived neurons are analysed by patch-clamp analysis (PCA), a manual technique 
which requires a small sample population of iPSC-derived neurons (105). Whilst this 
is a data-rich analytical method, it samples only a small number of cells and is 
therefore a poor representation of whole cell populations (Yajuan et al. 2012). 
Powerful, automated analytical techniques such as high throughput screening (HTS) 
and plate-based pharmacological analysis (PBP) are also available methods by which 
to screen cells’ reactions to NCEs. These techniques require larger sized cell 
populations (2 x 106 and 107 cell respectively), but offer high throughput analytical 
platforms. The level of scale-up required of the bioprocess required to manufacture 
each individual cell line is dependent on the analytical technique used for drug 
screening, along with characteristics of different analytical techniques (Figure 4.2).  
Two different manufacturing strategies were considered during this case study; 
manual bioprocess techniques were evaluated alongside an automated iPSC 
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bioprocess, whereby iPSC expansion and differentiation were carried out using the 
CompacT SelecT SC (Sartorius, Royston, UK). A decisional tool was applied primarily 
in order to select the most cost-effective process design in both instances. In this case 
study a brute-force search algorithm was used to identify cost-effective bioprocess 
designs (see Chapter 3). This was linked to a bioprocess economics model (defined 
in Chapter 3), and a database housing relevant information on candidate 
technologies. Process reproducibility in stem cell bioprocessing is a significant 
challenge. As such, stochastic modelling was also employed in this case study to 
ascertain the robustness of both manufacturing strategies using the Monte Carlo 
simulation method (see Chapter 3 for methods). 
 
 
 
 
 
 
 
 
 
Figure 4.2 iPSC-derived neuron population sizes required to satisfy the demands of 
different analytical drug screening techniques. The required population size dictates 
the scale of the bioprocess required to produce cells for each analytical method. The 
lower panels illustrate graphically key characteristics of each analytical technique.  
4.2.2 Process Overview 
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The process flowsheet used for the case study (Figure 4.1) employs processing of 
individual clones following the reprogramming stage; as such, the preliminary unit 
operations are of a constant scale regardless of the final number of iPSC-derived 
neurons produced from each cell line. Therefore, the main focus of this case study 
comprises the iPSC expansion and differentiation unit operations. Further details 
regarding the methods used and feeding regimes assumed for each unit operation 
can be found in (Table 4.1). Media changes are assumed to involve a full exchange 
of media within a process vessel. 
The planar technologies considered within the case study included well plates (WP) 
as well as standard and compact multi-layer versions of T-flasks (T, cT, 3-F, 5-F) and 
stacked vessels (L, cL). Their key input parameters are stored within the tool’s 
database (Table 4.2). This data was compiled using vendor websites and consultation 
with industry experts so as to properly capture the characteristics of each candidate 
technology.  Key process and cost assumptions are summarised in Tables 4.3 & 4.4. 
These values have been compiled via a thorough review of available literature on 
planar bioprocessing of iPSCs and their derivatives. All assumptions listed in Tables 
4.3 & 4.4 were then corroborated with industry experts to ensure they were 
representative. While sensible inputs and assumptions were sought, the primary aim 
of the paper was to demonstrate the application of the proposed methodology to 
provide visibility of the cost structure and the most significant process economics 
drivers for iPSC generation for drug screening applications.  Hence, the actual inputs 
and answers should not be seen as definitive but an illustration of how to approach 
such an assessment. The risk of batch failure was also considered. The manual 
bioprocess strategy was assumed to exhibit a higher probability of batch failure (4%) 
compared to the automated strategy (2%) given the greater human intervention and 
degree of open processing in the manual strategy. Failure rates were assumed to 
capture the worst-case scenario, i.e. failure occurs during the final stages of 
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differentiation. Therefore, the direct costs of iPSC expansion and differentiation for 
additional donor samples required due to process failure were added to the final COG 
figure within the deterministic model to account for additional processing as a result 
of the batch failure rate. Only iPSC expansion and differentiation were assumed to be 
repeated following a failed lot because of the cell banking procedure in place. 
Table 4.1 Methods and feeding regimes used within bioprocess unit operations in 
this case study 
Unit Operation Method Feeding Regime 
Erythroblast Expansion & 
Enrichment 
Culture-based expansion 
and purification of 
erythroblasts 
- Daily media replacement 
Cellular Reprogramming Sendai Virus 
transduction of 
Yamanaka factors 
- Media replacement every 
two days during transduction 
- Daily media replacement 
during iPSC generation 
period 
iPSC Expansion Monolayer 
10% of viable cells  
banked to safeguard 
against process failure 
during differentiation 
- Daily media replacement 
Differentiation Monolayer, small 
molecule based 
- Twice weekly media 
replacement 
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Table 4.2 Process technologies tested in this case study and their associated performance and cost parameters 
Technology 
Type 
(i) 
Surface Area 
(cm2/unit) 
(ai) 
Cost 
(£/unit) 
(Ccon i) 
 
Media 
Requirements 
(mL/unit) 
(Vreq i) 
Max units 
per Operator 
(ωop i) 
Incubator Capacity 
(Double Stack) 
(δinc i) 
Requires 
BSC 
Cabinet 
(Y/N) 
CompacT 
SelecT 
Capacity 
T-25 25 £1.54 7 4 100 Y - 
T-75 75 £2.21 18.75 4 100 Y 90 
T-175 175 £4.95 50 4 100 Y 90 
T-225 225 £5.27 56.25 4 100 Y - 
6-WPa 9.5 £2.10 2 24 600 Y - 
24-WPa 1.9 £2.66 0.5 48 2400 Y - 
L-2b 1272 £55.08 315 2 60 Y - 
L-5b 3180 £180.49 787.5 2 24 Y - 
cL-12c 6000 £287.69 1300 2 24 Y - 
3-Fd 525 £10.20 150 - - N 90 
5-Fe 875 £17.00 250 - - N 90 
cTf 1720 £63.58 500 - - N 90 
aWell plate 
bMultilayer planar vessels e.g. CellSTACK (Corning) 
c Compact multilayer vessel e.g. 12-layer HYPERStack (Corning) 
d3-layer T-flasks e.g. Triple Flask (Nunc) or Falcon Multi-Flask (Corning) 
e5-layer T-flasks e.g. Falcon Multi-Flask (Corning) 
f Compact multilayer flask e.g. 10-layer HYPERFlask (Corning) 
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Table 4.3 Assumed values for key process parameters 
Unit Operation (j) 
Seeding 
Density 
(cells/cm2) 
Harvest 
Density 
(cells/cm2) 
(dh,i) 
Yield/Harvest Yield/ 
Efficiency (%) 
Fold 
Expansion 
Erythroblast 
Enrichment 
1.5 ∗ 105 3.2 ∗ 105 25 (Yield) N/A 
Erythroblast 
Expansion 
1.5 ∗ 105 3.2 ∗ 105 95 (Harvest Yield) 2 
Reprogramming 
(Transduction) 
2.6 ∗ 105 2.6 ∗ 105 95 (Harvest Yield) N/A 
Reprogramming 
(Generation) 
104 104 0.5 (Efficiency) N/A 
iPSC Expansion 4.2 ∗ 104 3 ∗ 105 90 (per passage) 7 
Differentiation 3 ∗ 105 3 ∗ 105 35 (Efficiency) N/A 
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Table 4.4 Key process cost assumptions 
Cost Parameter  Valuea 
Media   
 Differentiation Media £0.55-£0.67/mL 
 Expansion Medium  £0.43/mL 
 Reprogramming Vector £664/ donor 
Labour  £60/hr 
Fixed Equipment   
 Incubator (Large) £11,890 
 Incubator (Small) £5,175 
 CompacT SelecT £550,000 
 Biosafety Cabinet £11,390 
Depreciation Period  10 Years 
Lang Factor (Manual 
Bioprocess Strategy) 
 23.7 
Lang Factor (Automated 
Bioprocess Strategy) 
 16 
aPrice ranges are provided where more than one type of media is used within a unit 
operation 
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4.2.3 Specific methodologies applied to this case study 
Labour Costs 
In this case study, labour costs, clab, are calculated as a function of the time required 
to carry out tasks specific to each unit operation of the iPSC bioprocess (ti). This is in 
contrast to methods detailed in Chapter 2 and applied in Chapters 4 & 5, where labour 
costs are considered a function of the number of operators to run a process. Labour 
has been calculated in the following manner in this case study because it was 
assumed that operators might have duties beyond this process. It is assumed that for 
each technology type an operator could handle a given number of units, ωj, within this 
time period. Therefore: 
𝑐𝑙𝑎𝑏 =  (
𝑢𝑖𝑗
𝜔𝑗⁄ ) ∗  𝑡 ∗ 𝑤  (4.1) 
 
where w represents the hourly cost of labour. Individual labour tasks and their 
durations can be found in Table 4.1.  
Stochastic modelling input distributions 
The probability distributions assigned to the values of process parameters are given 
in Table 4.2. For details on the stochastic modelling methodologies employed please 
refer to Chapter 3. 
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Table 4.5 Labour tasks associated with the bioprocess and their duration 
Labour Task Time Required (h) (ti) 
Media preparation 1 
Cell harvest 0.75 
Cell seeding 0.5 
Media replacement 0.5 
Viral transduction 1.5 
CompacT SelecT setup 2 
CompacT SelecT termination 2 
Culture check (manual) 0.5 
Culture check (automated) 0.25 
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Table 4.6 Probability distributions assigned to key bioprocess performance 
parameters in the stochastic Monte Carlo analysis of the manual and automated 
bioprocess strategies. 
Parameter Probability 
Distribution 
Type 
Manual 
Bioprocess 
Probability 
Distribution 
Profile (Min, Most 
Likely, Max) 
Automated 
Bioprocess 
Probability 
Distribution Profile 
(Min, Most Likely, 
Max) 
iPSC Expansion 
Harvest Yield 
Triangular 75%, 90%, 95% 85%, 90%, 95% 
iPSC Expansion 
Harvest Density 
Triangular 2.5 x 105, 3 x 105, 
3.5 x 105 
2.7 x 105, 3 x 105, 
3.3 x 105 
iPSC Expansion 
Fold 
Triangular 6.3, 7, 7.7 6.6, 7, 7.4 
Differentiation 
Efficiency 
Triangular 20%, 35%, 45% 30%, 35%, 40% 
Differentiation 
Harvest Yield 
Triangular 80%, 90%, 95% 85%, 90%, 95% 
Differentiation 
Seeding Density 
Triangular 0.8 x 104, 1 x 105, 
1.1 x 105 
0.9 x 105, 1 x 105, 
1,1 x 105 
Note: ‘Most likely’ values in the distribution profiles are taken from the base case scenario from the 
deterministic bioprocess economics model  
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4.3 Results and Discussion 
The decisional tool was used to assess the cost-effectiveness of alternative 
bioprocess designs across a range of different scales of production. A deterministic 
model was developed in order to carry out COG comparisons between different 
process designs and sensitivity analyses were used to further investigate economic 
drivers associated with the iPSC bioprocess. The tool was then adapted for stochastic 
modelling in order to evaluate the robustness under uncertainty of automated and 
manual bioprocessing strategies using the Monte Carlo simulation method. 
4.3.1 Deterministic Cost Modelling 
The optimal combination of process technologies for the final iPSC expansion stages 
and differentiation operation, for both the manual and automated bioprocess are 
depicted in Figure 4.3. The number of iPSC-derived neurons produced per cell line is 
representative of the size of cell populations needed to satisfy the demands of PCA, 
HTS and PBP analysis (moving vertically from the top to the bottom of the matrices). 
The cell population outputs per cell line required for each of these analytical methods 
are shown in Figure 4.2, and also in Figure 4.3. Annual throughputs of 10, 50 and 100 
cell populations have been shown to depict the effects of scale-out on optimal 
bioprocess design. The bioprocess throughput, in terms of cell lines produced per 
year, increases horizontally from left to right across each matrix. The matrices show 
the optimal technology size and the number of units required (in square brackets) per 
cell line for each scale tested.  
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a)  
 Cell lines produced per year 
Analytical Method 
[required output (iPSC-
neurons/cell line)] 
Unit Operation 50 100 
Patch Clamp Analysis 
[105] 
Expansion 
(final stage) 
6-WP [4] 6-WP [4] 
Differentiation T-25 [1] T-25 [1] 
High Throughput 
Screening [2 x 106] 
Expansion 
(final stage) 
T-75 [4] T-75 [4] 
Differentiation T-175 [1] T-175 [1] 
Plate-Based 
Pharmacological Assay 
[107] 
Expansion 
(final stage) 
L-2 [2] L-2 [2] 
Differentiation T-225 [4] T-225 [4] 
 
b)  
 Cell lines produced per year 
Analytical Method 
[required output (iPSC-
neurons/cell line)] 
Unit Operation 50 100 
Patch Clamp Analysis 
[105] 
Expansion 
(final stage) 
T-75 [4] T-75 [4] 
Differentiation T-75 [1] T-75 [1] 
High Throughput 
Screening [2 x 106] 
Expansion 
(final stage) 
T-75 [4] T-75 [4] 
Differentiation T-175 [1] T-175 [1] 
Plate-Based 
Pharmacological 
Assay [107] 
Expansion 
(final stage) 
T-175 [25] 3-F [11] 
Differentiation 5-F [1] 5-F [1] 
 
Figure 4.3 Matrices which illustrate the optimal bioprocess configuration for the final 
stage of expansion and differentiation. Matrices show the most cost-effective 
technologies for a) Manual bioprocess strategies and b) Automated bioprocess 
strategies across the range of scale investigated in this study. Lighter shaded cells 
indicate cheaper COG per cell line relative to other bioprocess designs shown in the 
matrices, where the lightest shade indicates the cheapest COG per cell line output 
value. 
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Depicting optimal technology sizing for manual bioprocessing shows that as the size 
of cell populations produced increases, there is a trend towards technologies with a 
larger surface area (Figure 4.3a). Larger technologies, which require fewer vessels, 
are selected as the optimal bioprocess design. For example 2 x 2-layer CellSTACK 
vessels (L-2) are preferred for the final expansion stage when producing 107 cells per 
cell line (for PBP), as opposed to 4 x T-75 flasks if 2x106 cells per cell line were to be 
produced (for HTS analysis). Larger vessels are preferred when larger cell 
populations are produced when a manual bioprocess strategy is employed as 
depicted by the direct cost breakdown for optimal technologies for the manual 
bioprocess at different production scales at a throughput of 50 donor samples per 
year for the final expansion stage and differentiation (Figure 4.4). The utilisation of 
available surface area in smaller technologies is higher, thus they make more efficient 
use of media. Material expenditures can be reduced if smaller cell populations are 
produced (such as those required for PCA and HTS analysis) if smaller technologies 
are used. This is exhibited by a 39% reduction in direct costs if T-75 flasks are used 
as opposed to L-2 vessels for the final iPSC expansion stage at the HTS scale (Figure 
4.4a).  
However, when satisfying the demands of PBP, the additional labour costs incurred 
by the use of large numbers of units of smaller vessels far outweigh the incremental 
reduction in material costs that such technologies offer within the manual bioprocess. 
The COG per cell line for the differentiation can be reduced by 76% if T-225 flasks 
are employed rather than T-25 flasks (Figure 4.4b). This is due to the reduction in the 
resultant labour costs associated with the use of T-225s. Darker shades within each 
area of the matrices (Figure 4.3) are illustrative of higher COG/cell line. Thus, the 
matrix also demonstrates the economies of scale that can be achieved when the 
number of cell lines produced per year increases. This is particularly true with regards 
to automated processing (Figure 4.3b), where a greater range in the COG between 
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different annual donor sample throughputs can be observed than for the manual 
bioprocessing strategy. 
A COG breakdown for the different equipment sizing configurations available for use 
in the final stage of expansion and differentiation for the automated bioprocess 
strategy, whereby 107 iPSC-derived neurons are produced per cell line at a 
throughput of 50 cell lines per year is shown in Figure 4.5. The use of smaller vessels, 
such as T-75s, necessitates the use of multiple CTS machines due to the number of 
vessels required for such technologies, which corroborates results displayed in Figure 
4.3b, in that larger technologies are preferred for this throughput in the optimal 
technology matrix. This is particularly true of vessels used during differentiation, a 
lengthy process that occupies equipment capacity for long periods of time.  
The optimal process configuration, where the technologies selected were 11 x T-75 
flasks for the final iPSC expansion stage and 1 x 5-F (5-layer T-flask) for 
differentiation, results in a maximum requirement of 1 CTS machine. However, were 
T-75s and T-175s to be used for the respective process steps above (as is optimal 
for producing cells for HTS analysis), then 4 CTS machines would be required to 
produce cell populations satisfying the demands of PBP analysis. The latter of these 
options results in only an incremental direct costs reduction (~1%), whereas the 
resultant indirect costs are 375% higher than the optimal process design. Larger 
technologies, which can house cell populations in a smaller number of vessels, are 
preferred as they do not have as significant an impact on automated processing 
equipment utilisation. Owing to the automated nature of this processing strategy, the 
use of multiple vessels does not impact significantly upon labour costs, unlike manual 
processing, where it is important to minimise the number of units required in order to 
drive down labour costs. 
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Figure 4.4 Direct cost breakdown for the optimal technologies at scales satisfying the demands of the three analytical drug screening 
techniques (PCA, HTS & PBP). Cost breakdowns are shown at a throughput of 50 cell lines/yr for a) the final stage of expansion and 
b) differentiation. Required iPSC-derived neuron outputs per donor are shown in brackets on the x-axis. Maximum values on the y-axis 
have been assigned to maintain scales whereby data can be clearly seen. Therefore for scales satisfying demands of PBP, direct 
costs beyond these values are labelled above the relevant column.
36288 10560 
19008 
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Analysis of COG breakdowns for manual and automated bioprocesses when the 
demands of HTS and PBP analysis at throughputs of 50 and 100 cell lines per year 
are satisfied shows that automated processing can significantly reduce labour costs 
associated with stem cell bioprocesses (Figure 4.6). This is particularly due to 
additional ancillary tasks associated with manual bioprocess strategies, such as 
media changes and cell seeding and harvesting. Material costs do not fluctuate 
greatly between manual and automated processing. However, savings on the cost of 
labour are outweighed by the additional indirect costs (a function of fixed capital 
investment required) for the automated bioprocess when 50 cell lines are produced. 
A 10% COG per cell line reduction is offered by manual processing when cells are 
produced for PBP analysis. At a throughput of 100 cell lines per year, the additional 
indirect costs associated with automated bioprocess strategies are spread across 
enough cell lines to provide significant COG reductions (19% at PBP scale) against 
the manual bioprocess - the cost of which is heavily weighted by labour costs. This is 
supported further by percentage COG breakdowns for the manual and automated 
bioprocesses when cell lines are produced to satisfy the demands of PBP analysis. 
At higher annual throughputs, direct costs make up a higher percentage of the COG 
breakdown. For the automated bioprocess, direct costs account for 41% of COG 
(70% for manual processing) when 50 cell lines are produced per year, compared to 
58% (72% for manual processing) if 100 cell lines are produced annually. This 
analysis provides evidence that automation of patient-specific iPSC bioprocesses can 
provide significant COG reductions at scales sufficient to warrant the additional capital 
expenditure. Indirect costs dominate the COG breakdown for the automated 
bioprocess (Figure 4.5) hence minimisation of the number of pieces of automation 
equipment must be achieved in order to curtail COGs.  
There is no significant reduction in either the labour costs or material costs for both 
the manual and the automated bioprocess at throughputs of 50 and 100 cell lines per 
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year (Figure 4.6). However, when the process is scaled out, smaller COG figures are 
realised as a result of reductions in the indirect costs per cell line. This suggests that 
economies of scale can only be achieved for patient-specific hiPSC bioprocesses 
requiring scale-out through shared use of fixed equipment. Bioprocess scheduling 
and equipment sizing in order to maximise use of fixed equipment and minimise the 
required size of cleanrooms must therefore be considered during process design in 
this area.  
It can be concluded that a threshold throughput exists where automated bioprocesses 
offer a COG reduction compared to a manual bioprocesses. This is in accordance 
with previous studies in stem cell bioprocess design (Simaria et al. 2014). When 
assessing the COG per cell line for both the automated and manual bioprocess at 
throughputs ranging from 50 to 200 cell lines, the point at which the automated 
bioprocess becomes more cost-effective than the manual bioprocess is at a 
throughput of 65 cell lines (Figure 4.7). The spike on the line representing COG per 
cell line for automated bioprocesses also depicts the throughput at which it is 
necessary to purchase additional automated processing equipment (a throughput of 
110 cell lines). The switchpoints identified between automated and manual 
processing are specific to the modelling assumptions made in this particular case 
study. 
The assumed cost of automation equipment is based upon the current purchase cost 
for a functional CTS machine. At the time of writing, this was the only piece of 
automation equipment that could fully support this bioprocess. In the future, other 
pieces of equipment may become available and competition may drive down the cost 
of automation equipment. The effect of the price of automation equipment price on 
bioprocess COG can be seen in Figure 4.8. 
171 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Brute-force algorithm outputs. COG breakdowns are shown for possible equipment sizing configurations for an automated 
process strategy. The x-axis displays different process platforms for the final expansion stage (top line) and differentiation (bottom line) 
at a throughput of 50 cell lines/yr, whereby populations of 107 cells are produced to satisfy the demands of PBP analysis. The scatter 
points on the chart show the number of Compact Select SC machines required for each process configuration.  
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Figure 4.6 COG breakdowns for manual and automated bioprocess strategies at 
throughputs of 50 and 100 cell lines. COG breakdowns are shown for the production 
of populations of 107 iPSC-derived neurons in order to satisfy the demands of PBP. 
Percentage changes in COG/cell line caused by implementing an automated 
bioprocess strategy are shown above columns representing automated bioprocess 
COG breakdowns. 
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Figure 4.7 COG per cell line at annual throughputs ranging from 50 to 200 cell lines 
of 107 iPSC-derived neurons for manual and automated processing.
 
 
 
 
 
 
 
 
 
Figure 4.8 Line chart displaying COG per cell line when purchase cost of automation 
machinery is varied. This chart shows the cost of goods per cell line for the automated 
and manual bioprocesses at throughputs of 50 and 100 cell lines when the purchase 
cost of an automation unit is varied from £150,000 to £600,000 per unit (default setting 
is £550,000).  
174 
 
4.3.2 Sensitivity Analysis 
In order to further identify key economic drivers associated with the iPSC-derived 
bioprocess, and to provide further understanding of where process development and 
optimisation resources might be best focused, a sensitivity analysis was carried out. 
Several process and cost parameters were varied to reflect their best and worst case 
values. The tool was used to test the resultant change upon the COG per cell line 
values that these variations. The Tornado charts (Figure 4.9) illustrate the effect on 
COG that variations in key parameters caused for a) the manual bioprocess and b) 
the automated bioprocess at a throughput of 50 cell lines per year (where cell 
populations that satisfy the demands of PBP are produced). The number of iPSC 
expansion stages required was the greatest economic driver for both the manual and 
automated bioprocess strategies (Figure 4.9). Variations in the number of iPSC 
expansion stages can occur due to fluctuations in key performance parameters. The 
impact of this parameter upon COG can be significant, as each additional iPSC 
expansion stage necessitates additional direct resources and fixed equipment 
capacity. Thus, a change in the number of iPSC expansion stages required within a 
bioprocess will significantly affect COG per cell line. 
Labour costs are also a significant cost driver for the manual bioprocess, resulting in 
an 18% difference in COG between the best and worst case scenarios. The fact that 
labour costs have been identified as a key process economic driver is perhaps 
unsurprising; this parameter dominates the COG breakdown at high cell line 
throughputs (see Figure 4.6). Similarly, the secondary cost driver for the automated 
bioprocess is FCI costs, which are the largest contributor to the COG breakdown for 
this process strategy (Figure 4.6).  
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Figure 4.9 Tornado plots showing the effect of variations in key bioprocess 
parameters on COG for a) the manual bioprocess strategy and b) the automated 
bioprocess strategy at a throughput of 50 cell lines/ year. Best case, base case, and 
Worst case values are shown in brackets on the Y-axis labels. Percentage changes 
represent the percent change as proportion of the base case value (e.g. for 
differentiation efficiency base case = 30%, therefore worst case differentiation 
efficiency = 30%*75%, the worst case value is therefore a differentiation efficiency of 
22.5%). NC = no change. 
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4.3.3 Stochastic Modelling 
The mean COG/cell line value for the automated bioprocess is higher than that of the 
manual bioprocess when producing 50 cell lines per year, whereas at 100 cell lines 
per year, this value is higher for the manual bioprocess, as described by the 
stochastic analysis (Table 4.7). These figures are consistent with the deterministic 
model results, which also show the same trend (Figure 4.6).  
The results of the Monte Carlo analysis (Table 4.7, Figures 4.10a & 4.10b) show that 
the standard deviation and range of COG values for the automated bioprocess 
strategy at throughputs of both 50 and 100 cell lines per year (£3,025 (GBP) and 
£3,221 respectively) are significantly lower than those of the manual bioprocess 
strategy (£8,481 and £9,493 at 50 and 100 cell lines per year, respectively). This 
suggests that the automated bioprocess is more robust from a bioprocess economics 
standpoint than the manual bioprocess. The frequency density curves and COG 
distributions (Figure 4.10a & 4.10b) follow a distinct pattern. They are bimodal with a 
positive skew and hence the majority of COG values are concentrated at the lower 
end of the distribution and are followed by a long tail with a smaller peak at the upper 
end of the distribution with higher COG values.  This is particularly true of the 
frequency distribution curves of the manual bioprocess, where the peaks at the upper 
end of the distribution where high COG values occur are larger compared to those for 
the automated bioprocess. One explanation of the shape of the frequency 
distributions can be illustrated in Figure 4.10c, which shows the relative frequency at 
which the number of iPSC expansion passages required for the manual bioprocess 
(at a throughput of 50 cell lines per year) rises from six (as in the base case) to seven 
based on process variability modelled in Monte Carlo analysis. The frequency 
distribution of the COG per cell line for the manual bioprocess from Figure 4.10a is 
also displayed on Figure 4.10c. This shows that the minor peak with high COG values 
that appears in Figures 4.10a & 4.10b is due to the requirement of an additional stage 
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of iPSC expansion owing to process variations modelled during the Monte Carlo 
simulation. Figure 4.10c also emphasises the importance of minimising the number 
of iPSC expansion stages as a strategy for minimisation of COG.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 A & B Please see overleaf for full legend
 
a) 
b) 
178 
 
 
 
 
 
 
 
 
 
Figure 4.10 Frequency distributions for the COG per cell line outputs for the 
automated and manual bioprocess strategies under uncertainty. a) Bioprocess scale 
of 50 cell lines per year and b) Bioprocess scale of 100 cell lines per year. Dashed 
lines depict individual COG per cell line outputs and continuous curves represent the 
frequency distributions of the COG per cell line outputs. c) Relative frequency of the 
different number of iPSC expansion stages for the manual bioprocess strategy for 50 
cell lines per year superimposed onto the COG per cell line frequency distribution. 
Bars represent the relative frequency of the number of iPSC expansion passages 
shown (bottom x-axis and left-hand y-axis) and lines represent the frequency 
distribution of COG per cell line (top x-axis & right-hand y-axis).  
c) 
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Table 4.7 Statistical parameters of the COG per cell line values for the manual 
and automated bioprocess strategies from the stochastic Monte Carlo analysis 
 50 cell lines per year 100 cell lines per year 
 
Manual 
bioprocess 
Automated 
bioprocess 
Manual 
bioprocess 
Automated 
bioprocess 
Mean (µ) £64,841 £66,655 £65,405 £48,601 
Standard 
deviation 
£8,481 £3,025 £9,493 £3,221 
P(COG < 
µautomated) 
0.81 0.93 0 0.89 
 
4.3.4 Can an acceptable COG for in-house manufacture of patient-specific 
hiPSC derived cell lines be achieved? 
List prices from vendors for a vial containing 106 non patient-specific hPSC-derived 
cells currently lie in the region of US$1000-2000. This study shows that, unlike non 
patient-specific stem cell bioprocesses, where both direct and indirect cost savings 
can be achieved on a per million cells basis via appropriate scale-up strategies 
(Simaria et al. 2014), economies of scale can only be achieved in patient-specific cell 
lines through shared use of fixed equipment. Direct costs per cell line do not fluctuate 
significantly, regardless of throughput (Figure 4.6). The market price of patient-
specific cell lines may therefore be assumed to be higher than their non-specific 
counterparts; not only because of the added expenditure as a result of scale-out 
processing, but also the added analytical value provided by such products in 
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responder vs non-responder studies and potential personalised medicine regimes 
(see Chapter 1). This is reflected in the fact that patient-specific hPSC-derived cell 
lines are marketed for ~US$50k (~£35k) for 107 cells, including the additional costs of 
iPSC derivation and genetic engineering.  
This case study reflects an in-house hiPSC-derived cell line manufacturing regime. 
According to the stochastic modelling above, the minimum COG per cell line that can 
be achieved is ~£45,000. This is significantly higher than current market prices for 
such products. In order for in-house production of cell lines for drug screening to be 
worthwhile, an acceptable COG per cell line must be below current market prices. A 
scenario analysis was designed to identify the process improvements required to 
reduce COG per cell line to below £35,000. Within the scenario analysis, reductions 
in the indirect costs and media costs have been assumed. A one-off new-build facility 
has been assumed for this case study in order to capture the fixed equipment costs 
associated with manufacturing patient-specific cell lines. In reality, such an in-house 
facility would likely be used for multiple research activities. To reflect this, indirect 
costs of 60% and 75% of the base case value have been investigated in this analysis. 
Established Big Pharma companies might also make use of existing experience in 
pharmaceutical reagent manufacturing in order to produce media components and 
small molecules required for certain unit operations in-house. This would allow some 
media components to be produced at cost price, rather than purchasing them at 
vendor list prices (as assumed in base case results).  
COG per cell line at both base case media costs and a 25% reduction in media costs 
have been modelled in this analysis. The process parameters varied in this analysis 
were the differentiation efficiency and iPSC expansion fold per stage. These 
parameters were chosen for two reasons; primarily they both impact upon the number 
of iPSC expansion stages required. This was identified as a key process economics 
driver in the sensitivity analysis (Figure 4.9). Secondly, advances in media 
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composition and morphogen delivery systems during iPSC expansion and 
differentiation are areas of concentrated research. Innovations in these areas have 
proven that improvements in these parameters are achievable on the base case 
values assumed in this case study(Chambers et al. 2009; Bardy et al. 2012; Chen 
and Thomson 2012; Surmacz et al. 2012; Ungrin et al. 2012; Lippmann et al. 2014). 
The in-house scenario considered in this project was for a single drug screening 
project application and hence the indirect costs were only spread across this activity. 
In future it is possible to envisage several drug screening applications where the 
investment is offset across several projects similar to how a vendor may achieve 
economies of scale. Hence the impact of lowering the indirect costs was explored. If 
indirect costs are 60% of base case value, there is a large window of operation 
whereby a COG <=£35k per cell line, even when media costs remain at the base case 
value (Figure 4.11a). Indeed, if the achievable iPSC expansion fold can be increased 
from 7to 10, then it would be acceptable for differentiation efficiency to remain at 35%. 
If media costs could be reduced by 25%, then a differentiation efficiency of 50% (up 
from 35% in the base case scenario) would be required for COG<=£35k per cell line, 
even if the iPSC expansion fold could not be improved (Figure 4.11b). The windows 
of operation shrink significantly at both base case and reduced media cost values 
when indirect costs increase from 60% to 75% of the base case values (Figure 4.11c 
& 4.11d). In this instance, improvements in both differentiation efficiency and iPSC 
expansion to 76% and 11, respectively, would be required. Less dramatic 
improvements would be necessary if media costs could be reduced by 25%. In this 
scenario differentiation efficiencies as low as 52% and iPSC expansion folds of 10 
could allow COG<=£35k per cell line to be achieved.  
The maximum indirect cost (% base case) whilst media costs remain at base case 
value whereby a COG<=£35k per cell line is still feasible was found to be 77%. When 
media costs are 75% of the base case values, this value increases to 81%. Both of 
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these instances would require improvements to produce a 12-fold expansion during 
iPSC culture and a differentiation efficiency of 79%. Conversion of hiPSCs to neurons 
at efficiencies beyond 80% have been reported (Lippmann et al. 2014) as have iPSC 
expansion folds of up to 11.3 over 7 days in planar conditions, or up to 28 in bioreactor 
conditions (Bardy et al. 2012; Marinho et al. 2012) Therefore, realising the windows 
of operation discussed above is not infeasible. In the event that fixed capital 
investment (or indirect costs) can be reduced by 25% or more there are realistic 
scenarios whereby in-house manufacture of patient-specific, iPSC-derived cell lines 
could be worthwhile for companies wishing to carry out responder vs non-responder 
studies as part of drug development regimes. Lower indirect cost values could be 
achieved by either retrospective fitting of an existing research facility, or by 
diversifying the functionality of a new-build facility. The scenarios analysed above 
also illustrate how changes to the bioprocess in terms of the key process parameters 
might impact upon COG and shows how the findings of this study might be applied to 
bioprocesses other than the one that is the focus of this work. 
The scenarios examined here determine an acceptable COG to be less than current 
market prices for patient-specific, hiPSC-derived cell lines. This is because this case 
study examines production of such cell lines for use in in-house studies. Were the cell 
lines discussed in this case study to be manufactured for sale, the acceptable COG 
figure would be far lower in order to take into account COG as a percentage of sales. 
Smith (2010) determines this value to be in the range of 40-60% for autologous 
products. It is possible to conclude that acceptable COG for patient-specific hiPSC-
derived cell lines designed for sale is in the region of £14,000-£21,000 per cell line 
(whereby 107 cells are produced for each line). It is assumed that a process producing 
cell lines for commercial sale would be of a far greater scale than the bioprocess 
examined in this study (i.e. 100 cell lines per year). Identification of process 
improvements required to reduce the COG derived in this study to such values is 
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therefore beyond the scope of this paper. However, future work will focus upon large-
scale bioprocess design strategies in order to maintain a supply chain of hPSC-
derived cell lines to a number of clients. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Scenario analysis to identify windows of operation where COG <=£35k/ 
cell line. Contour plots show the windows of operation where COG <=£35k/ cell line 
when a) media cost = base scenario and IDC = 60% of base case values b) media 
cost = 75% of the base scenario and IDC = 60% of base case values c) media costs 
= base case value and IDC = 75% of base case values d) media costs = 75% of base 
case value and IDC = 75% of base case. Shaded areas on the plots show windows 
of operation whereby COG<= £35,000/cell line, white areas of the plots represent 
windows of operation whereby COG>£35k/ cell line. IDC = indirect costs. 
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4.4 Conclusion 
A decisional tool is presented that consists of a bioprocess economics model with an 
integrated brute-force search algorithm. The tool has been applied to an industrial 
case study, in which patient-specific iPSC-derived neurons are produced for use in 
responder vs. non-responder studies as part of the development of NCEs to be used 
in personalised medicine regimes. Via the use of this tool, optimal equipment sizing 
regimes were identified for both a manual and an automated hPSC bioprocess. 
Furthermore, it can be concluded that whilst the most cost-effective option of the two 
process strategies tested is dependent on the throughput of the process, the use of 
automation equipment was found to result in a more robust bioprocess in terms of 
COG values when tested under uncertainty. Indirect cost reductions are required in 
order to achieve acceptable manufacturing COG. This might be done by 
retrospectively fitting existing facilities, or diversifying functionality of a new-build 
facility in order to offset some of the required fixed capital investment to other projects. 
Were an existing full-scale process to be adapted from a manual to an automated 
bioprocess it would be wise to take into account the cost and time required to train 
staff to use automated equipment. Furthermore, the logistics and costs of updating 
facility infrastructure to cope with automated processing should be considered in the 
case of retro-fitting an existing facility. This work modelled a relatively small scale 
bioprocess in commercial terms. However, the outputs can be of use in aiding 
decision making early on in bioprocess design for patient-specific cell line production 
at a variety of scales.  
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Chapter 5: An evolutionary optimisation approach to identify 
the cost-effective bioprocess strategies for the manufacture 
of an allogeneic hESC-RPE therapy 
5.1 Introduction 
Globally, AMD is the leading cause of vision loss. Its onset is brought about by 
degeneration a layer of cells known as the retinal pigment epithelium (RPE). AMD is 
an ideal target for a hESC-derived cell therapy for several reasons. First of all, it is a 
condition which is currently devoid of a curative treatment; at best current treatments 
can halt the progress of wet-AMD and there is no available treatment for dry-AMD 
(Nazari et al. 2015). Furthermore, current stem cell technology allows the derivation 
of hESC-RPE cells in a potentially unlimited supply (Klimanskaya et al. 2004; 
Schwartz et al. 2012) for the production of cell-based curative treatments. Finally, and 
perhaps most significantly, several proof-of-concept studies where a certain amount 
of visual function was restored using hESC-RPEs in rat models have led to the launch 
of several clinical trials which have begun to demonstrate that these cells can be 
safely implanted into human patients (Lund et al. 2006; Lu et al. 2009; Schwartz et 
al. 2012; Ilic et al. 2015; Nazari et al. 2015). In the UK, the annual incidence of AMD 
is estimated to be greater than 70,000 cases per year (Owen et al. 2012). This 
represents a large target market for cell therapy manufacturers in this sector. 
Allogeneic cell therapies are amenable to scale-up strategies, whereby larger lot sizes 
can be manufactured to realise the economies of scale that can be associated with 
commercial-scale manufacture of a product (Brandenberger et al. 2011). As 
discussed in Chapter 2, larger lot sizes may necessitate the need for larger, more 
scalable bioreactors and culture strategies including culture of cell on suspended 
microcarriers. This chapter therefore considers the use of both planar and 
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microcarrier-based cell culture strategies in order to evaluate potential inflection 
points where one culture platform may become more cost-effective than another. 
This study describes the development and application of a decisional tool that is 
capable of determining the optimal process flowsheet for an allogeneic hESC-RPE 
cell therapy across a variety of lot sizes and annual demands. The tool was applied 
to an industrial case study examining the manufacture of a low dose, allogeneic 
hESC-RPE therapy, the target indication of which is age-related macular 
degeneration. Four different bioprocess strategies were considered: spontaneous 
differentiation supported by planar technologies; a spontaneous differentiation 
supported by microcarrier-based bioprocessing; directed differentiation supported by 
planar technologies, and finally directed differentiation supported by microcarrier-
based bioprocessing. An evolutionary algorithm, introduced in Chapter 3, was used 
to determine the optimal process flowsheet across different manufacturing lot sizes 
and annual demands for each of these strategies. 
5.2 Case Study Set-up 
A case study was designed in order to examine four different bioprocess strategies 
by which to manufacture a hESC-derived RPE therapy that is to be delivered as a 
fresh patch of cells. The final product is delivered as a 6mm x 3mm patch of hESC-
RPE cells, implanted surgically onto the patient’s retina. 
5.2.1 Process overview 
Figure 5.1 outlines the stages of the manufacturing process for the product 
considered within this case study. The final product has a validated life-span of 8 
hours once the patch is cut. For this reason, it was decided that patch formation 
(whereby hESC-RPEs are plated on a permeable membrane and cultured in order 
for cell-cell junctions crucial to efficacy to form), should take place at secondary 
facilities close to point-of-care centres (Figure 5.1). Manufacturing must usually be 
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decentralised in some manner for fresh cell-based therapies due to time constraints 
on the shipment of such products (Medcalf, 2016). 
 
Figure 5.1 Process flowsheet considered in the RPE case study, including unit 
operations to be carried out at the primary manufacturing facility and secondary 
manufacturing facility. The left hand column refers to the stages of the unit operation 
(i=1,…,k) that were assigned as part of the evolutionary algorithm. 
5.2.2 Spontaneous vs. directed differentiation 
Two differentiation protocols were considered within the case study; an incumbent 
spontaneous differentiation (SD) process and a novel, directed differentiation 
process. The directed differentiation (DD) is characterised by an improvement in the 
efficiency (% target cells out/ % target cells in) of the differentiation process as 
compared to the spontaneous differentiation process. The DD protocol also results in 
an expedited process, reducing the total differentiation time to 19 days compared to 
12 weeks (84 days) for the SD process. However, the DD protocol involves the use 
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of a more costly media and this case study aimed to examine what trade-offs, if any, 
there were between the two protocols. Table 5.1 summarises the key process 
parameters assumed for all bioprocess strategies, all values have been corroborated 
with industry experts.  
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Table 5.1 Key bioprocess parameters associated with different manufacturing strategies tested in this chapter 
Unit Operation Harvest 
density (cells 
per cm2) 
Yield/Harvest yield/ efficiency (%) 
Fold 
expansion 
Time (days) 
SD-PL SD-MC DD-PL DD-MC SD-PL SD-MC DD-PL DD-MC 
hESC expansion (per 
passage) 
3x105 93 93 93 93 7 7 7 7 7 
Differentiation 3x105 0.75 0.75 90 90 N/A 84 84 19 19 
RPE Culture 5.5x105 93 90 93 90 6.18 42 42 42 42 
Vialling & 
Cryopreservation 
N/A 70 70 70 70 N/A <1 <1 <1 <1 
Product Formation 5.5x105 99 99 99 99 N/A 42 -140 42 -140 42 - 140 42 - 140 
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5.2.3 Comparison of different bioprocess strategies for manufacturing at 
primary facilities 
Two different cell culture techniques were considered for the differentiation and RPE 
culture unit operations within the bioprocess. The use of 2-D processing in planar 
vessels (PL) throughout the bioprocess was considered against the use of 
microcarrier-based (MC) differentiation and RPE culture in single-use bioreactors 
(SUBs); here it was assumed hESC expansion would still be carried out in planar 
vessels. Microcarrier-based culture allows a higher surface area to media volume 
ratio to be achieved for cell seeding (Jenkins & Farid 2015). Previous COG analyses 
have shown MC-based culture to be a more cost-effective process strategy than 
planar culture for stem-cell product manufacturing (Simaria et al. 2014; Hassan et al. 
2015). This case-study examined whether MC-based culture proves more cost-
effective than planar culture for small dose, allogeneic cell therapies. The cell culture 
platforms tested for hESC expansion, differentiation to RPEs, and hESC RPE culture 
are shown in Table 5.2. Additionally, cost parameters for reagents used within the 
bioprocess and unit prices of fixed equipment required to support the cell culture 
systems summarised in Table 5.2, can be found in Table 5.3 
Planar and MC-based differentiation and RPE culture were considered for the use of 
both the spontaneous and directed differentiation protocols described above. Thus, 
four bioprocess strategies were considered for the manufacture of the hESC-RPE cell 
therapy, these are shown in Table 5.4. 
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Table 5.2 Bioprocess technologies tested within this case study and their associated input parameters 
Technology Type 
 
Abbreviated 
name 
Surface area 
(cm2/unit) (a) 
Cost 
(US$/unit) 
Media 
requirements 
(mL/unit) 
Technology 
number (t) 
T-25 T-25 25 $2 7 1 
T-75 T-75 75 $2 18.75 2 
T-175 T-175 175 $9 50 3 
T-225 T-225 225 $10 56.25 4 
Triple Flask TrF 500 $14 150 5 
CellSTACK L-1 636 $59 787.5 6 
2-layer CellSTACK L-2 1,272 $74 315 7 
HYPERflask cT 1,720 $19 560 8 
5-layer CellSTACK L-5 3,180 $241 787.5 9 
12-layer HYPERStack cL-12 6,000 $575 1320 10 
Xpansion bioreactor (10-layer) XP-10 6,360 $2,506 1399.2 11 
40-layer CellSTACK with automated cell factory manipulator L-40 25,440 $1,265 6360 12 
Xpansion bioreactor (50-layer) XP-50 31,800 $5,586 6996 13 
120-layer CellSTACK with automated cell factory manipulator L-120 60,000 $3,000 13200 14 
Xpansion bioreactor (200-layer) XP-200 122,400 $13,980 139920 15 
1L single-use bioreactor with microcarriers MC-1L 13,844 $250 750 16 
5L single-use bioreactor with microcarriers MC-5L 69,221 $700 3750 17 
20L single-use bioreactor with microcarriers MC-20L 276,885 $2,000 16000 18 
50L single-use bioreactor with microcarriers MC-50L 692,212 $2,000 37,500 19 
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Table 5.3 Key cost parameters for the bioprocess including media and reagent 
costs, unit prices of fixed equipment used within the bioprocess, and assumptions 
regarding shipping costs associated with the bioprocess 
Cost parameter   Value 
Media   
 Expansion medium US$690/L 
 
Spontaneous 
differentiation medium  
US$355/L 
 
Directed differentiation 
medium 
US$1280/L 
 
RPE Culture and 
Formulation medium 
US$645/L 
 
CellStart coating (RPE 
Culture) 
US$1535/L 
Labour  US$120/hr 
Fixed Equipment   
 Standard incubator  US$17,850 
 CF40 incubator US$30,000 
 Biosafety cabinet US$17,100 
 ACFM US$425,000 
 
Xpansion series 
controller 
US$56,000 
 SUB rig US$45,000-US$105,000 
 
Aseptic vialling 
machine 
US$340,000 – US$1.48m 
 Controlled rate freezer US$136,500 
 
Depreciation period 
 
 
5 years 
Shipping Costs   
 Air transport (Aw) US$60 per dose 
 
Road transport from 1o 
to 2o facility (Rpf) 
US$725 per shipment 
 
 
Road transport from 2o 
facility to hospital (Rsf) 
US$50 – US$430 per 
shipment 
 
Road trasnsport from 1o 
facility to an airport 
(Rpa) 
US$600 per shipment 
 
Road transport from 
airport to 2o facility (Rw) 
US$600 per shipment 
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The different bioprocess strategies were tested at a variety of annual demands and 
manufacturing lot sizes, outlined in Table 5.5. There are estimated be over 70,000 
new cases of AMD in the UK annually (Owen et al. 2012). It is not unusual for first-to-
market therapies to achieve a 40% market share, particularly in a specialised sector; 
however this market capture might not be as significant when lead times are short 
(Mckinsey & Company 2014). This is likely to be the case because there is 
concentrated product development activity related to hESC-RPEs for AMD treatment. 
Therefore, a modest estimate of market capture for a new product such as this would 
be 8%-15% of the market.  The scales tested were therefore representative of the 
different phases of product development and different commercial scales, depending 
on the product’s share of the market. Early and late-phase clinical trial manufacture 
(10-100 doses per annum) is captured, through to commercial scale manufacturing 
to satisfying the UK market (1,000 – 10,000 doses per annum). Annual demands of 
up to 50,000 doses were tested in order to capture the optimal bioprocess design that 
could be used to satisfy a large percentage of the UK market, and also sections of 
the European market. 
Table 5.4 Description of the four bioprocess strategies that were tested using the 
EA in this case study 
SD-PL (existing process): 
Spontaneous differentiation with planar 
vessels used throughout. 
 
SD-MC: 
Spontaneous differentiation with 
microcarrier-based differentiation and 
RPE culture in 3-D SUBs (planar 
vessels used for all other unit operation). 
DD-PL: 
Directed differentiation with 
differentiation with planar vessels used 
throughout. 
DD-MC: 
Directed differentiation with 
microcarrier-based differentiation and 
RPE culture in 3-D SUBs (planar 
vessels used for all other unit 
operations). 
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The optimal bioprocess design for each strategy (at each production scale) tested in 
this study from a COG perspective was identified using the decisional tool described 
in Section 2. Annual demands ranging from the clinical scale to commercial 
manufacturing scales were tested in order to evaluate which bioprocess strategy was 
most appropriate from a COG perspective for different scenarios. 
Table 5.5 Matrix illustrating the number of manufacturing lots required per annum 
for the annual demands and lot sizes tested in this chapter, red boxes indicate 
infeasible scales of production where the number of lots/year exceeds 50 
 Doses
/lot 
        
Doses
/yr 
1 10 50 100 500 1,000 5,000 
10,00
0 
50,00
0 
1 1         
10 10 1        
100 100 10 2 1      
1000 1,000 100 20 10 2 1    
5,000 5,000 500 100 50 10 5 1   
10,00
0 
10,00
0 
1,000 200 100 20 10 2 1  
50,00
0 
50,00
0 
5,000 1,000 500 100 50 10 5 1 
 
5.2.4 Comparison of different manufacturing schedules at secondary facilities 
Patch formation necessitates the use of small-scale, planar vessels in order to 
support culture of differentiated hESC-RPEs on specially adapted polyester 
membranes in order to allow the formation of cell-cell junctions and adhesions; this 
provides functionality and viability to the final product following transplantation to the 
patient. Due to the fact that only small-scale well-plates are suitable for this operation, 
a rigorous analysis of different technologies was not performed for manufacturing at 
the secondary facility. Rather, different process schedules were evaluated. 
Three different process schedules have been evaluated using a bioprocess 
economics model, which calculates COG associated with patch formation and 
harvesting in the manner described for the BEM described in 2.3. The Gantt charts in 
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Figure 5.2 illustrate each of the proposed process schedules which are summarised 
in Table 5.6. 
Table 5.6 Description of the three proposed process schedules for operations at 
the secondary production facility 
Process 
Schedule 
Description 
Schedule A 
(Figure 5.2a) 
Enough patches to satisfy a single day’s demand undergo 
formation for the minimum validated period of 6 weeks (Table 3). 
A complete lot of patches are cut and harvested for delivery to the 
clinic on a daily basis. 
Schedule B 
(Figure 5.2b) 
Schedule B: Enough patches to satisfy weekly demands undergo 
formation for between the minimum validated formation period of 
6 weeks and 7 weeks. Patches are cut and harvested on a daily 
basis from the end of week 6 to the end of week 7 within a single 
lot schedule. 
Schedule C 
(Figure 5.2c) 
Schedule C: Enough patches to satisfy the demands of 14 weeks 
of doses undergo formation for between the minimum validated 
period of 6 weeks and the maximum validated period of 20 weeks 
(Table 3). Patches are cut and harvested on a daily basis from the 
end of week 6 to the end of week 20 with a single lot schedule. 
 
Different process schedules have been evaluated in order to test their effect on 
manufacturing COG they were also analysed to test their ability to de-bottleneck 
manufacturing at secondary facilities. 
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Figure 5.2 Gant charts representing patch formation and patch cutting for a) 
Schedule A, b) Schedule B, c) Schedule C. Details of each schedule can be found in 
Table 5.6. Patch cutting and harvest periods are illustrated by lighter shaded bars in 
the Gantt charts. 
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5.2.5 Comparison of different distribution strategies  
The bioprocess and intended manufacturing strategy outlined in Figure 5.1 resulted 
in a variety of different distribution strategies. Two variables were considered to 
assess the impact of distribution on the COG associated with the manufacture of the 
cell therapy: the number of hospitals served by each secondary facility and the 
number of secondary facilities whereby patch formation is to occur. 
In order to capture the time constraints associated with transfer of the final product in 
the form of a patch of hESC-RPE cells from the secondary facility to the clinic, a series 
of assumptions were made regarding the number of patients that could be treated by 
a single surgery team depending on the number of hospitals served by a secondary 
facility. These are shown in Table 5.7. If the number of clinics served by a secondary 
facility is larger, it was assumed that fewer patients could be treated in a single day. 
This is because it was assumed that the product would have to travel a greater 
distance to the clinic from the secondary manufacturing facility in these conditions. 
Therefore less time is available to perform the implantation surgery within the viable 
lifespan of the product once it arrives at the clinic.  
Table 5.7 Number of patients that can be treated in a single day depending on 
number of clinics served by a single 20 facility 
Parameter Conditions Value 
Number of clinics per 2o 
facility 
N/A 1 to 5 
Max treatments per surgery 
team 
One hospital per 2o 
facility 
5 
Max treatments per surgery 
team (2-4 hospitals per 
secondary facility) 
2 to 4 hospitals per 2o 
facility 
3 
Max treatments per surgery 
team (5 hospitals per 
secondary facility) 
5 hospitals per 2o 
facility 
2 
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In addition to an evaluation of the available technologies and strategies for primary 
manufacturing operations and scheduling options for secondary manufacturing, 
centralised versus de-centralised primary manufacturing was also assessed. The 
distribution scenarios in this study consider manufacturing and delivery of the cell 
therapy to clinics in both the UK and mainland member nations of the EU in mainland 
Europe. As discussed previously, the fact that the product must be delivered as a 
fresh entity to the clinic dictates that secondary, decentralised facilities must be 
employed. Therefore, distribution models were used to evaluate the impact that the 
number of secondary facilities have upon cost of goods and whether the use of a 
single centralised facility, or multiple de-centralised facilities for primary 
manufacturing would be more cost-effective. Figure 5.3 shows the distribution models 
that were evaluated within this study. The centralised model (Figure 5.3a) involves 
distribution from a single primary facility based in the UK to secondary facilities within 
the UK and mainland Europe. Process material is transported from the primary 
facilities to UK-based secondary facilities by road. Transport from the primary facility 
to EU-based secondary facilities was assumed to involve transport to airport by road, 
air-shipment to an airport within the EU, before final road transportation to the 
secondary facility. The decentralised model assumes that two primary facilities will be 
built; one in the UK and one within the EU on mainland Europe. Shipment of process 
material from the primary manufacturing facilities to secondary facilities will be by 
road transport. In all instances delivery of the final product from the secondary facility 
to the clinic is carried out by road transport. The costs associated with shipping can 
be found within Table 5.3, road transport costs were derived from quotes obtained 
from NHS-contracted couriers who regularly transport medicinal products under 
cGMP conditions. Air shipment costs were derived from conversations with industry 
experts. 
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Figure 5.3 Flowcharts illustrating the flow of process materials between primary and secondary manufacturing facilities, and then on to the 
clinic within the UK and mainland Europe when a) a single centralised primary facility is built in the UK, and b) two separate primary facilities 
are built; one located in the UK and one located in mainland Europe.
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5.3 Case Study Results and Discussion 
5.3.1 Comparison of bioprocess strategies: selection of cost-effective 
technologies 
Figure 5.4 shows the outputs the decisional tool derived from the functioning of the 
evolutionary algorithm (EA). The text matrices depict the most cost-effective 
technologies to be used for the final passage of expansion, differentiation and RPE 
culture for each bioprocess strategy tested, with the number of units required per lot 
given in square brackets.  
Figure 5.4 illustrates the impact of both the bioprocess strategy used and the scale of 
the bioprocess, in terms of demand and lot size, upon the type of technology selected 
as the optimal technology. The colours used in the matrix represent different 
categories of process technologies (see legend inset). For the directed differentiation 
and planar (DD-PL) option, the DD-PL matrix (Fig 5.4b) illustrates that single-layer T-
flasks remain the most cost-effective technology, even at lot sizes of 500 doses. 
Beyond this, multi-layer planar vessels, such as 2-layer CellStacks (L-2), or 5-layer 
CellStacks (L-5) are preferred. In comparison, the matrix representing the 
spontaneous differentiation route (SD-PL) (Fig 5.4a) shows that for both expansion 
and differentiation single-layer T-flasks are only the most cost-effective technologies 
at lot sizes of 10 doses. The switch to multi-layer planar vessels must be made at 
smaller lot sizes than if the DD-PL bioprocess were employed. Technologies used for 
RPE culture are generally the same across all scales for the SD-PL and DD-PL 
processes because the cell population size that is output from the differentiation unit 
operation is the same between the two strategies. Caveats to this rule do exist and 
instances where the optimal technology differs between the two RPE culture steps 
are due to the fact that the selected technology is more cost-effective to run in 
sequence with technologies used in previous unit operations. For example, at an 
annual demand of 50,000 doses where 5 x 10,000 doses per lot are manufactured, 
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one cL-12 unit is preferred for RPE culture in the SD-PL process (Fig. 5.4a) compared 
to one XP-10 unit for the DD-PL process (Fig. 5.4b). Solutions were found for lot sizes 
of 50,000 doses for the SD-PL bioprocess, however these have been marked as 
infeasible in Figure 5.4a as they exceeded the maximum number of vessels allowable 
per lot from a QC point of view in this instance.  
Figures 5.4c and 5.4d represent the microcarrier routes for both the spontaneous and 
directed differentiation (SD-MC and DD-MC) bioprocess strategies, respectively. 
Juxtaposed with the high-seeding densities reported for successful hESC 
differentiation and RPE culture, the small dose sizes required for a hESC-RPE 
therapy mean that microcarrier-based differentiation is infeasible at lot sizes below 
500 doses when SD is considered, this  lower limit increases to 10,000 doses when 
DD is considered. This is because the cell population sizes required to satisfy 
demands in these scenarios result in suspension bioreactor utilisation rates lower 
than 25%; this is the minimum allowable utilisation as defined by the vessels’ 
manufacturer (Sartorius Stedim 2017). Furthermore, RPE culture in SUBs is 
infeasible at lot sizes of 10,000 doses and below and thus was not considered for the 
SD-MC process at lot sizes ranging from 500 to 10,000 doses (inclusive).  
Similar to the data presented in Figures 5.4a and 5.4b (at feasible lot sizes), the SD-
MC bioprocess strategy necessitates the use of larger vessels than the DD-MC 
bioprocess strategy. At lot sizes of 5,000, 10,000 and 50,000 doses, SUBs with 
volumes of 5L, 20L, and 50L respectively are the preferred differentiation technology 
for the SUB-based bioprocess. Comparatively, at lot sizes of 10,000 and 50,000 
doses, single SUBs with respective volumes of 1L and 5L are preferred for the 
differentiation unit operation for the DD-MC bioprocess strategy.  
Examination of Figure 5.4 shows that SD-based bioprocesses necessitate the need 
for larger culture vessels during the expansion and differentiation unit operations. This 
is due to the fact that SD-based bioprocesses result in lower differentiation 
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efficiencies compared to their DD counterparts; therefore larger cell population sizes 
must be handled during the expansion and differentiation unit operations.  
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Figure 5.4 a) & b) Continued overleaf
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Figure 5.4 Matrices showing the impact on the optimal process technology for the final passage of expansion, differentiation and RPE cell culture 
unit operations when a) SD-PL, b) DD-PL, c) SD-MC, d) DD-MC bioprocess strategies are employed at different lot sizes and annual demands. 
For SUBs, the values represent the size of the bioreactor selected as optimal. For all technologies the number in square brackets represents the 
number of units required per lot. Only feasible annual demands are shown in c) and d). 
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5.3.2 Comparison of the manufacturing cost of goods associated with each 
bioprocess strategy 
Figure 5.5 offers a comparison between the four bioprocess strategies tested from a 
COG perspective. The values given in Figure 5.5a are the minimum COG per dose 
values for primary manufacturing for each given annual demand and lot size, as 
evaluated by the EA. Figure 5.5a illustrates the economies of scale that can be 
achieved in allogeneic cell therapy processing. This is evident from the difference in 
COG per dose from an annual demand of 100 doses (US$20,497 for 10 lots per year) 
and an annual demand of 10,000 doses (US$397 at 10 lots per year). This is possible 
because the bioprocess can be scaled-up in an allogeneic setting, as opposed to the 
scale-out strategy necessitated by autologous processes (Jenkins & Farid 2015).  
Figures 5.5b, c and d illustrate the percentage change in COG when use of the DD-
PL, SD-MC and DD-3D bioprocess strategies, respectively, is considered against the 
SD-PL strategy. Figure 5.5b illustrates that COG associated with the DD-PL process 
strategy are less than those associated with the SD-PL process strategy at all scales 
tested. In comparison, switching to the SD-MC bioprocess (Fig. 5.5c) from the SD-PL 
process only proves more cost-effective at lot sizes of 5,000 doses and beyond. 
Furthermore, the DD-MC bioprocess strategy proves more cost-effective than the SD-
PL bioprocess strategy in all feasible scenarios (Fig. 5.5d). 
A comparison of the DD-PL and DD-MC matrices (Fig 5.5b & 5.5d, respectively) 
shows that there is no significant difference in the COG associated with these two 
bioprocess strategies at lot sizes of 10,000 doses. Relative to the SD-PL bioprocess, 
a 1% reduction in COG can be achieved by using the DD-MC bioprocess strategy as 
oppose to the DD-PL strategy, at a lot size of 50,000 doses (1 lot per annum). In real 
terms, this is a 6% COG reduction when comparing the COG values for the two 
bioprocesses (US$54 for DD-MC vs. US$58 for DD-PL) (see Fig 5.6b). Both DD 
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bioprocesses prove more cost-effective than the SD bioprocess in all scenarios 
tested.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Matrices showing the impact on bioprocess COG when different 
bioprocess strategies are employed at different annual demands and lot sizes. a) 
COG per dose values (US$) when the most cost-effective process flowsheet is 
selected for the SD-PL bioprocess strategy. b) – d): Percentage change in the 
minimum COG/dose for given annual demands and lot sizes as compared to the 
values calculated for the SD-PL bioprocess strategy if the b) DD-PL, c) SD-MC, d) 
DD-MC bioprocess strategy were employed. Green cells within the matrices indicate 
a COG per dose decrease compared to the SD-PL bioprocess, red cells indicate a 
COG per dose increase compared to the SD-PL bioprocess. 
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In order to further investigate the trends featured in Figures 5.4 and 5.5, a detailed 
analysis of the COG and its constituent components was carried out (Figure 5.6a, 
5.6b, 5.6e and 5.6f). At annual demands of 5,000 doses, satisfied by 10 
manufacturing lots, the SD-PL bioprocess strategy proves to be more cost-effective 
than the SD-MC bioprocess. This is because the SD-MC bioprocess results in an 
increase in the indirect costs associated with production of the hESC-RPE therapy at 
this scale. SUBs require expensive fixed capital equipment; this is in contrast to the 
type of disposable vessel (2 x 12 cl-12 (12-layer CellStack)) used for the SD-PL at 
this scale. Despite resulting in an overall increase in COG at this scale, the SD-MC 
strategy results in a decrease in materials and labour costs (Figure 5.6a). This is 
because a single SUB can be used for the differentiation unit operation in each lot, 
as oppose to the multiple vessels required for the SD-PL bioprocess strategy (Fig. 
5.4). SUB culture using microcarriers offers greater growth surface area per volume 
of media used for adherent cells, therefore less media is required for the SD-MC 
bioprocess, hence materials costs are reduced if this bioprocess strategy is used. 
Furthermore, SUBs run in an automated manner, therefore less manual interaction is 
required when the SD-MC strategy is employed. This, along with the fact that only 
one unit is required for the differentiation process in the SD-MC bioprocess 
(compared to two for the SD-PL bioprocess strategy), results in decreased labour 
costs directly associated with this strategy when compared with the SD-PL bioprocess 
strategy. 
In contrast, at annual demands of 50,000 doses, satisfied by 5 manufacturing lots per 
year, it is the SD-MC bioprocess strategy that proves more cost-effective than the 
SD-PL strategy. At this production scale, the SD-MC strategy offers reductions in both 
direct (DC) and indirect (IDC) costs compared to the SD-PL strategy (Figure 5.6e). At 
this scale automated planar vessels in the form of 3 x 120-layer Cell Factories are 
required, along with an Automated Cell Factory Manipulator (Nunc, USA). The 
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additional cost of this machinery outweighs the capital expenditure associated with 
the 20L SUB control rig required for the SD-MC process strategy at this scale (Figure 
5.4).  
Figures 5.6e and 5.6f show that the DD-PL and DD-MC bioprocess can drastically 
reduce bioprocess COG by 73% compared to the SD-PL bioprocess at an annual 
demand of 50,000 doses. The DD bioprocess strategies utilise an improved 
differentiation protocol, whereby differentiation efficiencies are improved as a result 
of an improved media composition. Hence, smaller cell populations are required to 
be output from the hESC expansion unit operation and smaller cell populations are 
process during the differentiation unit operation. This is why materials costs are 
dramatically reduced if the DD-PL bioprocess strategy is used compared to either the 
SD-PL, or SD-MC bioprocess strategy at an annual demand of 5,000 doses (Figure 
5.7a). Labour costs are also reduced as a result of selecting either of the DD 
bioprocesses when compared to the SD-PL or SD-MC bioprocess because the length 
of the differentiation protocol is reduced from 84 days to 19 days. This reduction in 
the length of the bioprocess also affects materials costs (this equates to fewer media 
exchanges using DD protocols). Capital expenditure is also reduced when DD is 
employed; equipment utilisation is improved because more lots can be produced in a 
shorter period of time.   
There is only a 5% difference in direct costs between the DD-MC process strategy 
and the DD-PL strategy at an annual demand of 50,000 doses (Figure 5.6b & 5.6d). 
This is reflective of the fact that the cell populations required at this scale result in low 
utilisation of the 1L-SUB that is the preferred DD-MC technology for differentiation, 
which means that the bioprocess is unable to achieve full advantage of the increased 
surface area to volume ratio that is offered by SUBs.  
Figure 5.6b & 5.6f illustrate the effects that different bioprocess strategies have on 
the direct costs associated with each unit operation in the process. Here, the dramatic 
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direct costs reductions that can be achieved through use of the DD-PL and DD-MC 
bioprocess are depicted. Whilst the RPE culture costs remain the same as those for 
the SD-based bioprocesses, direct costs associated with the expansion and 
differentiation unit operations are significantly reduced (97% and 90% compared with 
the SD-PL and SD-MC strategies respectively). This is illustrative of the reduced cell 
populations required when DD is used as opposed to SD. The direct costs associated 
with differentiation are also significantly reduced with use of the SD-MC bioprocess 
strategy when compared the SD-PL bioprocess, whereas those associated with RPE 
culture and expansion remain approximately constant. This confirms that reductions 
in materials costs discussed in Figure 5.6a and 5.6b derive from SUB usage during 
the differentiation unit operation.    
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Figure 5.6 See overleaf for legend 
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Figure 5.6 Charts showing the effect of process scale and bioprocess strategy choice 
on COG and process robustness at annual demands of a) – d) 5,000 doses produced 
across 10 manufacturing lots and e) – h) 50,000 doses produced across 5 
manufacturing lots . a) & e): COG breakdown at c) an annual demand of 5,000 doses 
produced across 10 manufacturing lots and e) an annual demand of 50,000 doses 
produced across 5 manufacturing lots. b) & f): Direct cost breakdown by unit 
operation at b) an annual demand of 5,000 doses produced across 10 manufacturing 
lots and f) an annual demand of 50,000 doses produced across 5 manufacturing lots. 
c) & g): Box and whisker plots illustrating the effects of process variation on COG per 
dose at an annual demand of c) 5,000 doses produced across 10 manufacturing lots 
and g) 50,000 doses produced across 5 manufacturing lots. The dashed intercept on 
the y-axis displays the mean COG per dose value for the SD-PL bioprocess, the 
boxed values below the chart illustrate the probability (as assessed by Monte Carlo 
analysis) that the COG for a given bioprocess strategy will fall below the mean value 
of SD-PL bioprocess at an annual demand of 5,000 doses per annum. d) & h): Box 
and whisker plots illustrating the effects of process variation on annual throughput at 
an annual demand of d) 5,000 doses produced across 10 manufacturing lots and h) 
50,000 doses produced across 5 manufacturing lots. The dashed intercept on the y-
axis of each plot displays the annual demand and the boxed values below the plots 
illustrate the probability (as assessed by Monte Carlo analysis) that the annual 
throughput for a given bioprocess strategy will satisfy the annual demand. 
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5.3.3 Stochastic modelling of different bioprocess strategies under uncertainty 
Further to the deterministic bioprocess economics model that was used to capture 
the data shown in Figs. 5.6a, 5.6b, 5.6e & 5.6f, the Monte Carlo stochastic modelling 
technique was employed in order to assess the performance of the different 
bioprocess strategies under manufacturing uncertainty.   
The results of the Monte Carlo analysis show that at an annual demand of 5,000 
doses (Figure 5.6c), the median COG per dose of the SD-PL process (US$627) is 
slightly lower than that of the SD-MC bioprocess (US$640). This is consistent with the 
results of the deterministic cost model, whereby the SD-PL strategy proved more 
cost-effective than the SD-MC strategy (Fig. 5.6a). However, the spread of values 
shown by the whiskers of the box plots in Figure 5.6c illustrate that there is greater 
variation in the bioprocess COG for the SD-PL process than there is when the SD-
MC bioprocess is employed. This is reflective of the fact that bioprocesses in SUBs 
generally allow much greater control of a cells microenvironment and therefore 
process variation can be reduced if the SD-MC bioprocess is employed.  
Similar to the deterministic model, the median value for the COG of the DD-PL 
strategy proves to be significantly lower than that of both the SD bioprocess 
strategies. The greater process control allowed by the use of the DD strategy is 
reflected by the narrow range of COG values for this strategy as compared to the SD 
values (Figure 5.6c).  
Even under uncertainty the DD-PL strategy proved to be more cost-effective than 
both the SD strategies, indeed the Monte Carlo analysis found that COGDD-PL < COGμ 
SD-PL in 100% of the simulations carried out, where COGμ = the cost of goods value 
for a given process strategy determined by the Monte Carlo analysis; i.e. in all 
instances tested by the Monte Carlo analysis, COG for the DD-PL process was less 
than the COG found for the SD-PL process under base case conditions. The 
increased robustness of the DD-PL strategy compared to the SD-PL and SD-MC 
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strategies is also illustrated in Fig. 5.6d, which consists of box and whisker plots the 
output of the Monte Carlo analysis representing the number of doses produced per 
annum. The Monte Carlo Analysis shows that there is a 94% probability that the 
throughput of the bioprocess (T) will be greater or equal to the target annual demand 
(Tann) when the DD-PL bioprocess is employed, as compared to probabilities of 80% 
and 74% for the SD-MC and SD-PL bioprocesses respectively.  
At an annual demand of 50,000 doses the COG per dose output values of the Monte 
Carlo Analysis also follow a similar trend to that of the deterministic model in that the 
median value of the COG of the SD-MC, DD-PL and DD-MC bioprocesses (US$151, 
US$58 and US$57 respectively) are significantly lower than that of the SD-PL 
bioprocess (US$218). Indeed, the Monte Carlo outputs show that in all 1,000 
simulations the COG per dose values calculated for the SD-MC, DD-PL and DD-MC 
bioprocesses were lower than the COG value calculated for the SD-PL bioprocess in 
the deterministic model (COGμ SD-PL). Similar to the Monte Carlo analysis outputs at 
an annual demand of 5,000 doses, the Monte Carlo outputs at 50,000 doses per 
annum show a narrower spread of values for the MC bioprocess strategies as 
compared to their PL counterparts; this owes itself to the tighter process control of a 
cell population’s environment offered by SUBs. This pattern was observed for both 
output values of COG per dose (Fig. 5.6g) and output values of the number of doses 
produced per annum (Fig. 5.6h).  
Finally, the DD-MC bioprocess was shown to be the most robust of the four strategies 
tested under uncertainty at this scale; there was a 94% probability that the annual 
throughput (T) of this process will exceed the target annual demand (Tann) when 
tested at 50,000 doses per annum (Fig. 5.6h). This is compared to 92%, 81% and 
75% for the DD-PL, SD-MC, SD-PL bioprocess respectively. A wider range of values 
for the SD-PL and SD-MC strategies were observed than for the DD-PL and DD-MC 
process for both the COG per dose and annual throughput outputs of the Monte Carlo 
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analysis (Fig. 5.6c, 5.6d, 5.6g & 5.6h). This illustrates that when manufacturing 
uncertainty and variations in critical process parameters are taken into account 
directed differentiation platforms prove to be more robust from both a process 
performance and bioprocess economic standpoint. It is unsurprising that the DD 
bioprocess strategies proved more robust than their SD counterparts; numerous 
empirical studies have shown that the use of directed differentiation offers greater 
control of the differentiation process than spontaneous differentiation strategies.  
5.3.4 Appraisal of the four bioprocess strategies tested within this study 
Two differentiation strategies have been compared; spontaneous differentiation and 
directed differentiation. Empirical data shows that directed differentiation is both a 
more efficient and more robust means of generating hESC-RPE cells (Idelson et al. 
2009; Buchholz et al. 2013), as well as other types other progenitor cell type including 
neuronal cells and cardiomyocytes (Surmacz et al. 2012; Burridge et al. 2011).  
It can be concluded that in addition to generating larger number of target cells in a 
shorter timeframe, directed differentiation offers a significantly more cost-effective 
route to producing hESC-RPEs for cell therapies than spontaneous differentiation. 
Furthermore, the Monte Carlo analysis illustrates that directed differentiation 
protocols prove to be a more robust platform than their spontaneous counterparts 
from both a bioprocess economics and bioprocess performance perspective.  
A bioprocess economic comparison of microcarrier-based differentiation and RPE 
culture versus planar-based bioprocessing was carried out. Previous analyses have 
shown that microcarrier-based processing of cells for cell therapies can significantly 
reduce cost of goods compared to the use of planar technologies, particularly at large 
manufacturing lot sizes (Simaria et al. 2014; Hassan et al. 2016). Here we found that 
for a low-dose, allogeneic therapy microcarrier-based differentiation does not offer 
significant cost of goods savings, even at annual demands in the order of 104 doses 
if a directed differentiation protocol is employed. As stated previously, this is because 
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the small cell populations required for this strategy do not allow full realisation of the 
increased efficiency in media usage that has been shown to be offered by 
microcarrier-based processing (Wang et al. 2013; Panchalingam et al. 2015). 3-D 
bioprocess strategies do offer other advantages over many planar technologies, 
including the fact that the microenvironment of the cells can be better controlled, and 
the bioreactor environment more tightly controlled (Olmer et al. 2012). This can result 
in greater process robustness from both a process performance and economic 
standpoint, as illustrated by the stochastic modelling employed in this study.  
However, more advanced planar technologies, which have more in common with 
traditional bioreactors than manual planar vessels such as T-flasks, can also offer a 
well-controlled, robust process platform when directed differentiation protocols are 
employed. This study found that the differences between the DD-MC and DD-PL 
strategies were not significant from a COG perspective. Indeed for low-dose cell-
based therapies, such as the one investigated in this study, planar bioreactors may 
be a more suitable platform due to the cell population sizes involved in the bioprocess 
if they can be run in a controlled and contained manner. This is certainly true if the 
cell therapy development pathway is taken into account; the DD-MC bioprocess is 
unsuitable for lot sizes below 1,000 doses as this results in utilisation values below 
25%; the minimum advised by the manufacturer of such platforms (Sartorius Stedim 
2017). Therefore, in pre-clinical, and early phase trials the DD-PL bioprocess will 
likely need to be employed. Switching to the DD-MC bioprocess either in late-phase 
clinical trials or post approval will represent a significant investment (and large risk if 
done pre-approval). This investment will unlikely be recouped as the differences in 
cost of goods between the two strategies is not significant, even at annual demands 
of up to 10,000 doses. 
5.3.5 Comparison of bioprocess schedules for manufacturing at secondary 
facilities 
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Figure 5.7 displays the COG breakdown of manufacturing carried out at the 
secondary facility. It is clear from Figure 5.7a that at small, clinical production scales 
(10 and 100 doses per annum), schedule C, whereby patches undergo formation from 
between 6 weeks and 20 weeks, proves less cost-effective than schedules A and B 
(see Table 5.5/ Fig. 5.2 for production schedules), whereby each patch undergoes 
formation for 6 weeks, or 6 to 7 weeks respectively. This is largely due to increased 
IDC, which also prove to be significantly higher for process schedule C at commercial 
production scales (5,000 and 50,000 doses per annum, Figure 5.7b). The number of 
doses that must be processed at any given time in Schedule C is larger than the other 
process schedules. 14 weeks of doses must be incubated at any given time, which 
drives up the required incubator capacity, and subsequently IDC, at this stage of the 
process. Furthermore, the need to handle more doses at a single time means that 
more operators are required for Schedule C. This in turn results in the need for more 
biosafety cabinets to allow operators to work in Class A/B conditions required for 
manual processing. This is also why labour costs are higher for schedule C compared 
to schedules A and B; the fact that more patches must have their media replenished 
over a longer time period also results in slightly increased materials costs for 
Schedule C. Schedule A proves more cost-effective than schedule B at commercial 
production scales (Figure 5.7b). This owes itself to similar reasons as those described 
previously for schedule C, although they are less pronounced when schedules A and 
B are compared.  
There are logistical arguments for and against both schedule A and B. It could be 
argued that Schedule A offers more flexibility, for example fewer doses could be 
prepared for weekend surgeries (if these were considered at all). However, this option 
could be worked into schedule B without great difficulty. Schedule B is less 
challenging logistically; a maximum of 7 lots will be handled at a single time. This 
number rises to 42 with schedule A. The therapeutic material will need to be tracked 
217 
 
carefully throughout the duration of manufacturing at the secondary facility. Barcode 
tracking software packages such as Trakcel (Cardiff, UK) have made tracking and 
tracing of individual samples (or patches in this case) far simpler and therefore the 
logistical challenge presented by schedule A may not be the barrier that it once might 
have been.  
Given the insignificant differences in cost between production schedules A and B, the 
decision of which schedule to proceed with would likely depend on whether a 
manufacturer prefers a more responsive manufacturing schedule (process schedule 
A) or a schedule that offers greater logistical simplicity within the secondary facility 
(process schedule B).  
 
 
 
 
 
 
 
 
Figure 5.7 Bar charts representing COG breakdowns at the secondary manufacturing 
facilities for a) annual demands of 10 and 100 doses per year and b) annual demands 
of 5,000 and 10,000 doses per year. The process strategies refer to Schedules A, B 
and C; details of which can be found in Table 5.5.  
5.3.6 Effect of distribution strategies on shipping and manufacturing costs 
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Figure 5.8 illustrates the effect that both the number of secondary facilities and the 
number of hospitals per secondary facility have on COG at the secondary facility and 
shipping costs. A reduction in the number of facilities is advantageous because it 
reduces IDC associated with product manufacture. Furthermore, labour costs are 
reduced because the number of operators required at a single secondary facility 
remains the same regardless of the scale of the facility at the annual demand tested 
for this scenario (10,000 doses). 
 
 
 
 
 
 
 
 
Figure 5.8 Bar chart representing the COG breakdowns for secondary manufacturing 
and shipping costs (inclusive of transportation costs from 10 facility to 20 facility) when 
it is assumed that the therapy is administered at 10 hospitals within the UK. The 
assumed annual demand is 10,000 doses per year. 
 
Minimising the number of hospitals per facility proves more expensive because IDC 
and labour costs are increased as the number of required secondary facilities 
increases. Shipping costs are decreased in this scenario. Although the number of 
journeys from the primary facility to secondary facilities is increased when the number 
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of secondary facilities is increased, there is a reduction in both the distance and in 
the number of journeys required between the secondary facility and the clinic. Thus, 
the number of time-sensitive transports of the finished product that is required is 
reduced. Furthermore, small secondary facilities may be able to be built within, or 
adjacent to clinics; this would negate the need for a final road transport from the 
secondary facility to the clinic altogether. However, placing a manufacturing area 
within a hospital would not always prove feasible. This is particularly true of clinics 
based in city centres, or densely populated areas where space on hospital premises 
is likely to be at a premium. 
Increasing the number of clinics at which the product is available would likely increase 
the availability of the therapy to a larger proportion of a target market. However when 
dealing with public healthcare systems, it is likely to be the decision of the health 
services as to which hospitals will be licensed to administer a specialist therapy, or 
whether it will be added to local formularies. Furthermore, even in a private healthcare 
model, cell therapy manufacturers may be liable for patient transfer to and from 
specialist clinics that are able to administer the therapy in question and this may incur 
added costs.   
Figure 5.9a illustrates the COG breakdowns for the centralised primary manufacturing 
model and the decentralised primary manufacturing model at annual demands of 
20,000 and 50,000 doses. At annual demands of 20,000 doses (5,000 in the UK, 
15,000 in mainland Europe) it proves more cost-effective to use a centralised primary 
manufacturing model, whereby a single facility is based in the UK. However, at higher 
annual demands of 50,000 doses it proves more cost-effective to employ a 
decentralised primary manufacturing model whereby one primary facility is based in 
the UK and one primary facility is based in mainland Europe. This is because the 
reductions in shipping costs that are achieved using the decentralised primary 
manufacturing model (as compared to the centralised one), outweigh the additional 
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primary manufacturing COG that are inherent in the decentralised primary 
manufacturing strategy (Figure 5.9b). Whereas if a smaller target market is expected, 
a centralised primary manufacturing model may be a more appropriate strategy to 
employ for this type of cell therapy. At both annual demands tested, the decentralised 
primary manufacturing model resulted in a significant increase in primary 
manufacturing COG. This is a reflection of both the increased capital expenditure 
required to build multiple facilities and the reduction in economies of scale (discussed 
above) by dividing primary manufacturing operations between two sites (Trainor 
2016).  
The decentralised primary manufacturing model also resulted in a reduction in 
shipping costs as compared to the centralised primary manufacturing model at both 
annual demands tested. This is because the decentralised model obviates the need 
for air transport, or overseas shipment of process material from the UK to mainland 
Europe (Figure 5.3).Figure 5.9b displays the COG breakdown for the centralised 
primary manufacturing model. In this case, shipping accounts for 28% of total costs. 
Whilst shipping to the EU accounts for 27% of total costs, UK shipping only accounts 
for 1% of the same figure. This suggests that overseas shipment of process material 
contributes heavily towards total costs. This is further illustrated in Figure 5.9c, which 
illustrates the COG breakdown for the decentralised primary manufacturing model. In 
this instance shipping only accounts 6% of the total costs (4% EU shipping, 2% UK 
shipping).  
Although shipping costs can be reduced both in real terms and as a percentage if the 
decentralised primary manufacturing model is employed as opposed to the 
centralised model, the opposite is true of primary manufacturing COG (Fig. 5.9a-
5.9c). Figure 5.9 suggests that the larger the annual demands, the more likely it is 
that a decentralised manufacturing model will prove more cost effective than a 
centralised manufacturing model. The decentralised model will reduce interactions 
221 
 
with courier companies as it obviates the need for overseas shipping, which can be 
difficult to validate (O’Donnell 2015). However if multiple facilities are employed, it is 
essential to fully validate the manufacturing process in order to ensure that critical 
quality attributes of the product are kept within the validation space; i.e. it must be 
ensured that the product manufactured at each facility is consistent (Trainor et al. 
2016).  
.  
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Figure 5.9 Comparison of COG breakdowns for centralised vs decentralised manufacturing. a) Bar chart comparing the COG breakdowns when 
a single, centralised primary facility is built in the UK to when two separate primary facilities are built: one located in the UK and one located in 
the EU at annual demands of 20,000 doses per year and 50,000 doses per year. It has been assumed that 25% of doses will be distributed to 
the UK and 75% of doses will be distributed to the EU. b) & c) Pie-charts illustrating the COG breakdowns (including shipping) when b) a single, 
centralised primary facility is built in the UK to when c) two separate primary facilities are built: one located in the UK and one located in the EU. 
An annual demand of 50,000 doses per year was assumed in figures b and c.
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5.4. Case Study Conclusions 
This chapter shows how an evolutionary algorithm can allow rapid identification of 
optimal bioprocess designs. A decisional tool was contextualised using a 
representative case study, in which a low dose, allogeneic hESC-RPE therapy is 
produced. The tool was used to appraise four different bioprocess strategies including 
cross comparison of spontaneous versus directed differentiation protocols, and 
planar versus microcarrier-based differentiation and RPE culture unit operations. The 
outputs show that directed differentiation protocols can significantly both reduce the 
cost of goods and increase the process economic robustness associated with hESC 
derived cell-based therapy manufacturing. Additionally, the study found that for low 
dose cell-based therapies, there is no significant difference in the cost of goods or 
process robustness between planar and microcarrier bioprocesses when directed 
differentiation is employed, even at larger lot sizes. However, when larger cell 
populations were required (i.e. for spontaneous differentiation) microcarrier-based 
processing can offer significant manufacturing COG reductions compared to planar 
technologies.  
The tool was also used to evaluate whether centralised, or decentralised primary 
manufacturing would prove more cost effective. At lower annual demands (20,000 
doses), centralised manufacturing proved more cost effective; the savings in shipping 
costs associated with decentralised manufacturing failed to outweigh the additional 
capital expenditure associated with building an additional facility. At larger annual 
demands (50,000 doses), the reverse of this proved to be the case. This work sought 
to model a bioprocess at scales ranging from clinical (i.e. 10-100 doses per annum) 
to commercial (1,000+ doses per annum).  
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5.5. Measuring the performance of the evolutionary algorithm 
A single scenario was used to test the performance of the EA when applied to the MC 
and PL bioprocess strategies. This was done in order to provide a snapshot that was 
reflective of the EAs performance for both of these bioprocess strategies. In the 
scenario selected, the annual demand was assumed to be 5,000 doses and the lot 
size was assumed to be 500 doses. This scenario featured in the results and 
discussion of this case study, presented in Section 5.3. The EA was tested when it 
was applied to both the SD-PL and the SD-MC bioprocess strategies. This was to 
ensure that the algorithm was accurate and reliable when applied to both the PL and 
MC differentiation platforms, but also to test the performance of the EA against a 
brute-force search procedure in both instances. It was necessary to do this because 
the MC process strategy results in a smaller design space for the problem tested 
within this case study, therefore the performance of the EA relative to a brute-force 
algorithm would be different to that of the EA when applied to the PL process strategy.  
5.5.1 Metrics used to evaluate EA performance 
The performance of the evolutionary algorithm was measured using standard 
convergence metrics. The mean fitness (in this instance cost of goods) was measured 
for each generation across all algorithm runs, and the standard error of the mean 
(SEM) was used to quantify the convergence of the solutions produced by the EA. 
The standard error of the mean is the standard deviation of the sample mean’s 
estimate of a population. Therefore, the smaller the standard error of the mean, the 
greater the convergence of the solutions found by the EA, a standard error of the 
mean value of zero indicates that the solutions for each generation across all EA runs 
have converged fully. Selected scenarios that have been highlighted in Section 5.3 
were tested in order to ensure the reliability and accuracy of the EA.  
5.5.2 EA Performance 
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Figure 5.10 shows the average fitness value (Fig 5.10a) and the standard error of the 
mean average fitness value (5.10b) for each generation across the five EA runs when 
it was applied to the SD-PL bioprocess respectively for the selected scenario. Figure 
5.10a illustrates the optimisation carried out by the EA, with the average fitness value 
falling gradually across each successive generation, before it remains constant from 
generation 22 onwards (Point A). The steep gradients, which are apparent between 
early generations (e.g. 1 to 5), indicate that the EA is yet to find the optimal solution 
at this stage of the procedure, as each generation produces a solution that results in 
the cost of goods being minimised further as compared to the previous generation. 
The line representing the average fitness across all five EA runs has a gradient of 
zero from generation 22 onwards. This indicates the latest point at which the optimal 
solution was found by the EA across any of the five runs.  
Figure 5.10b, which displays the standard error of the mean fitness value of the best 
solution after each generation across all the EA runs illustrates the convergence of 
the EA outputs towards the optimal solution. The SEM has a value of zero from 
generation 22 onwards (Point B). This indicates that by this point, the solutions 
produced across all five runs of the EA are consistent and, as shown by the fact that 
fitness values illustrated in Figure 5.10a remain constant from this point, have 
converged upon the optimal solution.  
The mean fitness values across all five EA runs for each of the 25 generations and 
the standard error of these mean values for the MC bioprocess strategy are displayed 
in Figures 5.11a and 5.11b respectively. These figures follow the same pattern shown 
in Figures 5.10a and 5.10b; the gradient of the line representing the average fitness 
value for optimal solutions found by the EA remains 0 from generation number 20 
onwards (Point A, Fig. 5.11a). The standard error of the mean of the best solution 
found by the EA reaches 0 at generation 20, and remains at 0 from this point forwards 
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(Point B, Figure 5.11b). Together, these trends indicate that the optimal solution 
identifiable with the EA is reached by generation 20 across all five runs. 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Line plots illustrating performance metrics for the EA when it was applied 
to the SD-PL bioprocess. a) Line plot that shows the mean fitness value (in this 
instance the cost of goods per dose) of the best solution found across all five runs of 
the EA for each of the 25 generations. Point A identifies the point by which the optimal 
solution is found within all five EA runs, and the mean fitness value remains constant. 
b) Line plot that shows the standard error of the mean fitness value across all five 
runs of the EA for each of the 25 generations. Point B identifies the point at which the 
solutions across all five runs become consistent, and that the standard error of the 
mean remains zero.  
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The fact that the EA solutions converged for both the SD-PL and SD-MC bioprocess 
within 25 generations indicates that the EA can reliably identify the optimal solution 
for a bioprocess design problem within the number of generations used within this 
study. The reason that the EA reached a consistent optimal solution in fewer 
generations for the MC bioprocess than the PL bioprocess is likely to owe itself to the 
fact that the design space is smaller for the MC bioprocess scenarios than for the PL 
bioprocess scenarios; therefore the problem evaluated by the EA is less complex in 
this instance. 
The accuracy of the EA must was evaluated by comparing the optimal solution found 
using the EA against that produced by a brute-force procedure, which analysed every 
possible bioprocess design for a given scenario. Table 5.8 shows the optimal solution 
and fitness value found for the SD-PL bioprocess strategy, and the SD-MC 
bioprocess strategy using both the EA and a brute-force procedure. The solutions 
found using the EA are consistent with those found using the brute-force approach. 
This illustrates that the EA used here is capable of accurately determining the optimal 
solution to the bioprocess design problem to which it has been applied.  
The final measure of EA performance was the reduction in processing time that could 
be achieved using the EA when compared to the use of a brute-force procedure. To 
achieve this, a timer function that measured the running time was encoded within the 
algorithms used to execute the evolutionary and brute-force procedures. Whilst only 
one scenario was run for the respective PL and MC bioprocess strategies, it was 
possible to extrapolate a percentage in reduction in overall processing time that could 
be achieved using the EA procedure.  
Table 5.9 shows the processing time in hours required to run the EA and the brute-
force procedure for a scenario where an annual demand of 5,000 doses is satisfied 
via the production of 10 manufacturing lots (500 doses per lot). The time taken to run 
the EA in the SD-PL and SD-MC scenario is 0.56 hours. This compares to a time of 
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192.9 hours, which is required to run the brute-force procedure for the SD-PL strategy 
and a time of 14.3 hours to run the brute-force procedure for the MC strategy. When 
applied to the PL strategy, the EA results in a 99.7% saving in processing time 
compared a brute-force approach. This value is 96.1% when the EA is applied to the 
MC strategy. The reason that the EA results in a greater reduction in processing time 
for the PL strategy is that there are 15 technologies available for the RPE and 
differentiation unit operations when planar processing is considered; only 4 
technologies are available when microcarrier-based processing is assumed. 
Therefore more iterations are required when the brute-force procedure is applied to 
the PL bioprocess strategies compared to when it is applied to the MC bioprocess 
strategies. Contrastingly, the number of iterations required of the EA is reliant solely 
upon the population size, ψ, the number of generations, g, and the number of runs, r. 
Therefore, the processing time required to run the EA is constant regardless of the 
bioprocess strategy considered. This explains the difference in values describing the 
percentage reduction in processing time that can be achieved when the EA is applied 
to the respective PL and MC bioprocess strategies in place of a brute-force 
procedure. 
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Figure 5.11 Line plots illustrating performance metrics for the EA when it was applied 
to the SD-MC bioprocess. a) Line plot showing the mean fitness value (in this instance 
the cost of goods per dose) of the best solution found across all five runs of the EA 
for each of the 25 generations. Point A identifies the point by which the optimal 
solution is found within all five EA runs, and the mean fitness value remains constant. 
b) Line plot showing the standard error of the mean fitness value across all five runs 
of the EA for each of the 25 generations. Point B identifies the point at which the 
solutions across all five runs become consistent, and that the standard error of the 
mean remains zero.   
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Table 5.8 Comparison of solutions found using brute-force algorithm compared to 
the EA at a lot size of 500 doses and annual demand of 5,000 doses 
 SD-PL SD-MC 
Algorithm used Brufe-force EA Brute-force EA 
COG per dose US$623 US$623 US$761 US$761 
Optimal technologies 
(Expansion) 
(Diff 1) 
(RPE Culture) 
cL-12[2] 
cL-12[2] 
T-225[1] 
cL-12[2] 
cL-12[2] 
T-225[1] 
cL-12[2] 
MC-1L [1] 
T-225[1] 
cL-12[2] 
MC-1L [1] 
T-225[1] 
 
 
Table 5.9 Comparison of the processing time required to run the EA as compared 
to the brute-force search algorithm at a lot size of 500 doses and annual demand 
of 5,000 doses 
 SD-PL SD-MC 
Percentage reduction in 
processing time as a 
result of using the EA as 
compared to brute-force 
algorithm 
99.7% 96.1% 
Algorithm used Brufe-force EA Brute-force EA 
Time taken (hrs) 192.9 0.56 14.25 0.56 
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Chapter 6: Application of multi-attribute decision making 
analysis to an allogeneic CAR-T cell bioprocess  
6.1 Introduction 
Many chimeric antigen receptor (CAR) T-cell therapies currently in development are 
autologous. This has been reflected by the focus of the majority of process design 
commentaries and analyses in this area to date (Kaiser et al. 2015; Levine 2015; 
Levine et al. 2017). However, recent advances have allowed the silencing of T cell 
receptor (TCR) expression on T cells derived from normal healthy donor so as to 
remove their alloreactive properties in order to avoid attacks on recipients’ tissues 
and cells (Valton et al. 2015). This has paved the way for the development of 
allogeneic CAR-T cell therapies. A major advantage of an allogeneic CAR-T therapy 
is that it could be used as an off-the-shelf treatment in acute oncology cases if a 
patient is either too ill to provide their own T-cell sample, or if they cannot provide the 
requisite number of T-cells required for the manufacture of an autologous product. 
Further to this, universal cell therapies align with traditional scale-up strategies and 
greater economies of scale could be realised with such a product. Allogeneic CAR-T 
cell therapies have the potential to enable more affordable treatments when 
compared to their autologous counterparts that are estimated to command a price 
bracket of US$150k – US$650k (Pierson 2015; Walker and Johnson 2016; Hettle et 
al. 2017).  
Advances in technologies have seen platforms such as the following being evaluated 
in cell therapy bioprocessing applications: gas-permeable vessels (e.g. G-Rex 
(Wilson Wolf, New Brighton, MN, USA)) (Vera et al. 2010), rocking motion bioreactors 
(e.g. Xuri Cell Expansion System (GE Healthcare, Chicago, IL, USA)), and contained, 
integrated bioprocess platforms (e.g. CliniMACS Prodigy (Miltenyi Biotec, Bergisch 
Gladbach, Germany)) (Kaiser et al. 2015). Further to this, technologies used for the 
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concentration of T-cell populations following cell culture have also improved. Spinning 
filter membrane technologies (Wegener 2014) (e.g. Lovo Cell Processing System 
(Fresenius Kabi, Lake Zurich, IL, USA)) and fluidised bed centrifuge systems (e.g. 
kSep (Sartorius, Göttingen, Germany)) (Sartorius Stedim 2016), along with integrated 
systems mentioned above where the cell culture chamber also acts as a centrifuge, 
now offer efficient means of cell concentration in a closed environment.  This 
represents a welcome shift from more conventional, planar technologies that do not 
offer the process control, flexibility, or potential for scale-up associated with modern 
technologies. Despite these advances, cost of goods (COG) associated with the 
production of CAR-T cell therapies are still a major challenge facing products of this 
nature.  
This chapter investigates bioprocess design associated with allogeneic CAR-T cell 
therapy manufacturing. Currently available technologies are considered from both an 
economic perspective (as shown in Chapters 4 & 5 for PSC-derived products), but 
also from an operational perspective in order to provide a representative case study 
demonstrating  the application of multi-attribute decision making (MADM) analysis to 
the cell therapy bioprocessing field.  
Multi-attribute decision-making (MADM) analysis provides a mechanism for 
qualitative, as well as quantitative attributes of a solution to a bioprocess design 
problem to be evaluated. MADM requires that all attributes are considered across an 
equivalent measurement scale, this is usually done by converting all attributes to 
dimensionless units on a finite rating scale. This method therefore allows preference 
decisions to be made on the basis of multiple attributes for an array of different 
problem solutions (Yoon and Hwang 1995). MADM analyses have previously been 
applied within various decision support tools in the biopharmaceutical sector in order 
to evaluate bioprocess designs on the basis of operational, environmental, and 
economic attributes (Suzanne S. Farid et al. 2005; Pollock et al. 2013).  
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This is the first instance of the application of a computational MADM analysis to a cell 
therapy bioprocess design problem. 
6.2 Incorporation of MADM analysis into a decision support tool 
MADM analysis was incorporated into the decision tool constructed in Microsoft Excel 
(Microsoft Corporation). This was done by adapting the typical tool architecture 
described in Figure 3.1 to include MADM analysis, as shown in Figure 6.1. In this 
instance, industry experts were asked to rate different process technologies on a 
scale of 1-10 for the operational attributes considered in this Chapter. These ratings 
made up the qualitative data described in Figure 6.1.  
The bioprocess economics model was used to calculate quantitative data in order to 
compute the financial attributes (COG, fixed capital investment) considered in the 
MADM analysis. In order to capture the uncertainty in ratings and importance 
weightings assigned to each attribute considered within the MADM analysis, 
probability distributions were assigned a) to the ratings assigned to each attribute for 
each process design evaluated within the MADM analysis and b) the importance 
weightings assigned to each attribute considered in the MADM analysis. The 
probability distributions were then used as the inputs for a Monte Carlo simulation in 
order to characterise the variability in the weights and ratings of the financial and 
operational attributes.  
The Monte Carlo simulation was set up and run as described in Section 3.6 of this 
thesis; the only difference being that input distributions were assigned to MADM 
inputs rather than process parameters in this instance. Section 3.7 recounts the 
methodology associated with the MADM analysis. This study aims to capture 
uncertainty associated with the MADM analysis. The resultant attribute weightings 
and decision matrix for the evaluation of allogeneic CAR-T cell therapy process 
designs can be found in Sections 6.3 & 6.4 of this chapter.  
234 
 
 
 
 
 
 
 
 
 
Figure 6.1 Decisional tool framework used within this chapter. The framework 
introduced in Section 2 has been adapted here to incorporate the MADM analysis. 
Information from the process economics model is fed into the MADM component of 
the tool, along with qualitative data obtained from responses to surveys completed by 
industry experts. Data was handled by the database in the same manner as 
previously described. 
6.3 Case Study Setup 
6.3.1 Tool Application 
The decisional tool was applied to a case study designed to evaluate the use of 
different process technologies for the manufacture of an allogeneic CAR-T cell 
therapy product. At this time, and with limited clinical experience, it was estimated 
that CAR-T cell therapy dose sizes will vary depending on the target indication from 
~104- 1012 cells per Kg, with the majority of those tested in the region of 106 – 109 cells 
per dose (Hartmann et al. 2017). The annual demand is also likely to vary dependent 
on target indication; rare haematological malignancies may only warrant an annual 
market size numbering in the low hundreds, whereas more common indications may 
235 
 
require thousands of doses per year. In this instance, a target dose size of 108 target 
cells and an annual demand of 1,000 doses was set as the base case scenario as 
these values are believed to be the near the midpoint.  The effects of dose size and 
annual demand on COG were analysed using the bioprocess economics model; dose 
sizes ranging from 107 to 109 total cells and annual demands ranging from 500 to 
5,000 doses were tested as the extremes using the model.  
The bioprocess economics model was used to compute COG and FCI requirements 
for different bioprocess designs; these economic parameters were then combined 
with the operational ratings for different technologies in order to create a MADM rating 
for each process design tested using the tool.  
The cost of manufacturing viral vectors is an important cost aspect in CAR T-cell 
therapy production, and more widely in gene therapy manufacturing. However, in this 
instance it was assumed the manufacturer outsoutced viral vector manufacturing to 
a CMO, the cost of viral vector produciton was therefore not considered in this case 
study and was considered as a ‘per lot’ cost. Furthermore, exploring the process 
economics of viral vector manufacturing is a subject for a significant body of research 
in itself and should be considered in future research. 
6.3.2. Process Overview 
The bioprocess in question is outlined in Figure 6.2, where it is broken down into unit 
operations. This process flowsheet differs from a typical autologous process in that 
additional unit operations in the form of electroporation and purification are required. 
Electroporation is utilised in order to transfer genetic material that silences the genes 
causing expression of T-cell receptor αβ (TCR). The silencing of TCR expression 
prevents alloreactivity of these cells upon transplantation to the recipient (Valton et al. 
2015). Purification, or enrichment, of TCR- cells at the end of the bioprocess is 
required  (Figure 6.2) in order to attain a targeted level of purity of TCR- cells amongst 
the total cell population that forms the therapy in this instance. 
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Three categories of cell culture technology were tested within the model; tissue 
culture flasks (TCFs), including T-flasks and manually operated stacked culture 
vessels; gas permeable vessels (GPVs); and finally rocking motion bioreactors 
(RMBs). Key input parameters regarding these technologies are Table 6.1.  
The concentration technologies tested included fluidised bed centrifugation (FBC), 
spinning membrane filtration (SFM), automated media removal (AMR) – to be used 
in conjunction with GPVs only – and finally an integrated process technology offering 
the potential for cell culture, concentration and purification in a contained, all-in-one 
platform (INT). Key input parameters pertaining to concentration technologies can be 
found in Table 6.2, where data is also available for the purification technologies 
considered in this study; namely a standalone magnetic-activated cell sorting platform 
(MACS) and a MACS platform within the INT technology described above. Where INT 
is used for purification, the platform was also assumed to be used for concentration 
as well. Static cell culture bags were assumed to support transduction and activation 
unit operations, whereas electroporation was carried out using the AgilePulse 
machine (BTX, MA, USA). 
 
 
 
 
 
 
Figure 6.2 Process flowsheet for the production of an allogeneic CAR-T cell therapy.  
A base case viral transduction efficiency of 70% was selected as it is within the range 
reported in (Yang et al. 2008), as well as consistent with values seen during process 
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development work carried out by Pfizer (data not shown). Within the sensitivity and 
scenario analyses, viral transduction efficiencies ranging from 50% to 90% were 
used. Key process and cost assumptions associated with the bioprocess, including 
reagent and material costs, labour costs, fixed capital equipment costs and specific 
process yields can be found in Table 6.2.  
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Table 6.1 Cell culture technologies considered within this case study and their associated performance and cost parameters 
Equipment Type Name Volume 
(L) 
Working 
culture 
volume (L) 
Minimum  
Utilisation 
Maximum 
Cell Density 
Single-use 
vessel 
costs 
Fixed 
equipment 
costs 
Perfusion rate 
Rocking Motion 
Bioreactor (RMB) 
50L RMB 50 25 20% 3.50E+07 $793.75 67,500 30% - 100% of 
WV depending 
on cell 
concentration 
20L RMB 20 10 10% 3.50E+07 $778.13 67,500 
10L RMB 10 5 10% 3.50E+07 $765.63 67,500 
2L RMB 2 1 30% 3.50E+07 $739.06 67,500 
Planar culture flask 
(CF) 
L-5 1575 1.6 100% 4.00E+06 $198.44 N/Aa 
Media addition 
based on cell 
population 
L-2 787.5 0.8 100% 4.00E+06 $183.59 N/Aa 
L-1 315 0.3 100% 4.00E+06 $73.57 N/Aa 
T225 50 0.05 100% 4.00E+06 $8.64 N/Aa 
Gas permeable 
vessel (GPV) 
GPC500 5.5 5.5 10% 4.00E+06 $951.50 15,000a Media addition 
based on cell 
population 
GPC100 1.1 1.1 10% 4.00E+06 $190.30 15,000a 
GPC10 0.1 0.1 10% 4.00E+06 $156.48 15,000a 
Integrated 
bioprocess 
platform (INT) 
INT 3.8 0.65 4% 3.50E+07 $2,512.00 235,500 N/A 
aIndicates that additional fixed equipment such as incubators and BSCs are required – please see table X for details on this equipment 
WV = working volume 
 
 
 
239 
 
Table 6.2 – Cell concentration and cell purification (purification) technologies considered in this case study and their associated cost and 
performance parameters 
Concentration Technologies 
Equipment Type Name Maximum input Maximum 
cell density 
Viable cell 
yield 
Target 
cell yield 
Disposable 
equipment costs 
per run (US$) 
Fixed 
equipment 
costs (US$) 
Fluidised bed 
centrifugation (FBC) 
FBC 114 N/A 80% N/A 1,800 281,000 
LoVo SFM 7.2L 1.6 85% N/A 537 79,500 
Integrated bioprocess 
platform (INT) 
INT 3.5 x 1010 cells 0.65 86% N/A 3,000 235,500 
Purification Technologies 
Equipment Type Name Maximum input Maximum 
cell density 
Viable cell 
yield 
Target 
cell yield 
Disposable 
equipment costs 
per run (US$) 
Fixed 
equipment 
costs (US$) 
Stand-alone immuno-
affinity purification 
MACS 3.5 x 1010 cells N/A 95% 80% 2,217 55,000 
Integrated bioprocess 
platform-based 
immune-purification 
INT 
3.5 x 1010 cells 
 
N/A 95% 80% 3,000 235,500 
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Table 6.3 Key cost assumptions used within the bioprocess economics model 
Cost Parameter  Value  
Media & Re-agents   
 Activation beads US$454/mL 
 Electroporation buffer US$785/L 
 TALEN plasmid US$6,500/mg 
 Expansion media US$300/L 
   
 LoVo buffer US$100/L 
 FBC buffer US$80/L 
 INT concentration buffer  US$300/L 
 Purification buffer US$2,157/L 
 Purification re-agents US$3,636 per 1010 cells 
Labour   
 Operator cost US$120,000/yr 
Fixed Equipment   
 Incubator US$27,000 
 BSC US$12,000 
 AgilePulse electroporator US$32,400 
Process parameter  Value 
Daily population 
doublings (cell culture) 
 1.38 
Viral transduction 
efficiency 
 70% 
Electroporation efficiency   70% 
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6.3.3 Multi attribute decision making under uncertainty: Attribute identification, 
ranking and weighting  
The attributes tested within this case study fell into two categories; financial and 
operational. Attributes and their rank, in terms of importance, were determined via 
consultation with industry experts. The final list of attributes, the category to which 
they are assigned, and the importance weighting assigned to each attribute are listed 
in Table 6.4. Weightings have been assigned probability distributions to capture the 
uncertainty in these values. These distributions were utilised in the stochastic MADM 
analysis. The COG and fixed capital investment associated with each process design 
were selected as the financial measure used in the MADM analysis. The COG is a 
key quantitative measure of the cost-effectiveness of a bioprocess, and has therefore 
been included in this analysis. FCI represents the upfront costs required to build a 
new facility fit for housing a bioprocess. Typically, many companies involved in cell 
therapy product development are academic spin outs and SMEs (Maciulaitis et al. 
2012). Many of these players are likely to view the upfront costs associated with a 
process design as a key factor to consider with regards to bioprocess design. Equally, 
larger companies may view high FCI costs as a significant risk associated with a 
particular project; FCI was therefore included in the MADM analysis.  
Qualitative attributes, such as process control, and process containment are vital to 
the robustness and reproducibility of cell therapy bioprocesses. These are two areas 
upon which product quality is dependent. Furthermore, ease of scale-up and ease of 
operation are important attributes to capture in the MADM analysis. For instance, 
technologies such as AMRs are not commonly associated with high fixed equipment 
costs, unlike FBC and SFM units. It is important to translate these qualitative trade-
offs into quantitative measures within the MADM analysis. The likely validation effort 
supported by different technologies is also important to capture. For example, 
technologies which rely on manual operators and are therefore more prone to human 
242 
 
error and may require additional validation studies in order to prove the consistency 
of product quality over multiple production lots.  
Table 6.4 Attributes considered in the MADM analysis, along with their respective 
weightings and probability distributions 
Attribute 
Category 
Attribute Name Importance Rank Weighting 
Financial FCI 1 Uniform (90,100) 
 COG per dose 2 Uniform (40, 100) 
Operational Process control 1 Uniform (85,95) 
 Process containment 2 Uniform (65, 75) 
 Ease of scale-up 3 Uniform (45, 65) 
 Ease of validation 4 Uniform (30, 60) 
 Validation effort 5 Uniform (10, 40) 
 
6.4 Results and discussion 
This section discusses insights from the process economics analysis of alternative 
whole bioprocess flowsheets for allogeneic CAR-T cell therapies. It provides a 
breakdown of the COG categories for each flowsheet as well as the bottlenecks and 
cost drivers in each case. The cost analysis is extended using a stochastic MADM 
analysis to weigh up the financial and operational attributes of each flowsheet. 
6.4.1 Bioprocess economic analysis 
The bioprocess economics model was used to compute COG and the achievable 
number of doses per lot (or per donor) for different bioprocess designs. The optimal 
equipment sizing regimes, where manufacturing COG was the objective function, for 
each of the process flowsheets was identified using the brute-force search method 
detailed in Section 3.5. The optimal equipment sizes for each process design (from 
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here on in referred to by their flowsheet number), in terms of category of technology 
used, are displayed in Table 6.5.  
Figure 6.3 shows the relative COG per dose values, broken down into constituent 
cost categories, associated with each bioprocess flowsheet. Whilst the optimal 
process flowsheet (Flowsheet 2), in terms of COG, is highlighted in Figure 6.3, COG 
differences of <5% are considered insignificant due to the margin of error associated 
with the COG model. Percentage values above each column in the chart refer to the 
COG difference relative to the optimal flowsheet. 
Table 6.5 Flowsheet configurations considered within the bioprocess case study 
(equipment sizes shown where relevant) 
Flowsheet 
Number 
Cell culture Cell concentration 
Cell purification 
(purification) 
1 RMB (10L) FBC MACS 
2 RMB (10L) SMF MACS 
3 RMB (10L) INT INT 
4 GPV500 AMR MACS 
5 L-5 FBC MACS 
6 L-5 SMF MACS 
7 L-5 INT INT 
 
Flowsheets 1-4, which all involve RMB or GPV as the cell culture platform, all lie within 
10% of one another (Figure 6.3). However, Flowsheets 5-7, for which TCF is the cell 
culture platform, all have a COG value at least 20% larger than the Flowsheet 2 
(optimal COG). Figure 6.3 shows that the major difference in the COG between 
flowsheets including TCF compared to those where cell culture is supported by RMB 
and GPV is the labour costs. Flowsheets 5, 6 and 7 require seven, seven and six cell 
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culture units respectively; this is compared to one unit for Flowsheets 1-3 and to two 
units for Flowsheet 4 (table insert, Figure 6.3). Hence, more operators are required 
for flowsheets that include TCF; this is reflected in the increased labour costs. This 
reinforces the greater scalability of RMBs compared to TCFs 
 
 
 
 
 
 
 
 
Figure 6.3 Stacked column chart displaying manufacturing COG breakdown per dose 
for each process design. Numbers on the x-axis refer to the process design numbers 
introduced in Table 6.5. The dashed line intersecting the y-axis at US$7,500 
represents the COG value that is equal to 15% of target selling price. Panels inset 
below the x-axis indicate the number of culture vessels required per lot for each 
process design. 
Capacity limitations and their consequences on lot size and number of lots required 
are illustrated by the capacity bottleneck schematics and inset panels for the four 
highest ranked flowsheets (determined by COG) in Figure 6.4. Indeed Flowsheet 3, 
where INT is used, can produce 78 doses per lot; this is compared to 90 doses per 
lot for Flowsheets 1, 2 & 4, where FBC, SMF and AMR are the respective 
concentration technologies. T. Therefore, because VT costs are calculated on a ‘per 
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lot’ basis, Flowsheets 3 and 7 result in increased viral transduction costs compared 
to other flowsheets (Figure 6.3).  
When INT is not considered for cell concentration, the capacity of current cell 
purification platforms is the limiting factor on the number of doses that can be 
produced per lot (Figure 6.4).  
A target selling price (TSP) of US$50,000 was selected based on costs for marketed 
cellular therapies being in the range of ~US$1,000 to US$100,000 (Bravery 2012); 
an approximate midpoint of these values was chosen for calculations in this case 
study. However, at this time in the development of CAR-T cell therapies, it is not 
possible to determine what the actual selling price will be, but estimates are potentially 
in the several hundred thousand dollar range for autologous CAR-T cell products 
(Pierson 2015; Walker and Johnson 2016; Hettle et al. 2017).  In the biologics industry 
typical values for COG as % sales are reported from 15% to 40% in order to recover 
R&D, sales and marketing costs (Smith 2012). In order to maximize the sensitivity 
model, a figure on the very low end of this range (15%) was selected (Smith 2012; 
Simaria et al. 2014; Hassan et al. 2015), which translates in to a COG target of 
US$7,500 in this case study. 
6.4.2 Effect of dose size and annual demand on manufacturing COG 
Different annual demands and dose sizes were investigated in order to test their effect 
on the manufacturing COG of the four highest ranked Flowsheets (according to 
COG), and whether the target of a COG value of less than 15% of TSP was realistic 
across these scenarios. 
The trend displayed within Figure 6.5a, whereby COG per dose decrease as the 
annual demands increase in consistent with economies of scale that are associated 
with scale-up of allogeneic cell therapies; reductions in labour costs and the 
divestment of FCI costs across a larger annual demand are the causes of this. This 
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is concurrent with both current opinion in the field of cell therapy bioprocessing and 
previous analyses examining process economics in the cell therapy sector (Simaria 
et al. 2014), and data presented in Chapter 5.  
 
Figure 6.4 Schematic and inset panels summarising the capacity bottlenecks, doses 
produced per lot, and number of lots required per annum for the process flowsheets 
with the lowest COG per dose values. Unit operations are shown in the panels on the 
left of the figure. The capacity bottleneck (in terms of number of cells that can be 
handled) is overlaid for each process flowsheet and is positioned according to the unit 
operation where this occurs. This label indicates the unit operation whereby the 
number of cells that can be handled by the technology used within a given flowsheet 
is the limiting factor on the scalability of the process design.  
At the highest tested annual demand of 5,000 doses per year, Flowsheet 2 still 
exhibits the lowest COG figure; this equates to ~13% of TSP, as shown by the scatter 
plot in Figure 6.5a – which displays COG values for the four flowsheets across the 
different annual demands. Flowsheets 1 and 4 also exhibit COG values that are less 
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than 15% of TSP. Only Flowsheet 3 exhibits COG > 15% of TSP; this is due to the 
increased viral transduction costs associated with this Flowsheet that are discussed 
in Section 6.4.1.  
At annual demands of 500 doses per annum all four process flowsheets tested 
resulted in scenarios where COG>15% of TSP. As with other demands that were 
analysed, Flowsheet 2 resulted in the lowest COG figure, which was approximately 
17% of TSP. Similarly, Flowsheet 3 proved to have the highest COG, whereby COG 
is equal to ~19% of TSP. At all annual demands the COG for Flowsheet 1 and 
Flowsheet 4 fell within 1% of each other’s value, indicating that there is no significant 
difference between these process designs from a COG perspective.  
Figure 6.5b shows that changes in COG associated with changes in dose size are 
more dramatic when compared with those associated with changes in annual demand 
(Figure 6.5a). For dose sizes less than 108 target cells, a COG per dose value of 
<=~15% of sales is achievable. For dose sizes of 5x108 and above, manufacturing 
costs exceed far beyond this value; as high as 70% greater than TSP in the case of 
Flowsheet 3 at a dose size of 109 cells. As dose size increases, so too does the 
number of lots required per year. This is because number of doses produced per lot 
decreases as dose size increases. The dramatic rises in COG associated with 
increase in dose size observed in Figure 6.5b can be attributed to VT costs, which 
are carried out on a ‘per lot’ basis. Owing to the fact that large dose sizes result in 
COG that greatly exceed the 15% of TSP target set, therapies for indications that 
require increased dose sizes may prove challenging from a reimbursement 
perspective. The sales price achieved by a cell therapy will likely be determined by 
its quality and efficacy relative to currently available comparators, and key 
performance indicators as described by health technology assessments (HTAs). 
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Figure 6.5 Scatter plots indicating the effect of a) annual demand and b) dose size 
on the manufacturing COG per dose for Flowsheets 1-4. Dashed lines on the plots 
that intersect the x-axis at US$7,500 indicate the COG value that is equal to 15% of 
target selling price. 
6.4.3 Sensitivity analysis: identification of key process economic drivers 
A sensitivity analysis was carried out in order to identify key process economic drivers 
associated with the process. Here, as with the same analysis carried out in Chapter 
4, process input parameters were varied by ±15% of their original value in order to 
assess their impact on COG. For example, when the base case viral transduction 
efficiency, 70%, was varied by ±15% the worst case value was 59.5% and the best 
case value was 80.5%. 
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The tornado chart in Figure 6.6 illustrate the changes in COG that variations in input 
parameters effect. Transduction efficiency and electroporation efficiency proved to be 
the greatest economic drivers associated with this bioprocess, each resulting in a 
30% swing in COG when altered by ± 15%. Both these parameters have a direct 
impact on the number of target cells that can be produced per lot; this is why they 
effect such a major change in COG when varied. Purification technology capacity was 
ranked third in the sensitivity analysis. Figure 6.4 shows that the capacity of currently 
available cell purification technologies causes a capacity bottleneck; therefore, an 
increase in this parameter would increase achievable lot sizes and thus reduce the 
number of viral transduction process required to satisfy annual demands. The tornado 
charts show that the cost of goods per lot of viral transduction has a significant impact 
on COG; it is the parameter ranked fourth in the sensitivity analysis. This is to be 
expected given the fact that the cost of viral transduction dominates the COG 
breakdowns shown in Figure 6.3. 
Finally, it is of note that variations in the cell culture expansion fold have little impact 
on COG. This is in contrast to the data presented in Chapter 4, whereby cell culture 
expansion fold (expressed as number of expansion stages required) was a key 
process economic driver. However, in this instance it has little effect because of the 
DSP capacity bottlenecks mentioned in Section 6.4.1; a higher expansion fold may 
create incremental reductions in material costs associated with cell culture, but will 
not impact on the number of doses that can be produced per lot. 
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Figure 6.6 Tornado charts showing the effect that a ±15% change in key parameters 
has upon the manufacturing COG per dose in terms of a percentage change. Best 
case values, whereby COG per dose decrease relative to the base case are shown 
in blue. Worst case values are shown in red. 
6.4.4 Scenario Analyses  
Based on the results of the sensitivity analysis described in Section 6.4.3, scenario 
analyses, or gap analyses, were carried out in order to identify process improvements 
or cost reductions necessary to achieve a target COG value. In these analyses, the 
impact of simultaneously varying two or more key economic drivers upon the COG 
was measured. This allowed the identification of the amount by which current process 
yields and efficiencies, or process costs, need to improve in order to hit a target COG. 
Analyses were performed using Flowsheet 2 as the basis for improvements in COG 
as this design resulted in the minimum COG per dose value. 
The process parameters varied in this analysis were the transduction efficiency and 
electroporation efficiency. These parameters were chosen because they were 
identified as key economic drivers by the sensitivity analysis. Furthermore, both viral 
transduction technologies and mRNA plasmids used in electroporation have seen 
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rapid advances in recent years and it is feasible that further improvements in the 
efficiencies observed in these unit operations could be achieved.  
Additionally, the cost of viral transduction per lot was tested in the scenario analyses, 
as was the capacity (in terms of number of cells) of cell purification platforms. Again, 
these were shown to be key economic drivers in the sensitivity analysis (Section 
6.4.3). The price to the cell therapy manufacturer in this instance is negotiated with a 
contract manufacturing organisation (CMO), which is assumed to produce the viral 
vector used in the transduction stage of the bioprocess. This results in a ‘viral 
transduction cost per lot’. As with other bioprocess sectors (not least the cell therapy 
field); advances in the technologies and reagents used in the production of viral 
vectors are being made. This is likely to result in reduced COG for the CMOs 
producing viral vectors; it is therefore not unreasonable to assume that cell therapy 
manufacturers will put pressure on these CMOs to reduce the selling price to reflect 
this. Thus, the cost of viral transduction may be reduced.  
Purification technologies are limited in capacity and throughput; this has been the 
subject of many commentaries and reviews within the cell therapy bioprocess field 
(Weil and Veraitch 2013; Weil et al. 2017). As competition amongst manufacturers of 
purification platforms increases, and as demand from the process sector increases, 
it is likely that the capacities of these technologies will increase.  
Having explored whether current processes can meet a cost target of COG as 15% 
TSP earlier (Figure 6.3), further scenarios were then carried out to see how much 
better the performance would need to be if the target was COG had to be even lower, 
set at 10% TSP. Figure 6.7a indicates that viral transduction efficiency must be 
increased to 90% from 70%, along with a 22% increase in the purification capacity 
from the base case scenario, in order to achieve a COG as 10% TSP (Point B, Figure 
6.7a). Alternatively, a 50% increase in purification capacity and a minor increase in 
viral transduction efficiency to 73% could achieve this target (Point A, Figure 6.7a).  
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This is a similar scenario to that where both reductions in the viral transduction cost 
per lot, and the viral transduction efficiency are varied. Point A in Figure 6.7b 
illustrates that a reduction in viral transduction costs per lot of 38% is required, 
assuming viral transduction efficiency remains at the base case value. However, as 
shown by Point B in Figure 6.7b, improvements in viral transduction costs alone are 
not sufficient to achieve COG equal to 10% of TSP. Furthermore, when both viral 
transduction and electroporation efficiencies are varied (Figure 6.7c), when 
electroporation efficiency is increased to 84%, viral transduction efficiency is required 
to be 90% for COG equal to 10% of TSP to be achieved. 
Figures 6.7b and 6.7c indicate that significant process improvements are required in 
order to reach COG values equal to 10% of TSP, particularly if the capacity of cell 
purification platforms were to remain unchanged. Therefore, to analyse whether an 
increase in process capacity at the cell purification stage would have an effect on the 
required process improvements in other areas in order to achieve COG equal to 10% 
of TSP, the scenarios described by Figures 6.7b and 6.7c were re-run under the 
assumption that the capacity of the cell purification technology had increased by 25% 
(Figure 6.7d & 6.7e). Direct cost fluctuations that would be associated with this 
increasedl purification technology capacity were also considered in COG 
computations.   
Figure 6.7d illustrates that if a 25% increase in cell purification technology capacity is 
assumed, then a 21% reduction in the viral transduction cost per lot will result in COG 
equal to ~10% of TSP (Point A, Figure 6.7d). Furthermore, if viral transduction costs 
can be improved from 70% to 88% then COG equal to 10% of TSP can be achieved 
(Point B, Figure 6.7d). If the capacity of cell purification platforms improved by 25%, 
electroporation efficiency must be improved from 70% to 89% to achieve COG equal 
to ~10% of TSP (Point B, Figure 6.7a). 
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The scenario analyses in this section offer evidence that allogeneic CAR-T cell 
therapies can achieve COG values as a percentage of TSP similar to early 
biopharmaceutical products. They also illustrate how COG of 10% of TSP may be 
achieved. Depending on what are deemed to be the most feasible or achievable 
process improvements, the window of operation will be directed towards different 
regions of the contour plots. For instance, if viral transduction efficiency can be easily 
improved then process engineers may target Point B in Figures 6.7a-e, however if 
improvements in other parameters prove more feasible, then a window of operation 
whereby COG ≈ 10% of sales close to Point A in Figures 6.7a-e may be targeted. 
However, at this time in development, it must be emphasized that both COG and TSP 
are not definitively known as there as currently no examples of marketed therapies in 
this space, and as such, the model should be used as a tool to determine the relative 
importance of altering various process parameters on COG 
In order to reduce COG, it is likely that improvements in current process technologies 
will be required (Figures 6.7a, d & e). Previous case studies and reviews have 
commented on the lack of scalable, high resolution purification (sometimes referred 
to as purification) platforms (Weil and Veraitch 2013; Weil et al. 2017). The scenario 
analyses above indicate that improvements in this area of cell therapy bioprocesses, 
alongside the maximisation of potential yields of target cell types via the improvement 
of vector delivery systems, are key to reducing the manufacturing COG burden 
associated with allogeneic cell therapy bioprocessing. Whilst these scenario analyses 
provide an example of where process development efforts can be focused in order to 
provide maximum COG reductions, future work should also consider the cost of 
development in order to produce the improvements discussed above. The overall 
impact this might have on projet valuation metrics should be considered in order to 
fully understand the cost-benefit trade-off of such development efforts. 
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Figure 6.7 please see next page for figure legend 
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Figure 6.7 Contour plots that illustrate improvements in key process and cost 
parameters required to achieve COG value ≈ 10% of target selling price (TSP). Point 
A indicates the point on the contour lines shown in each plot whereby a) 
improvements in cell purification technology capacity, b) & d) the reduction in viral 
transduction cost per lot, and c) & e) electroporation efficiency is maximised in order 
to achieve COG ≈ 10% of TSP. Point B indicates the point on the contour lines shown 
in plots a) – e) whereby viral transduction efficiency is maximised in order to achieve 
COG ≈ 10% of TSP. Plots b) & c) consider scenarios where the capacity of cell 
purification technology remains at the base case value. Point A on the respective 
plots indicates the required bioprocess performance whereby COG is safely below 
15% of TSP. Plots d) & e) consider scenarios where the capacity of cell purification 
technology is assumed to be 25% greater than the base case scenario. 
6.4.5 The effect of parallel DSP processing on capacity bottlenecks and COG 
In Chapter 3, the fact that only one DSP unit per process has been permitted was 
outlined, to prevent parallel processing of samples and pooling of process streams 
following DSP operations. In order to evaluate the effect that the permission of 
running DSP operations in parallel had upon the bottlenecks associated with the 
bioprocess basic equipment sizing calculations were run for a scenario whereby 
multiple DSP units were permitted to process each donor’s sample. The results of this 
analysis for the four key process flowsheets are detailed in Figure 6.8. The results 
indicate that purification would no longer be the bottleneck or restricting factor on the 
scalability of the bioprocess and that the number of doses produced per lot would 
range from 311 to 334 as oppose to 75 to 90 as was previously described. 
Interestingly, Flowsheet 3, containing the Prodigy would now allow for the greatest 
number of doses to be produced per lot; previously this Flowsheet produced the 
smallest number of doses per lot.  
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Figure 6.8 Schematic and inset panels summarising the capacity bottlenecks, doses 
produced per lot, and number of lots required per annum for the process flowsheets 
with the lowest COG per dose values. Unit operations are shown in the panels on the 
left of the figure. The capacity bottleneck (in terms of number of cells that can be 
handled) is overlaid for each process flowsheet and is positioned according to the unit 
operation where this occurs. This label indicates the unit operation whereby the 
number of cells that can be produced due to process limitations is a constraining 
factor on the scalability of the bioprocess. 
The permission of parallel DSP processing also has a significant impact upon COG. 
This is evidenced in Figure 6.9, where Flowsheet 3 is now the optimal process 
platform from this perspective. Interestingly, it is possible to achieve a COG < 15% of 
TSP with Flowsheets 1-4 in this scenario. Multiple GPV reactros are required in order 
to culture the 150billion cells that the expansion process is capable of producing. 
Therefore labour costs increase significantly for this technology compared to larger 
technologies such as the RMB technology. The COG for Flowsheet 2, when only one 
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DSP unit per lot is permitted, have been included for comparison. Across all 
flowsheets in the new scenario, where parallel DSP is permitted, activation and 
transduction costs are reduced significantly compared to the scenario when only one 
DSP unit per lot is permitted. This is because the number of lots required to satisfy 
1,000 doses per year has been reduced from 12 to four. Viral transduction costs are 
calculated on a per lot basis and can therefore be reduced in the number of lots per 
year can also be reduced. Overall, this analysis suggests the COG can be 
significantly reduced if parallel DSP processing is permitted. Equally, the process can 
be de-bottlenecked at the purification stage of the process in this scenario.  
 
Figure 6.9 Stacked column chart displaying manufacturing COG breakdown per dose 
for each process design. Numbers on the x-axis refer to the process design numbers 
introduced in Table 6.5. The dashed line intersecting the y-axis at US$7,500 
represents the COG value that is equal to 15% of target selling price. Panels inset 
below the x-axis indicate the number of culture vessels required per lot for each 
process design.  
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6.4.6 Multi attribute decision making analysis under uncertainty 
MADM analysis was applied in this case study in order to evaluate potential process 
designs on the basis not only of financial attributes, but also operational attributes. In 
this case study, the use of MADM proved particularly instructive due to fact that the 
four top-ranked process flowsheets from a COG perspective all resulted in COG 
values within 10% of the optimal solution. MADM analysis was therefore be used to 
definitively select between different process designs in this instance. A stochastic 
MADM analysis was applied to Flowsheets 1, 2, 3 & 4, as defined in Section 6.3.2. 
An online of the methodology used to calculate aggregate scores can be found in 
Section 3.7. 
Uncertainty data was incorporated into the ratings given to the qualitative operational 
attributes for each technology by assigning appropriate probability distributions. 
Triangular distributions were assigned to each attribute for each flowsheet, to 
represent their minimum, most likely, and maximum values. The resultant decision 
matrix for the evaluation of the four bioprocess flowsheets is therefore shown in Table 
6.6. 
Qualitative operational benefits 
Table 6.7 contains the mean dimensionless ratings scored by each process flowsheet 
for each attribute when evaluated using the stochastic MADM analysis. The data 
contained within Table 6.7 indicates that Flowsheet 3 ranks highest for process 
control amongst the four flowsheets. This is due to the INT platform’s ability to run 
both concentration and cell purification unit operations within a controlled 
environment in an automated manner. This attribute was ranked the most important 
amongst respondents to a survey sent to bioprocess professionals. Process 
containment, referring to a bioprocess’ ability to run without exposure to the 
surrounding environment was also ranked high in terms of its importance amongst 
operational attributes. Flowsheets 1, 2 & 3 all achieved high ratings amongst 
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respondents for this attribute. Table 6.7 shows that Flowsheets 1, 2 & 3 containing 
rocking motion bioreactors were rated favourably compared to Flowsheet 4, 
containing GPV, for all operational attributes aside from ease of operation. This is due 
to the automated media removal device used for media exchanges associated with 
GPV as oppose to complex perfusion culture strategies used within the RMB platform. 
In order to test whether the apparent operational benefits associated with Flowsheets 
1 and 3 outweigh the high score achieved for the FCI attribute achieved by Flowsheet 
4, it was necessary to consider the aggregate scores achieved by each process 
flowsheet in the MADM analysis. 
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Table 6.6 Decision matrix for the evaluation of different process designs  
Attribute 
Original rating data Feasible Range 
Flowsheet 1 Flowsheet 2 Flowsheet 3 Flowsheet 4 Worst Value Best Value 
COG per gram 7,829 7,630 8,220 7,888 9,500 6,500 
FCI 932,574 556,797 703,097 623,397 500,000 1,000,000 
Process control Triang(6.8, 7.3, 7.8) Triang(6.8, 7.3, 7.8) Triang(5.5, 6.0, 9.5) Triang(5.2, 5.7, 6.2) 0 10 
Process 
containment 
Triang(8.2, 8.7, 9.2) Triang(8.2, 8.7, 9.2) Triang(8.5, 9.0, 9.5) Triang(5.5, 6.0, 6.5) 0 10 
Ease of scale-up Triang(6.5, 7.0, 7.5) Triang(5.8, 6.3, 6.8) Triang(6.0, 6.5, 7.0) Triang(5.0, 5.5, 6.0) 0 10 
Ease of operation Triang(6.2, 6.7, 7.2) Triang(6.8, 7.3, 7.8) Triang(6.5 ,7.0, 7.5) Triang(7.8, 8.3, 8.8) 0 10 
Validation effort Triang(6.5, 7.0, 7.5) Triang(6.2, 6.7, 7.2) Triang(5.5 ,6.0, 6.5) Triang(5.2, 5.7, 6.2) 0 10 
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Table 6.7 Summary of weighted dimensionless ratings for each attribute and 
process flowsheet tested within the MADM analysis 
Parameter 
Flowsheet 
1 2 3 4 
COG per dose 75 84 58 73 
Fixed capital investment 5 40 26 34 
Ease of operation 22 25 23 28 
Process control 63 63 50 47 
Validation effort 10 9 8 8 
Ease of scale-up 37 32 34 28 
Process containment 60 60 62 39 
 
Multi-attribute decision making analysis under uncertainty 
The cumulative frequency distribution of the aggregate score of the alternative 
process flowsheets was generated and is displayed in Figure 6.10. Initially, equal 
importance of operational and financial attributes was assumed (i.e. R1 = R2 = 0.5).  
 
 
 
 
 
 
 
Figure 6.10 Cumulative frequency curves showing the spread of aggregate MADM 
scores as under uncertainty. Aggregate scores were generated over 1,000 Monte 
Carlo simulations. 
262 
 
The cumulative frequency curves for Flowsheets 2 and 4 do not intersect with each 
other, or any other curves on the chart. However, Flowsheets 1 and 3 intersect with 
one another just above the median value. Flowsheet 1 achieved a preferable 
aggregate score compared to Flowsheet 3 in 51% of Monte Carlo simulations. 
Flowsheet 3 also resulted in the greater range of values compared to Flowsheet 1. 
This indicates that the uncertainty associated with Flowsheet 3 is greater than 
Flowsheet 1, and therefore whilst the median aggregate scores are approximately 
equal, it may be that Flowsheet 1 is considered preferable to Flowsheet 3 due to the 
reduction in variability of its aggregate score. Flowsheet 2 is clearly the preferred 
alternative of all the options presented in Figure 6.10. It is therefore possible to rank 
the alternatives in order of preference; Flowsheet 2, Flowsheet 4, Flowsheet 1, 
Flowsheet 3.  
Multi-attribute decision making analysis: Sensitivity to financial and operational 
weightings 
The results of reconciling trade-offs between financial and operational outputs using 
a single multi-attribute score are discussed in this section. Previous sections of this 
work have focused on identification of the preferred process design when operational 
and financial attributes were given equal ratings. Here, overall strategy scores were 
calculated for each process design using MADM analysis across a range of 
combination ratios. These combination ratios reflect the relative importance of 
financial and operational attributes in process design. The financial combination ratio, 
R1, and the operational attribute combination ratio, R2 were assigned such that R1 + 
R2 = 1 under any circumstance. Therefore if one combination ratio is varied, the other 
is adjusted to reflect this change.  
In this instance, the weightings assigned to each individual attribute were kept 
constant and were not subject to uncertainty. The average weightings assigned to 
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each attribute during the Monte Carlo simulation described previously in this section, 
shown in Table 6.4, were applied for the purposes of this deterministic analysis. 
The combination ratios were then assigned a values ranging from 0 to 1 (at intervals 
of 0.1). Figure 6.11 depicts the sensitivity of the overall aggregate score for each 
flowsheet to the financial and operational combination ratios at an annual demand of 
1,000 dose per year and a dose size of 108 target cells per dose.  
If the operational attributes are considered approximately twice as important as the 
financial attributes (R2=0.65, R1=0.35), Flowsheet 4 is ranked bottom of the four 
flowsheets tested using MADM. However, when financial attributes are considered at 
least as important as economic attributes (R1=R2=0.5), Flowsheet 4 is ranked above 
Flowsheets 1 and 3, despite all flowsheets obtaining a similar ranking for COG per 
dose. Flowsheet 4 is ranked favourably to Flowsheets 1 & 3 due to its superior FCI 
ranking; the GPV technology is characterised by low FCI costs. Flowsheets 1 & 3 are 
ranked approximately equally across scenarios tested; they scored similarly in both 
economic and operational categories. Flowsheet 3 is favoured slightly owing to the 
greater process containment offered by this strategy, and a reduction in FCI costs. 
Indeed in scenarios where operational attributes are considered 9 times (or greater) 
the importance of economic attributes, Flowsheet 3 is the top ranked technology, 
although the difference between the aggregate scores for Flowsheets 1, 2 and 3 in 
these instances are not significant. Flowsheet 2 is the top ranked flowsheet in all other 
scenarios tested; it offers significant operational and economic benefits in comparison 
to Flowsheet 4 due to the process containment and process control offered by RMB 
cell culture devices.  
The FCI rating for Flowsheet 3 is also significantly higher than Flowsheets 1 and 2, 
due to the relatively low cost of the SMF technology, as opposed to FBC or INT, used 
for cell concentration.   
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Figure 6.11 Spider plots showing depicting the sensitivity of the overall aggregate 
MADM score for each process design to variations in the financial attribute 
combination ratio, or the importance given to financial attributes within the MADM 
analysis. The sum financial attribute combination ratio (R1) and operational attribute 
combination ratio (R2) (not shown on chart) are always equal to 1.  
6.5 Conclusion 
A case study has been presented whereby a decisional tool, consisting of a 
bioprocess economics model, information database, and MADM analysis, has been 
developed in order to facilitate decision making with regards to process design for an 
allogeneic CAR-T cell manufacturing process. Cost-effective equipment sizing 
regimes were identified for alternative process flowsheets. Flowsheets consisted of a 
variety of different technology platforms to support cell culture, concentration of cells, 
and purification of target cell populations. The difference in COG values of three of 
the process designs evaluated within the study did not exceed 10% compared to the 
most cost-effective design (in terms of COG per dose). It was found that using tissue 
culture plastic cultureware such as T-flasks and multilayer vessels proved to be 
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significantly more costly than rocking motion bioreactors or gas permeable vessels. 
A sensitivity analyses indicated that viral transduction efficiency, electroporation 
efficiency, viral transduction cost per lot and the capacity of downstream processing 
equipment (in terms of cell numbers) were the key process economic drivers; 
improvements required to bring about a COG per dose value significantly below 15% 
of target selling price were subsequently identified using scenario analyses. MADM 
analysis was also able to identify that the flowsheet consisting of rocking motion 
bioreactor, spinning filter membrane, and a standalone MACS platform as the 
preferred process design when both financial and operational attributes were taken 
into account. Future work in this section may focus upon a more wide-ranging study 
of available technologies to consider additional process designs. Furthermore, 
comparisons between allogeneic and autologous CAR-T cell COG should be made 
in order to identify scales whereby one product type is more economically viable than 
the other. This analysis must also take into account the fact that both allogeneic and 
autologous therapies may not be feasible or indeed available depending on the 
condition of the patient and indication targeted.  
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7. Conclusion & Future Work 
7.1 Conclusions 
The work presented in this thesis has focused on the development of a series of 
decisional tools in order to demonstrate their applicability to the field of cell therapy 
bioprocessing. The tools developed within this work have aimed to capture the 
technical, financial and operational aspects of cell therapy bioprocessing. 
Additionally, process related uncertainties, inherent in current cell therapy bioprocess 
techniques, were captured using stochastic risk modelling.  
The applicability of the tools was demonstrated through a series of industrially 
relevant case studies. Namely, a series of tools were developed that evaluated 
strategies for the production of patient-specific iPSC-derived cell lines for drug 
screening purposes, the manufacture and distribution of a low dose allogeneic hESC-
derived therapy, and the production of an allogeneic CAR-T cell therapy.  
An investigation into the techniques and technologies used to produce cell therapies 
enabled the identification of common unit operations, such as tissue acquisition, cell 
culture, and harvest of cells, across production processes for different cell therapies. 
In addition to the identification of common unit operations, processes specific to the 
manufacture of certain types of cell therapy were also identified. These included 
differentiation of hPSCs to target cell types, viral transduction and electroporation 
required for the genetic modification of T-cells in the production of allogeneic CAR-T 
cell therapies, and cell purification (or purification) steps in order to select for a subset 
of target cells amongst a broader population. The aforementioned investigation 
enabled the development of prototype bioprocess flowsheets for each case study; 
these flowsheets were subsequently used as the basis of which unit operations were 
included in the decisional tools that were developed.  
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Following the investigation into current practices within cell therapy bioprocessing, a 
series of computational tools were developed and were set-up according the methods 
and framework set up in Chapter 3. A Brute-force algorithm was applied in Chapter 4 
as a means of identifying optimal bioprocess designs according to an objective 
function, in this instance this was the manufacturing cost of goods per unit. However, 
when faced with a case study that presented a large problem domain, as in Chapter 
5, an evolutionary algorithm was developed in order to streamline the identification of 
optimal bioprocess design. Chapter 6 demonstrates the applicability of multi-attribute 
decision making (MADM) to cell therapy bioprocessing; here, a combination of 
financial and operational attributes were evaluated in order to provide a more holistic 
analysis of available process designs. 
The bioprocess economics associated with manufacturing patient-specific iPSC-
derived cell lines for the purposes of drug screening were investigated using a 
decisional tool in Chapter 4. A case study was developed that compared manual and 
automated bioprocess strategies. In this instance the tool was used to carry out 
equipment sizing calculations and produce data with which to carry out economic 
analyses of different process designs. Via the use of a decisional tool, it was 
determined that the most cost-effective process design (manual or automated) was 
dependent upon the scale and the throughput of the bioprocess. Key economic 
drivers were identified and stochastic modelling outputs suggested that automated 
platforms resulted in a more robust bioprocess. Finally, it was determined that indirect 
cost reductions are required in order to achieve an acceptable COG value for in-
house manufacture of iPSC-derived cell lines for drug screening. Owing to the 
demonstration of the applicability of the tool to a non-GMP process, it was 
hypothesised that such a tool could also be applicable to GMP based production of 
cell therapies.  
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In Chapter 5, a decisional tool was applied to a process design problem involving the 
scale-up of a manufacturing process for a low dose, allogeneic, hESC-derived RPE 
therapy for the treatment of macular degeneration. An incumbent bioprocess, which 
contained a lengthy and inefficient spontaneous differentiation protocol, was 
compared to a directed differentiation protocol. Additionally, the use of planar-based 
technologies was compared, from a cost of goods perspective, to microcarrier-based 
differentiation in stirred suspension bioreactors. An evolutionary algorithm was 
incorporated into a decisional tool in order to streamline the identification of cost-
effective bioprocess designs. Stochastic modelling was used to capture uncertainties 
associated with each manufacturing strategy and to establish the robustness of 
different process designs. Further to this the effects of centralised vs. decentralised 
manufacturing on COG associated with a fresh cell therapy product were evaluated. 
The results of Chapter 5 suggest that planar-based bioprocess platforms still have a 
large part to play in the production of low dose cell therapies, particularly at relatively 
small scales of production. 
A decisional tool that combined metrics computed using a bioprocess economics 
model (e.g. COG per dose, fixed capital expenditure) with operational criteria (e.g. 
ease of scale-up, process containment) is presented in Chapter 6. Here, a range of 
alternative bioprocess designs for the manufacture of an allogeneic CAR-T cell 
therapy are considered from both a financial and operational perspective. A multi-
attribute decision making approach was used so as to provide a more holistic 
evaluation of available process designs. This approach was able to capture a variety 
of factors that should be taken into consideration when making process design 
decisions, not just the manufacturing COG as in previous chapters. Combination 
ratios were used to demonstrate how the ranking of alternative process designs 
changed according to the priority given to either operational or financial metrics 
computed by the tool.  
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One of the most significant challenges to the cell therapy field is the development of 
bioprocesses that can manufacture products at a scale and cost relevant to market 
demands. Whilst manufacturing costs are just one piece of a complex jigsaw that 
determines the commercial success of a cell therapy product, they underpin many 
important commercial elements of a cell therapy; their consideration during 
bioprocess design is crucial. Therefore, this work has demonstrated how decision 
support tools, such as those introduced in this thesis, can help inform effective 
process design during the development of cell therapy products. 
7.2 Future Work 
The implementation of the decisional tools developed as part of this thesis within 
industrially relevant case studies demonstrates their application to the field of cell 
therapy bioprocessing. However, this thesis represents the early application of such 
tools to the cell therapy sector. Future work could therefore focus on either the 
development of the tools to provide further insight into the bioprocess economics of 
cell therapy development and manufacturing, or to establish the decisional tools 
developed in this thesis as a more generic, user-friendly, potentially commercially 
available platform. 
The fixed capital investment cost estimates derived within this thesis were based 
initially on a Lang Factor derived by Pollock et al. (2013) for biopharmaceutical 
bioprocesses based on the use of disposable technologies (Chapter 4). Following 
this, a Lang Factor method currently under development at UCL, which is specifically 
tailored to the cell therapy bioprocess sector, was used (Chapters 5 and 6). Accurate 
representation of fixed capital investment costs is dependent on this Lang Factor 
system and its development should be at the forefront of future work programmes. 
This will require communication with cell therapy manufacturers and business leaders 
in order to obtain benchmark data that can be used to test the accuracy of a novel 
cell therapy Lang Factor for estimation of fixed capital investment. However, the Lang 
270 
 
Factor approach, and it relevance to the cell therapy sector, is not as clear as it is for 
the chemical and biochemical engineering industries. Ratios between facility costs 
and TEPC vary drastically for cell therapy bioprocess designs depending on the 
classification of cleanroom and surface area required for different types of equipment 
required in the cell therapy industry. Therefore in the future, facility costs may be more 
accurately estimated by approximating the surface area and classification of clean 
room required for a given bioprocess design. This approach may be more accurate, 
but would require a greater number of calculations than the Lang Factor approach; in 
turn, this could drive up computing times associated with bioprocess economics 
models. It may therefore be appropriate to try and identify suitable Lang Factor-type 
ranges dependent on cleanroom classifications. 
Additionally, work carried out in parallel to this thesis by Hassan et al. (2016) has 
highlighted the effects of process changes during product development on the 
economic performance of cell therapy products, this was done using project 
performance metrics such as NPV. Moving forward, it is important to recognise that 
whilst a process design might be identified as more cost-effective than a given 
alternative, the effect of process change on the profitability of a product must also be 
considered. Therefore, one area of future work may be to integrate the work of 
Hassan et al. (2016) with the tools presented in this thesis in order to introduce the 
opportunity for broader analyses to be performed. This will also allow manufacturing 
design decisions to be made based on development timelines and costs, not only 
manufacturing cost of goods.  
In Chapter 5, centralised vs. decentralised processing was considered. The choices 
available to cell therapy manufacturers with regards to available process 
technologies, manufacturing locations and distribution strategies are increasing. 
When considering decentralised facilities as a manufacturing strategy, future work 
should consider the additional costs behind the use of multiple facilities. For example, 
271 
 
the costs of commissioning and inspection of the facility as well as regional variations 
in the facility regulations should be considered. The requirement of Qualified Persons 
and the additional costs this might incur if multiple facilites are used should be also 
be considered in future models. Addiionally, the impact on validation and 
comparability studies across multiple sites should be considered, again this should 
take into account regional variations in regulatory requirements in these areas. 
Further studies could investigate novel distribution strategies, such as installing clean 
rooms in hospitals, or so called ‘GMP in a box’ manufacturing, and their impacts on 
shipping and manufacturing costs.  
In Chapter 6, when considering the impact of percentage improvements in process 
paramaters on potential cost of goods reductions, the increased costs associated with 
process development efforts were not included within the modelling framework. In this 
instance, these scenarios were designed to give thought ‘spaces to play’ with regards 
to process development, future work should take into account the effects of process 
development efforts and resources associated with these when estimating potential 
impacts on manufacturing cost of goods. 
Finally, consideration of the ‘per unit’ costs of viral vector manufacturing may be an 
important aspect for future work; in this study a ‘per lot’ cost was used. However, this 
proves difficult to justify when considering scale-up or scale-down of the bioprocess. 
A ‘per unit’ cost for a viral vector would allow a more flexible approach to the economic 
analysis. 
From a programming perspective, the tool developed in Chapter 5 is somewhat 
complex; the size of the problem domain necessitated the use of an evolutionary 
algorithm. Even so, running the algorithm proved to be a lengthy process, taking up 
to 24 hours dependent on the number of scenarios (lot sizes and demands) run. 
Ideally, the process economics model, and linked algorithm, should be further 
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developed in order to reduce the time required for each simulation in order to improve 
the speed at which optimal process designs are identified.  
The decisional tools developed as part of this thesis are very specific in their current 
form; they are tailored for the bioprocesses that they are designed to capture. Whilst 
this is an advantage in that they are sophisticated and thorough in their appraisal of 
a bioprocess, they do not offer a lot of flexibility. Their application may therefore be 
limited beyond the case studies described in this thesis (NB this is a note about the 
specific models, not the approaches described in this work, which are widely 
applicable to the whole cell therapy field). Future work could therefore focus on the 
development of the tools themselves. In order to further develop the tools, and 
potentially make them an attractive tool available for license by cell therapy 
manufacturers, future work should focus on the generification of the tools presented 
here. This is to say that whilst it is important to capture the specifics of individual 
bioprocesses, the tools presented here may be more widely applicable if they could 
be developed such that user interfaces would allow users to input their own process 
flowsheet and select technologies pertinent to a given process design from a central 
database. The effort involved in translating the tools described in this thesis to a 
product for general use in the cell therapy field would be considerable and require 
advanced expertise in computer programming. However, comparable products are 
available in the biopharmaceutical field in the form of BioSolve (Biopharm Services, 
Chesham, UK).  
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Appendix A: An integrated experimental and economic 
evaluation of cell therapy affinity purification technologies 
A1. Foreword 
This section of the appendix contains the manuscript for a paper submitted to 
Regenerative Medicine. The work presented in the manuscript was carried out jointly 
the manuscript’s first author, Dr Ben Weil, and the author of this thesis. I, Michael 
Jenkins, carried out the bioprocess economic modelling methods described in 
Section 2.2 of the manuscript. Dr Weil was responsible for the experimental work and 
results described in Sections 2.1. The manuscript was drafted as a joint effort 
between Dr. Ben Weil and I, with additional input from other listed authors within the 
manuscript.  
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Appendix B: Papers published, or submitted for publication 
as part of this thesis 
The following papers, published during the course of this thesis are included in the 
appendix below:  
Jenkins, M.J. & Farid, S.S., 2015. Human pluripotent stem cell-derived products: 
Advances towards robust, scalable and cost-effective manufacturing strategies. 
Biotechnology Journal, 10(1), pp.83–95. 
Jenkins, M.J. et al., 2016. Patient-specific hiPSC bioprocessing for drug screening: 
Bioprocess economics and optimisation. Biochemical Engineering Journal, 108, 
pp.84–97. 
The following paper and book chapter have also been produced as part of the work 
carried out in preparation of this thesis. Weil et al. (2017) can be found in Appendix A 
and the book chapter has not been included to its length, however the content is 
largely based upon Chapters 1 & 2 of this thesis.  
Weil, B.D. et al., 2017. An integrated experimental and economic evaluation of cell 
therapy affinity purification technologies. Regen Med, 12(4), pp.397-417 
Jenkins, M.J. & Farid, S.S., 2017. Bioprocesses for Cell Therapies. In G. Jagschies 
et al., eds. Handbook of Bioprocessing. Elsevier, p. In press. 
A final paper has also been drafted, based on Chapter 6 of this thesis. This will be 
submitted to Biochemcial Engineering Journal in Q4 2017. 
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Appendix C: Validation 
C1: Introduction 
This section of the appendix was produced as part of the Bioprocess Validation MBI 
Course undertaken as a mandatory component of the EngD in February 2014. The 
section represents an overview of the validation challenges associated with the 
production of patient-specific cell lines for drug screening. However, broader 
regulatory and validation issues affecting the scale-up of cell therapy bioprocesses 
are also considered. 
C2: Key Validation Issues 
C2.1 Final Product Functionality 
iPSC-derived cells can be used to assess efficacy and toxicity of NCEs. In order for 
the cells to be used as a viable screening tool they must be homogeneous between 
patients in terms of the functionality of the cells. Currently, iPSC-derived neurons are 
produced for in-house use at Pfizer using planar platforms. Variations in product 
quality could occur due to differences in holding times used during cell harvest steps. 
Thus, appropriate holding times must be defined so that cell functionality and potency 
is not affected during processing. Critical quality attributes (CQAs) must be defined in 
order to ensure proper product characterisation. In stem cell processing this can 
include measuring biomarker expression, analysis of cell morphology to determine 
the type of cell and its potency. Functionality assays such as ion-channel assays can 
be used to carry out QC and QA tests on samples from iPSC-derived neuron 
populations. Acceptable ranges for each of these parameters should be defined in 
order to allow process validation to take place and prove the robustness of the product 
C2.2 Choice of Media 
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Advances in stem cell bioprocessing were hindered for a long period by the 
widespread use of complex media containing animal derived components. This is 
especially true of differentiation processes, which often rely on exogenous growth 
factors to direct pluripotent stem cells to a specific fate. A directed differentiation 
protocol to induce neuronal differentiation through the use of small molecules has 
been developed (Surmacz et al. 2012), thus reducing the reliance on growth factors. 
From a validation this is an important step as it allows a QbD approach to designing 
differentiation processes because there is an understanding of why components drive 
differentiation to a specific lineage, rather than simply knowing what happens when 
cells are exposed to certain growth factors. This is also the case for cell culture media, 
where rational design of new, defined media has sought to analyse and understand 
the key functions of complex components of media and simplify such media by only 
including the necessary compounds. This will allow a QbD approach to process 
design to be adopted with regards to developing windows of operation to be created 
with respect to the concentrations of molecules added to the media, as well as the 
timepoints at which such molecules are added to the media (this is particularly 
important in directed differentiation protocols). 
C2.3 Reproducibility of Process 
Process automation is a growing trend within cell therapy bioprocessing. It is thought 
that automation will improve process reproducibility by negating some of the variability 
introduced by manual processing of stem cells such as: 
• creation of possible points of contamination throughout the bioprocess 
• idiosyncrasies of lab technicians  
Automated processing will thus help define and understand the design space of cell 
therapy bioprocess as it will allow cause and effect relationships to be identified 
between CPPs and CQAs, whereas manual processing can skew these relationships 
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due to the inherent variability associated with this method. Automated processing is 
also far more reliable than manual processing and thus can help de-risk a validated 
process 
C3. Validation and regulatory issues affecting process scale-up 
Scale-up of stem cell therapies is a crucial stage of bioprocess development. This will 
involve creating larger populations of cells in order to create processes with a higher 
throughput; in cases where patient-specific cells are being produced this is likely to 
be a scale-out process. For allogeneic, or universal products, a scale-up operation is 
more appropriate. There are variety of validation issues that come with implementing 
the scale-up strategies investigated in this thesis. It is clearly important to assess what 
are the critical process parameters when seeking to adapt a process and justify an 
acceptable operating space so as not to adversely affect CQAs of the final product. 
C3.1 Conversion from Static, Planar Culture Vessels to Dynamic, 3-D 
Bioreactors 
Trends in stem cell bioprocessing suggest that 3-D bioreactors may need to be 
employed in order to meet demand in terms of cell numbers and to reduce facility size 
requirements. Shifting to dynamic, bioreactor based  bioprocessing presents a 
number of issues from a validation perspective. The effect of shear stress on cells is 
not fully understood. It may be possible to harness shear forces within bioreactors to 
modulate cell fate, however, before this is done process development studies must 
successfully define the effect of shear forces on cell colonies. Novel process 
analytical tools (PATs) should be applied in order to quantify the effect of shear of 
CQAs associated product quality. Microfluidic tools and other USD devices are well-
placed to serve such a purpose. This will enable a well-defined operating space that 
should be independent of scale for dynamic culture of hiPSCs and their derivatives.  
C3.2 Adaptation from Monolayer to Microcarrier Culture 
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Whilst monolayers and microcarriers both offer culture platforms for adherent cells, it 
is important for microcarrier properties to be fully characterised in terms of their effect 
on cells’ microenvironment and activity (self-renewal vs differentiation). It is important 
to consider the mechanical properties of microcarriers as well as their exterior 
biochemical properties when validating their use for hiPSC processes (Sart et al. 
2013). The effects of mechanical properties, such as stiffness and size, of 
mircocarriers on hiPSC colony size and spreading should also be factored into any 
process design decisions. It will also be important to use microcarrier coatings which 
are fully defined and free of xenogeneic products. Synthetic coatings are preferable 
due to lot-lot variatbility that can occur with recombinant proteins. The integrity of both 
cells for diagnostic purposes and those that are intended for use as cell therapies 
must be ensured by the removal of animal-derived components from the process 
stream. Defined microcarrier coatings will also allow the effects of each component 
of the coating to be quantified in terms of its effect on stem cell activity. Full 
characterisation of the effcts of different polymers on the coatings of microcarriers will 
allow and QbD approach to rational design of microcarriers for stem cell 
bioprocesses. It is likely that microcarriers may be produced by a CMO, but an 
understanding of their properties is still crucial in order to develop large scale, robust 
processes. 
C3.3 Large-Scale Harvest Strategies 
Dynamic culture also presents issues with regards to harvesting cultured/ 
differentiated cells. Process development studies must identify whether or not the 
dynamic nature of 3-D bioreactors has any impact upon a) the concentration of 
harvest enzyme required b) the holding time required for harvest using enzymatic 
dissociation and the effects of these parameters on CQAs such as cell functionality/ 
viability. Additionally, it might be that changes to the process to reduce COGs might 
occur, one such modification could be the use of thermo-sensitive microcarriers that 
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degrade at specific temperature to obviate the need for enzyme-based harvest 
strategies (which will reduce material costs associated with hiPSC bioprocesses). 
Again, it is important to adopt a QbD approach to carry out rigorous experimentation 
in order to understand the effects such a modification might have on CQAs 
determined by Pfizer to define the quality of their product. 
